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Abstract
Identification of functional variants underlying inherited diseases and complex
phenotypes is a major bottleneck in human genetics. Although population-based discovery
such as genome-wide association studies (GWAS) are yielding novel loci and disease genes
for complex diseases, significant single-nucleotide polymorphisms (SNPs) in GWAS may not
be causal but simply in linkage disequilibrium with the causal SNP. Evaluation of every
individual SNP is impractical and expensive. As exome sequencing of patients is becoming
more economical, in silico bioinformatic methods that can be used to identify potential causal
variations are needed.
The aim of this thesis was to assess the applicability of current computational
methods for distinguishing pathogenic SNPs from bystanders in linkage disequilibrium to
complex diseases and to explore ways in which they might be improved.
The state of the art is represented by amino acid substitution (AAS) methods, which
have been developed over the last ten years. Many of these knowledge-based systems are
predicated on data from Mendelian diseases, reflecting historical progress in delineating the
genotype-phenotype relationship. They have had some success in identifying pathogenic
mutations in cancer and in Mendelian diseases. However, predictions by these AAS methods
may not translate well to interpretation of disease-associated variants in complex diseases.
My study showed that current AAS methods are more likely to correctly identify pathogenic
mutations in phenotypes of Mendelian inheritance and somatic mutations in cancer that
involve loss of function (e.g. tumor suppressors in cancer). It is likely that the more subtle
variants in complex diseases, particularly gain-of-function variations, will be missed by the
current suite of programs.
Furthermore, even when these methods are successful in predicting a pathogenic SNP,
they are not helpful in defining the cause of its pathogenicity, as many of them only give a
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binary output or a score predicting the impact of the substitution. With the number of SNPs
reported increasing every day, it is important to elucidate how a SNP affects the protein’s
function, particularly in a way that can be tested.
Several studies have suggested that context is an important variable in determining the
impact of an amino acid substitution. For example, a study that differentiated mutations in
intracellular, extracellular and transmembrane (TM) regions of G-coupled receptors showed
that inclusion of the context specification in the prediction method increased its accuracy. I
chose coiled-coils as a specific context to study because they are very common structural
subunits in proteins. Coiled-coils are twisted rope-like structures present in many protein
complexes. Like disordered regions, another type of generic linker of globular protein
domains that have more specific functions, coiled-coils are involved in important protein-
protein interactions. Coiled-coil regions are found in over 2,000 genes of the human genome
such that 0.9% of all protein residues form coiled-coils.
I assessed the impact of disease mutations versus polymorphisms in coiled-coil
domains in Uniprot by modelling the structural and functional impact of variants in silico
with the coiled-coil prediction program Multicoil. Disease mutations tended to be more
destabilizing than polymorphisms; but interestingly, polymorphisms were more frequently
associated with predicted changes in the oligomerization state. An interesting finding of the
study was that coiled-coil regions are more frequently associated with pleiotropy than
proteins in general; and importantly, the coiled-coil region itself often encodes the pleiotropy.
As coiled-coil regions are known to be mediators of protein-proteins interactions, this study
provides indirect support in humans for work in yeast that showed that genes with a larger
number of protein-protein interactions are important in pleiotropy. I discuss how this work
contributes to a general understanding of the molecular basis of pleiotropy.
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Amino acid substitutions in proteins that introduce or modify a site of post-
translational modification may also have large phenotypic effects. These may have
deleterious loss-of-function or gain-of-function consequences in the organism but may also
have beneficial effects, giving the organism a competitive advantage and becoming fixed in
the population. In my third study, I looked at the acquisition of cysteine residues in proteins
during evolution. Cysteine is an unusual amino acid: its abundance in proteins is less than its
neutral frequency the frequency that would be expected based on the number of Cys codons
in the genetic code, suggesting its introduction has a ‘cost’ to the organism. Using
phylogenetic techniques I studied the introduction of cysteine residues in proteins with the
specific aim of understanding contexts in which the gain of a cysteine residue is allowed.
This study suggested that successful incorporation of Cys may be limited to very select
contexts in proteins, specifically those where reduction of the Cys can be effected by existing
enzymes of redox homeostasis in organisms. This work should be of use in distinguishing
deleterious and beneficial gain-of-function variations in proteins, as well as contribute to an
understanding of the evolution of thiol-based redox signaling systems.
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Chapter 1: Research aim
The primary aim of this research was to extend Gentrepid (Ballouz et al., 2011) to
enable prediction of structural and molecular effects of missense variations at the amino acid
level (Figure 1.1). The principal aim of this thesis was to work towards this aim through
several well-defined goals.
Figure 1.1: The principle aim of current work is to extend Gentrepid, a candidate gene prediction tool to enable
identification of causal nsSNPs at the molecular level.
Aim 1: To assess the current methods used to predict the pathogenicity of variations
called as amino-acid substitution (AAS) methods, particularly their applicability to complex
disease. These informatic methods typically take a “one size fits all” approach to assessing
the impact of a substitution through look-up tables. Characteristics of the disease such as the
heritability (ie somatic or germline) and the mode of inheritance, and characteristics of the
resident protein are generally not taken into account.
Aim 2: To develop methods for making pathogenicity predictions that take protein
context into account.
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For Aim 1, I reviewed all the major AAS Programs and benchmarked their
performance on somatic mutations, distinguishing between loss-of-function and gain-of-
function mutations, and on mutations in complex diseases. Unsurprisingly, the systems,
which are largely trained on data from Mendelian diseases, performed poorly on data from
complex diseases, but they were also poor in calling gain-of-function somatic mutations. This
work was submitted for publication in the peer reviewed Molecular Genetics and Genomic
Medicine Journal as “In silico prediction of pathogenicity of missense substitutions: the
perspective for complex diseases” reviewing current pathogenic predictors and assessing
their performance in case of complex disease.
For Aim 2, I investigated the difference between known Mendelian disease mutations
(DM) and polymorphisms (PY) in a specific context: coiled-coil regions of proteins. This
context was chosen because it is a major component of the human proteome (12%). This
work showed that, in line with previous work, Mendelian mutations are largely associated
with loss of stability of the coiled-coil region. One of the novel findings from this work was
that polymorphisms (PY) could also have large effects on protein structure but in different
ways to Mendelian mutations, specifically in altering the oligomerization properties of
proteins and the position and nature of conserved irregularities in the protein structure.
This work has been provisionally accepted for publication as “Mapping genotype-
phenotype correlation in coiled-coil oligomerization domain of the human proteome” in the
peer reviewed Human Mutation Journal.
Previous work has also implicated modification to functional residues as important in
disease states. One aspect of this is alterations to residues involved in post-translational
modifications. The Wouters laboratory has a long-standing interest in post-translational
modification of cysteine residues, which are implicated in thiol-based redox signaling
pathways. These pathways underlie disease states involved in oxidative stress. In my third
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paper, I investigated how these mutations are introduced into proteins during evolution. I was
specifically interested in investigating why these mutations are retained and become fixed in
the population.
This work was published as “Potential role of glutathione in evolution of thiol-based
redox signaling sites in proteins” in the peer reviewed journal Frontiers in Pharmacology.
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Chapter 2: Introduction
The molecular basis of disease2.1
With the extensive growing catalogue of human diseases, immediate attention is
required for the development of therapeutics and cures. Literature reports suggest that there
are over 7,000 diseases but we have cures and treatments only for 500 of them (Upton and
Degette, 2015). For a healthier society, a direct proportion between disease and cures should
exist, but in reality, an inverse relationship exists between the two. Many different factors
such as regulations and costs involved in drug development, and the complexity in
identifying the genetics behind the disease can be attributed to this phenomenon. However,
technology has evolved over time and the research in this arena is rigorously moving at a
brisk pace.
Figure 2.1: Schematic representation of factors that
influence the development of therapeutics. Role of
variants involved in a disease and the methods used to
identify the causal variants play a significant part in
this process.
As depicted in Figure 2.1, development of therapeutics depends on several factors.
Knowledge of molecular and cellular basis of diseases is required, which is vital for
identifying the mechanisms of disease pathogenesis. There has been limited success in
deciphering the pathogenesis of diseases. For instance, Online Mendelian Inheritance in Man
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(OMIM), a database of inherited genetic disorders contains 4,692 phenotypes with some
information about the molecular basis and 1,630 phenotypes of unknown molecular basis
origin (Hamosh et al., 2005). This is because dissection of biology for the disease depends on
the identification of disease genes. With at least 30,000 genes identified in the human
genome, only 10% (as of August 2013) of the genes with harmful variations have been
mapped to phenotypes (OMIM, 2013). This implicates the complications around
identification of disease genes, which is mainly due to the mode of inheritance involved in
diseases. However, genes themselves are not responsible for a disease but the occurrence of
biological variations in them that play a crucial role in determining the disease (Piro and Di
Cunto, 2012). The Single Nucleotide Polymorphism database (dbSNP), a database of single
nucleotide variations, reported 40,822,423 single nucleotide polymorphism (SNP) variations
between December 2015–February 2016 (dbSNP, 2016). The bottleneck here is to
discriminate causal variants from those that are simply in linkage disequilibrium. It is
relatively hard to understand the effects of variation in sequence and the elucidation of
molecular mechanisms (Thusberg and Vihinen, 2009). Complexity increases where the
manifestation of genetic variation associated with the same disease are mutually exclusive
among individuals. With this perplexity in medical research, identification of disease genes
and variations involved in human disorders to establish genotype-phenotype correlation has
become the primary goal for genetics.
Various technologies and methods have been deployed to identify disease genes and
causal variants and have come a long way in this regard. It is currently possible to
simultaneously analyze hundreds and thousands of variations in any individual's genomic
DNA to find association between a given disease and a genetic variation. However,
technological advances have also given rise to new problems on handling millions of data
points associated with genetic studies. Despite the availability of human genetic linkage map,
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determining the DNA sequences responsible for specific traits remains ambitious in human
genetics, for at least those phenotypes which are very subtle and modest (Botstein and Risch,
2003). This indicates the necessity for more sophisticated mathematical, statistical and
computational models to better understand the complexity.
Given the complexity in identifying molecular basis of diseases, a detailed review was
carried out to understand how these factors influence this process. Success and limitations of
technical advancements and methods developed over the years to identify disease genes and
functional variants will also be discussed concluding with suggestions to improve existing
methods.
Understanding the genetics of diseases2.2
In 1865, Gregor Mendel formulated two laws—Law of Segregation and Law of
Independent Assortment, which best described the inheritance pattern of seed color, plant
height and seed shape in peas (Mendel, 1996). Not until 1900s, when these observations were
rediscovered by Sir Archibald Garrod while studying the human hereditary disorder
alkaptonuria were these laws widely accepted by researchers (Garrod, 1902, Melvin and
Speer, 2006). However, Mendel’s observations remain one of the most important
contributions, which still govern the modern era of genetics. Mendel’s first law suggested
that a pair of factors (alleles) responsible for a trait segregate independent of the other during
meiosis. The second law stated that, the hereditary material for different traits assort
independently of the other during the formation of gametes.
These hereditary materials were termed as genes, which were discovered almost 90
years after Mendel’s postulated the laws of inheritance. They are linear structures present in
the chromosomes containing information for human development, organ development and
biological function. The location of a gene in the chromosome is called its locus. Genes are
made up of a pair of factors called alleles. Pair of alleles can be homozygous (similar) or
      


heterozygous (different) as shown in Figure 2.2. Any deleterious change to this hereditary
entity results in a disease. Locus of a gene and the allele heterogeneity play an important role
in governing the type of diseases.
Figure 2.2: Structure of chromosome. Chromosomes
contain genes that govern characteristics of an organism.
Alleles of a gene can be the same or different. In this
representation, genes for hearing are homozygous as
both forms of allele are the same. But in case of gene of
eye colour, alleles are heterozygous. Colour of the eye
will depend on the dominant allele.
Diseases have a spectrum of genetic basis (Figure 2.3). At the narrow end of the
spectrum are Mendelian or monogenic diseases that are caused by changes in a single gene.
The pattern of inheritance in these diseases is simple and straightforward, as they mostly
follow the laws of Mendelian inheritance as explained previously. Alleles whose loci are on
an autosomal gene can be inherited in a dominant or recessive manner; similarly, alleles
having loci on the X chromosome are transmitted as either X-linked recessive or X-linked
dominant disorders. The hallmark of dominant inheritance is that only a single allele is
required for the phenotype regardless of whether the gene is located on the autosome or on
the X chromosome. In an autosomal recessive trait, two copies of a trait allele must be
present for it to be expressed.
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Figure 2.3: Influence of genetic and environmental factors on complex diseases (Adapted from Strachan & Read
2004).
On the broader end of the spectrum are complex diseases that have irregular pattern of
inheritance that is influenced by both genetic and environmental factors (Figure 2.3). Factors
such as incomplete penetrance, epistasis, and pleiotropy contribute to the development of
such diseases. In incomplete penetrance the clinical phenotype does not manifest with the
variation and depend on the modifier genes and the environment (Stern, 1956). Modifier
genes influence pleiotropic and epistatic effect. Examples of diseases observed in different
scenarios are summarized in Table 2.1. Polygenic disorders caused by interaction of many
genes are also located in the broader end of the spectrum. Examples include common and
prevalent diseases like Diabetes, Hypertension, Crohn’s disease etc.
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Table 2.1: Definitions of terms used in regards to diseases
Disease Definition Example
Rare Diseases that affect a small number of people compared to
the general population (Thiene et al., 2007)
Charcot-marie-
Tooth disease
Polygenic Diseases determined by many genes of mild effect Diabetes mellitus
Oligogenic Multiple genes consisting of major genes, which have
large effects and clear patterns of inheritance, and minor
genes, which have modifier effects (Chial, 2008). Major
genes may be components of non-redundant metabolic
pathways or components of large molecular complexes
(Nachury et al., 2007).
Bardet-Biedl
Syndrome (BBS)
Monogenic Diseases caused by mutation (one dominant/two recessive
allelic variants) in one gene (Gallati, 2014)
Cystic fibrosis
Epistasis Gene interaction where one gene interferes/masks with the
expression of the other gene (Rose and Bell, 2012)
Autoimmune
diseases
In recent years, another group of diseases has evolved with a spectrum in between
Mendelian and complex diseases, known as oligogenic disease. It is different from polygenic
and single gene diseases, as it neither involves a single gene nor many groups of genes. It
involves more than one but only a small number of genes. The genes involved have a
modifier effect on the other genes (Chial, 2008), exhibiting more like an epistasis effect
(definition in Table 2.1). For example, BBS is known to be associated with eight BBS loci
(Katsanis, 2004), where the presence of variation in one gene affect the phenotype and its
severity.
Depending upon the type of variation involved in a gene or a group of genes, a
clinical condition is manifested.
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Role of variations in disease2.3
Variations in genes technically occur in the alleles of a gene. Depending upon the
frequency of an allele, a variation can be termed as mutation or a polymorphism (PY).
Mutations are more sporadic and radical changes that occur rarely with the minor allele
frequency (MAF) is less than 0.1%. However, disease-causing alleles could be maintained at
a higher frequency if they were under positive or balanced selection, with disease offset by a
beneficial phenotype as in sickle-cell disease and malaria resistance (Melvin and Speer,
2006). Generally, mutations cause rare or Mendelian diseases. They are rare because
mutations that cause strongly deleterious phenotypes as seen in case of most Mendelian
diseases will be lost to purifying selection.
On the contrary, any loci with allelic variations of MAF > 0.5% are described as
polymorphisms. They occur more frequently than mutations. A comprehensive analysis on
these variations in described in section 2.3.2. Association of PYs with disease are more
commonly observed in case of complex diseases.
How do common variations play a role in the disease? Common diseases as explained
previously depend on both the genetic background of the individual and the environmental
factors. They often have late onset, with mild or no obvious impact unlike Mendelian
diseases. As to how rare variants may be fixed in the population over time, mildly deleterious
alleles can rise to moderate frequency, particularly in populations that have undergone recent
expansion (Reich and Lander, 2001).
2.3.1 Variations in Mendelian disease
Most of the mutations in Mendelian diseases cause more distinctive changes to the
genetic element making them deleterious. However, beneficial mutations also exist. Changes
in the genetic code can result in loss or gain of function of the gene product leading to disease
associated phenotypes. Such changes can be as subtle as a single base-pair change (point
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mutations), such as the thymine-to-alanine substitution that alters the β chain of haemoglobin
A from its wild type to its haemoglobin sickle cell state; or involve extensive multi-codon
deletions, such as those observed in Duchenne Muscular Dystrophy (Melvin and Speer,
2006). Such different types of mutations involved in diseases are explained below.
Point mutations involve single nucleotide changes and the effect can be silent,
missense or nonsense (Figure 2.4). Silent mutations as the name suggests are silent changes
that do not alter the amino acid in the encoded protein as a result of the nucleotide base
change. These mutations do not generally affect the protein structure. However, a recent
study conducted by Kimchi Sarfaty and her colleagues showed that two silent mutations in a
human protein that pumps toxins have a subtly different shape compared to the wild type and
they make cancer cells resistant to chemotherapy (Pearson, 2006). In thalassemia, a sense
mutation changed a stop codon (TAA, Ter) to glutamine (CAA, Glu), creating a much longer
and non-functional protein. However, the effect of silent mutations on protein production was
shown in yeast and bacteria back in the 1980s (Chamary and Hurst, 2009).
On the other hand, missense mutations occur when a different amino acid is encoded
as a result of change in the nucleotide base (Maquat, 2001). Missense mutations are mainly
characterized underlying genetic diseases as they tend to change the protein’s structure and
function (Wang and Moult, 2001). However, they are rare variants observed only in a small
fraction of cases with minor allele frequency of less than 0.5-1% (Raychaudhuri, 2011).
Nonsense mutations are caused by nucleotide changes which introduce a premature
stop codon. Nonsense mutations truncate the synthesis of protein and result in molecular
process such as nonsense-mediated decay (NMD) (Thermann et al., 1998, Zhang et al., 1998,
Holbrook et al., 2004, Chang et al., 2007). It has been estimated that about half of all
nonsense mutations cause NMD (Han et al., 2007, Yamaguchi-Kabata et al., 2008).
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Figure 2.4: Different types of point mutations.
Three different types of point mutations exist—
missense and non-sense, changing the wild protein
sequence; and the third being a silent mutation.
Most of the diseases in humans identified to date
are characterized by missense mutations.
Other types of small DNA changes are called indels. They are another rare type of
variation which involve micro-insertions/deletions in the gene resulting in changes in the
length of the polypeptide chain. They result in frame shift mutations completely altering the
sequence of a protein (Chuzhanova et al., 2003) (Figure 2.5 ). One of the most commonly
studied genetic diseases, cystic fibrosis is caused by deletion of three nucleotides which
results in the removal of phenyl alanine in the 508th position (Collins et al., 1987). Although,
there are many other mutations in the cystic fibrosis transmembrane conductor regulator
(CFTR) gene, it is the most prominent mutation.
Chromosomal aberrations are completely different from the above two as they involve
duplication, gross deletion or exchange of chromosomal segments (Figure 2.5). Down
syndrome is the most common chromosomal abnormality caused by the presence of all or
part of third copy of chromosome 21 (Grant et al., 2010).
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Figure 2.5: Changes in DNA that involve more than one base. Deletions, duplications, inversions and
insertions result in altering the length of the underlying DNA sequence. To the right are translocations
that involve exchange of chromosomal segments (DarwinWasRight, 2012).
2.3.2 Variations involved in complex disease
Nearly every human gene and genomic region is marked by these sequence variations
called single nucleotide polymorphism (SNPs) that are found every 1000-2000 nucleotide
bases. They were first identified in 1980s using restriction enzymes to identify the presence
or absence of restriction sites (Botstein et al., 1980). By definition, SNPs are variations of
one single nucleotide base sequence between members of same biological species or paired
chromosomes in humans and have a low rate of recurrent mutation (Figure 2.6)
(Sachidanandam et al., 2001). In order to consider a single nucleotide variation as a SNP, the
minor allele frequency (MAF) should be 0.5% or even greater (Collins et al., 1998). These
allelic variations are marked with a common evolutionary heritage and therefore, these SNPs
reflect past mutations. To be precise, SNPs enable identification of the ancestry of genes by
analyzing the shared patterns of SNPs (Stoneking, 2001). Several comparative studies on
identical and fraternal twins (Martin et al., 1997) suggest that DNA polymorphism is one of
the factors associated with susceptibility to many common diseases, every human trait,
individuality and inter-individual difference in drug response (Shastry, 2007).
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Figure 2.6: Structure of a SNP. SNPs serve as
genetic markers (National Institute on Drug
Abuse, 2016).
2.3.2.1 Types of SNPs
SNPs, like mutations are classified into different types based on their consequence
and location (Figure 2.7). SNPs can be primarily classified based on their location in the
gene—coding (cSNP) or non-coding (ncSNP). Coding SNPs can be further classified into
synonymous SNP (sSNP) or non-synonymous SNP (nsSNP) based on their consequence.
sSNPs are like silent mutations whereas nsSNPs are similar to missense mutations.
Furthermore, nsSNPs may have effect on the protein structure or function. With the non-
coding SNPs, it is important to examine if they are present in the gene regulatory regions or
not, as complex diseases arises from quantitative difference in gene products (Chakravarti,
2001).
Figure 2.7: Different types of SNPs. However, only nsSNPs have a effect on the protein’s structure and
function. See section 2.3.2.1 for abbreviations.
The distribution of human SNPs from the dbSNP database build 139 with respect to
each function class is shown below (Figure 2.8). SNPs were observed more in the intronic
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regions, as only a minor proportion of variations occur in the coding region of the genome.
Among the coding non-synonymous SNPs (missense, frame shift, non-sense), missense SNPs
(nsSNPs) was found at a higher frequency than any other SNPs of the same class. This
correlated with previous estimates by Halushka et al. (1999), where they showed 50% of
SNPs encoded in the noncoding regions, 25% leading to nsSNPS and remaining 25% as
silent mutations. Thus, coding missense SNPs found at a higher frequency than others (except
intronic regions), play an important role in identification of disease genes (Martin et al.,
1997). Missense mutations and nsSNPS are two important entities that facilitate the
identification of molecular basis of diseases.
Figure 2.8: Distribution of SNPs. SNPs were collected from the dbSNP database build 139 with respect to
function class.  SNPs in introns are highly concentrated.
2.3.2.2 Importance of SNPs
Although other types of variations exist such as indels and copy number variants,
SNPs are the most common type of variation accounting for almost 90% of sequence
differences (Collins et al., 1998). The number of SNPs reported over a period of time from
different resources is shown in Table 2.2. As of April 2016, the total number of SNPs in the
human genome reported in the dbSNP database is 40,822,423 (dbSNP, 2016).
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Table 2.2: Number of coding and non-coding SNPs reported over a period of time
Author Year Number of SNPs reported
Collins et al. 1998 ~500,000 cSNPs
Halushika et al. 1999 ~500,000 ncSNPs
200,000 silent cSNPs
200,000  nsSNPs
Cargill et al. 1999 240,000-40,000 nsSNPs
Sachidanandam et al. 2001 60,000 cSNPs
dbSNP 2016 40,822,423 nsSNPs
SNPs play a major role in medically important traits elucidating the likelihood of a
person acquiring a phenotype of interest, or how one would respond to a particular treatment
(Chakravarti, 2001). Even if a single SNP is not directly responsible, groups of SNPs
observed in a region can be used as a genetic marker to locate genes that may influence such
phenotypes (Stoneking, 2001). The high impact of research turned towards SNPs is due to
their ability to act as genetic markers in case of complex phenotypes. They are widely used to
identify disease genes.
Identification of disease genes2.4
Identification of disease genes has been a major problem in genetics since 1900’s.
Even after the completion of the human genome, only 10% of the genes (as of August 2013)
have been mapped to phenotypes (OMIM, 2013), which still suggests that better methods are
required to identify disease genes. Many Mendelian genetic disorders have been mapped to
specific genes or a set of genes. However they are limited to high risk, variant alleles that
segregate in rare families (Mayeux, 2005). For example, Orphanet, a database of rare diseases
contains about 5,856 diseases mapped to 3,573 disease genes (Orphanet, 2016, Weinreich et
al., 2008).
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The paradigm in common/complex disorders is obviously different from Mendelian
diseases, mainly because of involvement of more than one gene as well as intervention of
non-genetic factors (Prokunina and Alarcn-Riquelme, 2004). Also, any specific mutation is
not specifically necessary or sufficient enough for phenotype expression in case of complex
diseases. In these cases, an individual mutation leads to a disease only under specific genetic
background or upon exposure to environmental factors such as infections, drugs,
contaminants, UV radiation, etc. In spite of having a genetic background, complex genetic
disorders generally segregate in a non-Mendelian fashion (Prokunina and Alarcn-Riquelme,
2004). Thus, identifying factors that contribute to the development of complex diseases is a
considerable challenge. Hence in the past two decades, relatively few genes have been
identified for complex diseases (Glazier et al., 2002).
Principles used to characterize Mendelian diseases can also be held against complex
diseases. For example, Mendel’s laws regarding the transmission of genes and alleles at loci
are as important to the study of resemblance between relatives in genetically complex disease
as in Mendelian disease; the same holds true for the extent and result of the differing types of
mutations (Melvin and Speer, 2006). This may partly assist to unravel the mystery behind
complex traits (Botstein and Risch, 2003). However, the relationship between Mendelian and
complex disease is blurred (Badano and Katsanis, 2002). It is mainly because of the
challenges that genes involved in complex diseases put in forth which include locus
heterogeneity, epistasis, low penetrance, variable expressivity and pleiotropy and limited
statistical power (Lander and Schork, 1994, Risch, 2000). It includes diseases such as
schizophrenia where the claims of linkage studies have been extremely difficult to verify
(Glazier et al., 2002). Different approaches have been used to elucidate the mechanism
behind diseases mostly of which are based on the genetic markers present in the human
genes.
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2.4.1 Methods of identifying disease genes
Over the years, many methods have been developed for the identification of disease
genes. These include studies associated with a single gene and multiple genes involved in a
disease. Every method is unique and has shown success in identifying the disease genes for
Mendelian and complex diseases. Figure 2.9 shows the comparison between the methods
used to identify the genes causing a disease in the past and in the present. An important entity
is that current systems are automated versions of previously available methods. For example,
candidate gene methods were used earlier to identify the disease genes in vitro, but now the
system is automated and many in vitro candidate gene prediction tools exist (Oti et al., 2011).
Figure 2.9: Methods used for identification of disease genes in the past and recent present (McCarthy et al.,
2003).
2.4.1.1 Linkage Analysis
As discussed in the previous section, Mendelian diseases are fairly predictive whereas
it is tough to analyze the origins of a complex trait. Nevertheless, there was no general
method available until 1980 even for simple Mendelian diseases that could possibly correlate
changes in DNA with a disease (Botstein and Risch, 2003). The first ever genome-wide
linkage analysis using anonymous DNA polymorphisms was proposed in 1980 (Botstein et
al., 1980). Later on, linkage studies have been widely used to interpret the genetic basis of
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diseases. Linkage analysis depends on the inheritance pattern of widely spaced markers
across the genome and the diseases, in families with affected individuals (Botstein et al.,
1980). It is merely a one to one correspondence between genotype and phenotype in case of
Mendelian diseases such as Huntington and cystic fibrosis. But, it can fail in cases of large
cohorts involving heterogeneity or complex inheritance (Botstein and Risch, 2003). Linkage
studies have led to identification of the genetics behind many rare, inherited diseases.
However, limitations of linkage analysis includes identification of common genetic risk
factors and low resolution due to the limited number of cross-overs (Risch and Merikangas,
1996). Furthermore, it is not suitable for complex diseases unless the genotype-phenotype
correlation is robust (Terwilliger and Goring, 2000). Hence, the effectiveness of a method to
identify the genetics of diseases depends on its performance for complex traits.
2.4.1.2 Candidate gene studies
Candidate gene studies were used as an alternative approach for linkage studies to
improve the accuracy and coverage in gene prediction. These methods attempt to analyze the
association between disease and the variants in genes that may already have been reported in
being involved with a disease (Witte, 2010). Once a candidate gene has been identified, the
activities of protein products specific to the gene were studied (Botstein and Risch, 2003).
However, these methods tend to ignore most of the genome and hence miss the majority of
the causal regions (Hirschhorn et al., 2002, Lohmueller et al., 2003). It is therefore difficult
to predict the genetics of complex diseases which requires large scale testing by association
analysis (Risch and Merikangas, 1996).
2.4.1.3 Genome Wide Association Studies
Genome wide association studies (GWAS) are based on the ‘common disease,
common variant’ hypothesis (Manolio et al., 2009). They attempt to find disease association
by comparing common genetic variants in large number of affected individuals with those
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that of controls (Lander, 1996, Risch and Merikangas, 1996). The first large scale GWAS
was studied for seven complex traits by comparing the genomes of 2,000 individuals against
3,000 case controls (Wellcome Trust Case Control Consortium, 2007). GWAS analyses if a
specific allele within a marker is associated with a disease or not, unlike linkage analysis
where the marker is analyzed for association (Mayeux, 2005); and performs better than the
above two methods overcoming their weakness to deliver definitive results for common
diseases (Wellcome Trust Case Control Consortium, 2007, Witte, 2010). While linkage
analysis is the most powerful method for identifying rare and risk alleles in Mendelian
diseases, genetic association analysis is considered to be the best method for identifying
genetic variants related to common complex diseases (Neale and Sham, 2004, Hirschhorn
and Daly, 2005). It has shown relatively a huge success and the past decade has seen a
dramatic increase in the utilization of association studies for different complex disorders
(Lander and Schork, 1994, Risch, 2000).
2.4.1.4 Success and limitations of GWA studies
The first wave of GWA studies successfully identified common variants and novel
loci associated with numerous polygenic diseases (McCarthy and Hirschhorn, 2008). These
include 32 for Crohn’s disease (Lettre and Rioux, 2008), 14 for prostate cancer (Easton and
Eeles, 2008), 15 for Type 2 diabetes (Mohlke et al., 2008) and 40 for height (Gudbjartsson et
al., 2008, Lettre et al., 2008, Weedon et al., 2008). It definitely improved our understanding
of the genetic basis of many complex traits (Wellcome Trust Case Control Consortium,
2007). However, these identified loci explain only a fraction of the inherited contribution,
whereas the remainder of variants, which are most likely to be associated with a disease,
remain unidentified. One of the limitations of GWAS has been the small effect sizes of loci
identified by them and the failure in identifying new loci for some diseases in a large sample
size (Moore et al., 2010). Several large scale GWA studies have been conducted over the past
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years and one of the most significant study was conducted by the WTCCC on seven complex
diseases (Wellcome Trust Case Control Consortium, 2007). However, far fewer genes have
been identified than anticipated and the translation of this knowledge into clinical trials
remains limited (Sanseau et al., 2012). Also, the genotype-phenotype association signals are
quite noisy and require multiple testing of large number of SNPs at the same time.
Automated candidate gene prediction systems have been used to re-analyze the noisy
GWA results to prioritize disease genes. As reviewed in Wouters et al (2011) many methods
have been developed solely to identify the disease genes from the signals identified from
GWA data. One such method is our in-house system, Gentrepid which predicts and prioritize
candidate genes (Ballouz et al., 2011). Currently, Gentrepid includes two methods-common
module profiling (CMP) and common pathway scanning (CPS) (Ballouz et al., 2011). Since
prediction of candidate genes depends on the annotations, it includes genes and gene products
annotations to prioritise the candidate genes. A number of bioinformatics tools, databases and
ontologies are integrated with the system. It includes Pfam for domain predictions, multicoil
for coiled-coil, SignalP for prediction of signal peptide and TMHMM for the presence of
trans membrane regions.
Candidate gene prediction methods identify potential gene candidates involved in a
disease using SNPs as markers. However, they use many SNPs to prioritize disease genes and
may include SNPs that are simply in linkage disequilibrium. At the molecular level, the
challenge still remains in identifying the significant nsSNP most likely to be associated with
the phenotype. Another generation of predictors has evolved over the last decade, at the
exome level, which are most likely to enable the identification of causal nsSNPs at the
molecular level.
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Chapter 3: Pathogenic predictors
Introduction3.1
Identifying functional SNPs is a major bottleneck in human genetics. GWA and
candidate gene studies predict more than a dozen SNPs from the association signals. But it is
unlikely that all the SNPs are causal and most of them would be simply in linkage
disequilibrium with the causal SNP. It is important to identify the actual causal SNP, which
may contribute to the phenotype. Evaluation of every individual SNP is impractical and
expensive too. In silico and exome sequencing bioinformatics methods are economical and
less labor intensive.
Association studies and candidate gene prediction tools are more genome and gene-
centric. In order to identify the causal SNP at the functional level, search space should be
narrowed to the molecular level. Hence informatics methods called pathogenic predictors or
amino acid substitution (AAS) methods were developed to distinguish harmful variations
from the harmless ones. They are in silico tools that are capable of analyzing multiple
variations simultaneously. They are cost effective as they are freely available online or to
download.
Unlike gross gene lesions, insertions, deletions or nonsense mutations, which affect
the length of a polypeptide, or translation process, nsSNPs and to a lesser extent missense
mutations, exert more subtle effects on protein’s structure and function. It is quite difficult to
predict the consequences of nsSNP because a single amino acid change may lead to multiple
effects (Thusberg and Vihinen, 2009).
nsSNPs associated with diseases tend to have characteristics different from the neutral
ones. The prediction of the consequences of these nsSNPs is a major research challenge as
the rapid growth of genomic tools has produced vast amount of information about genetic
variation among individuals (Steward et al., 2003, Mooney, 2005, Ng and Henikoff, 2006,
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Karchin, 2009). The pathogenicity of an nsSNP is determined by the degree to which it
affects the function of the protein. This in turn is influenced by the amino acid substitution
which is complicated by factors such as genetic background and the environment that
determine the severity of the phenotype (Stone and Sidow, 2005).
When amino acid substitutions change the physicochemical properties sufficient
enough to alter protein’s structure and function, they gain clinical attention (Krawczak et al.,
2000, Stone and Sidow, 2005). However, the most severe variations are likely to result in
lethal phenotypes that cannot be tolerated (Steward et al., 2003). In general, protein
molecules are tough and can tolerate minor alterations in the amino acid sequence (Poussu et
al., 2004, Pajunen et al., 2007). A nsSNP can be deleterious, if
a) it leads to disruption of a site that is directly involved in the function of a
protein (e.g. a catalytic residue, a residue involved in ligand binding, or that
forms a critical interaction with another protein), or
b) it causes destabilization of protein structure, leading to protein degradation, or
c) the amino acid substitution abolishes protein function because of loss of the
structural framework that enabled the functionality of the protein in the first
place (Wang and Moult, 2001).
Many different methods have been developed to facilitate detection of functional
SNPs from the neutral ones by applying a set of prediction rules based on either sequence or
structure. Most widely used predictors are listed in Table 3.1.
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These methods provide invaluable insight about the effect of a pathogenic variation
by utilizing various bioinformatics tools and databases to build their channel of prediction.
Primary information required by these methods is the gene, protein and variation data. All
these data are retrieved from major databases which are explained in detail below.
Databases3.2
Databases play a significant role in bioinformatics research driven towards
understanding the effect of mutations and the structural basis of diseases. All the mutations
and their related data dispersed throughout the literature are accumulated in these databases
in an organizational manner and they serve as primary information hub for research. There
exist more than 800 databases for human genetic variation but only few are more widely used
which are reviewed below (Johnson, 2009).
3.2.1 SNP databases
Storage of SNPs and their related data have vastly assisted the genetic studies linking
genetic and phenotypic variation (Sunyaev et al., 2001). The most widely used database is
dbSNP maintained by NCBI. It currently holds 89,232,381 human SNPs (dbSNP build 147;
genome build 38.2) mapped to the human genome (dbSNP, 2016). It is a comprehensive
repository for SNPs, short deletions and insertions. It is a freely available resource used for
various tasks such as mapping of variation to the genome, providing unique identifiers to
variations, estimating the functional effects of variants and population allele frequencies and
designing assays to measure specific variants (Johnson, 2009). The dbSNP variants are
mapped to the genome and included in the genome browsers such as NCBI, UCSC and
EMBL allowing easy integration of SNP information with other features of genome
annotation.
Another database of central importance in SNP world is the International HapMap
Project which holds ~1.6 million SNPs from 11 worldwide populations (phase III)
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(Consortium, 2010). The HapMap project compares the genetic sequences of different
individuals to identify chromosomal regions where genetic variants are shared and provides a
useful platform of population-based information for large-scale genetic association projects.
Similar to dbSNP, it also provides valuable information related to SNP variants in different
population groups including allele frequency, recombination rates, hotspots and reference
samples for genotype assay design and in vitro experiments (Consortium, 2010). The largest
public catalogue of human variation and genotype data is the 1000 Genomes Project, a seven-
year project which was recently completed sequencing the genomes of 2,504 people across
five continental regions capturing common and rare variation (Birney and Soranzo, 2015).
There are many other SNP databases aimed at characterizing variations such as
Japanese SNP database (JSNP) (Hirakawa et al., 2002), the ThaiSNP database, the Taiwan-
Han Chinese SNP database, SNP@ethnos (Park et al., 2007), the CEPH genotype database
and ALFRED (Rajeevan et al., 2003). However, many of these databases rely on or extend
upon dbSNP or HapMap (Johnson, 2009), ALFRED is most prominent amongst them
because it includes variants information from the most diverse sample encompassing  more
than 680 populations. Databases reporting on diverse samples have a variety of potential uses
including estimating expected population control frequencies for SNPs of interest, deriving
power calculations for SNP studies, and estimating population ancestry measures (Johnson,
2009).
3.2.2 Mutational databases
Another valuable resource in genetic research is the central mutational databases
(CMBD). CMBDs include disease-associated mutations and their related information such as
associated clinical phenotype, type of mutation and frequency of the allele. OMIM and the
Human Gene Mutation Database (HGMD) are two primary repositories for disease associated
mutations together containing >10,000 annotated disease genes (Steward et al., 2003).
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OMIM is a publicly available knowledgebase online resource which stores information about
genes and the genetic disorders combining expert curated summaries of the literature with
information on allelic variants and searchable by SNP identifier (OMIM, 2013). The
additional link to other genetic databases such as DNA and protein sequence, PubMed
references, general and locus-specific mutation databases, HUGO nomenclature, MapViewer,
GeneTests, patient support groups and many others make them a primary tool in terms of
molecular medicinal research (OMIM, 2013) .
On the other hand, HGMD is a comprehensive collection of germ-line mutations in
nuclear genes associated with inherited diseases. It includes cDNA reference sequences,
splice junction data, disease-associated and functional polymorphisms. It also provides links
to data present in publicly available online locus-specific mutation databases (Cooper et al.,
2006). It is not freely available for download unlike OMIM (for educational institutions) and
it requires a subscription.
Likewise, there are other genes specific databases called locus specific databases
(LSDBs), which are “a collection of sequence variants in a specific gene that causes a
Mendelian disorder or change in phenotype” (Cotton et al., 2008). There are more than 800
LSDBs, however most of them exists for cancer susceptibility genes such as BRCA1 and
BRCA2, MLH1 and MSH2, TP53, CDKN2A (Greenblatt et al., 2008). They are very useful to
study all mutations in a specific gene, since LSDBs generally have more mutations compared
to CMDBs (George et al., 2008). Conduit databases, such as HOWDY (Hirakawa, 2002),
MutDB (Mooney, 2005), Phencode (Giardine et al., 2007), SAAPdb (Cavallo and Martin,
2005) and KMDB/MutationView (Minoshima et al., 2001) which link information from
CMDBs, LSDBs, genome browsers and protein databases have emerged that integrate
clinical and phenotypic information with genomic data and information about the gene
product.
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Protein sequence resources such as Uniprot contain manually annotated protein
entries with information related to protein’s sequence and structure. Currently Uniprot
contains 550,960 protein sequence entries from five different taxonomies including bacteria,
viruses, archaea and eukaryote (Uniprot, 2016). Moreover, it provides cross-reference links to
other major sequence, structural, protein family, protein interaction, mutation, genome
annotation, enzyme & pathway and phylogenomic databases (Yip et al., 2008).
Most of the amino acid prediction methods retrieve information from the above-
mentioned SNP and mutational databases for their experimentation, prediction and validation
purposes. They retrieve disease-associated mutations, which are used as the test data; and
polymorphisms, which are used as control dataset. Hence, these databases serve as the
fundamental and building elements of molecular medicinal research. Without these
databases, it would be very strenuous to pool all the information and develop an automated
system.
In addition to these resources, current prediction systems use various features at the
sequence and the structural level to determine the pathogenic variant. An overview of
important features considered by most of the methods is reviewed in detail in further sections.
Protein properties considered for the evaluation of mutations3.3
Not all variations result in a disease or a phenotypic effect. It is important to
understand the properties or features that make a gene or protein resistant or susceptible to
causing a disease. Mutations causing Mendelian diseases confer radical changes to proteins
(Wang and Moult, 2001, Broeckel and Schork, 2004, Subramanian and Kumar, 2006). Many
differences have noted between disease-associated mutations and polymorphisms. Disease
associated mutations are located at structurally and functionally important sites such as <5%
solvent accessibility or in beta-strands, active sites, sites involved in disulfide bonds or
evolutionary conservation sites (Sunyaev et al., 2000). These mutations may affect protein
      

function through a number of mechanisms, such as changes in transcription, RNA processing,
protein expression, folding of the polypeptide chain, stability of the folded state, post-
translational modification, interactions with binding partners, and alterations to catalysis.
Below is an overview of few (but not limited to) structural and functional parameters
that could possibly be altered by the presence of disease associated mutations.
3.3.1 Sequence Conservation
One of the widely used features by AAS methods is sequence conservation. Disease
associated mutations are over represented at positions that are evolutionarily conserved for so
many years (Sunyaev et al., 2001, Mooney and Klein, 2002, Miller et al., 2003, Ng and
Henikoff, 2003, Briscoe et al., 2004) and are underrepresented at positions that are vulnerable
to change frequently (Miller and Kumar, 2001, Briscoe et al., 2004). Knowledge about
evolutionary conservation is valuable such that it provides insight on the role of a particular
residue on the protein’s structure and function. It also gives information about what amino
acid substitutions can be tolerated at a particular position without imparting any negativity on
the whole protein (Miller and Kumar, 2001). The physico-chemical properties of conserved
residues are required to maintain structural integrity and function of the protein. For example,
the hydrophobic residues located in core of a protein are highly conserved and these residues
can usually be identified in multiple sequence alignment (MSA). Any radical changes to
residues in this core would have a drastic impact on the structure and function. Porphyria,
caused by accumulation of uroporphyrins in the liver and plasma involves a Leu195Phe
substitution where a hydrophobic leucine is replaced by a large aromatic phenylalanine in the
hydrophobic core resulting in rearrangement of side-chains (Steward et al., 2003).
3.3.2 Physico-chemical properties
Some AAS methods evaluate properties of the wild-type residue and the variant when
analyzing conservation. Each amino acid has specific properties, which sets it apart from
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similar residues to make its continued existence favorable. It is important to understand the
positioning and properties of the 20 amino acids in the proteins as they direct us in
understanding many biological processes and characterize functional effects of mutations
(Pal et al., 2006). Biophysical and chemical properties such as hydrophobicity, size, and
charge and side chain composition are used as classification features for sequence based
methods. The Venn diagram below shows the fundamental properties of amino acids and
different groups to which each amino acid belongs (Figure 3.0). The amino acids in the same
group are more closely related and vice versa. A review of the literature showed that amino
acid substitution substantially occurs between physico-chemically similar residues (Sainudiin
et al., 2005). For instance, there is a higher probability of aromatic residues being replaced by
aliphatic residues of similar size such as Phe by Leu but not Trp to Val (Betts and Russell,
2003). Based on these properties, many prediction methods evaluate the physical and
chemical distance between the wild-type and the mutant residue.
Figure 3.0: Properties of amino acids.
Substitution of similar amino acids impacts less
than the chemically different amino acid (Betts
and Russell, 2003).
3.3.3 Substitution matrices
Prediction methods score the amino acid substitution based on the severity of the
amino acid change. In case of methods that use multiple sequence alignments, two categories
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of variations are predicted to be pathogenic—a) substitutions occurring at evolutionary
constrained position and b) substitutions found outside of the cross-species range of variation
(Tavtigian et al., 2008). A pairwise comparison of the biochemical and physical
characteristics of amino acids are computed along with the conservation. Position-specific
amino acid probabilities can alternately be derived from standard substitution matrices rather
than homologs of the protein in question. In such cases, different substitution matrices such
as Blosum62 (Henikoff and Henikoff, 1992), Grantham matrix (Grantham, 1974) and
PAM250 are used to quantify the amino acid conservation (Chan et al., 2007). PAM and
Blosum are derived from multiple sequence alignments of large protein sets where PAM is
based on the alignment of closely related sequences and Blosum is based on the alignment of
evolutionary divergent sequences. Blosum62 scores the amino acid substitutions based on the
frequency of occurrence of the residue at a particular position and ranges from -1 to +11 for
radical and identical changes respectively (Henikoff and Henikoff, 1992). On the other hand,
the Grantham matrix is a chemical index which designates a chemical difference between two
amino acid resides where the scores range from 5-215 for minor and critical substitutions
respectively (Grantham, 1974).
3.3.3.1 Structural features
Protein structural features are assumed to provide more detailed predictions, as they
tend to consider both internal and exterior features important for structural specificity and
functionality (Chasman and Adams, 2001, Sunyaev et al., 2001, Terp et al., 2002, Herrgard
et al., 2003, Stitziel et al., 2003). Structural features around the site of substitution are
generally used such as solvent accessibility, carbon-beat density, crystallographic B-factor
and the difference in free energy between the new and the old amino acid (Ng and Henikoff,
2006). The amino acid substitution prediction score is given based on the changes observed
for all the features observed above.
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In 2001, Wang & Moult compiled a set of rules to differentiate disease-associated
mutations from normal species variation. They evaluated structural and functional features
including protein stability, folding, ligand binding, catalysis, regulation by allosteric and
other mechanisms, post-translational modifications and the interactions such as hydrophobic,
hydrogen bond, van der Waals, electrostatic interactions and disulfide bonds (Wang and
Moult, 2001). Wang & Moult's dataset chiefly consisted of mutations resulting in Mendelian
diseases. In further work, Reumers et al. (2009) studied a set of 39 structural properties
including protein stability, aggregation propensities, H-bonds, Van der Waals contribution
etc. and demonstrated that none of these properties can solely differentiate the two datasets of
disease-associated mutations and polymorphisms that might play a role in complex diseases.
However, these features still play a role in differentiating disease-associated mutations from
the neutral variations.
3.3.3.2 Secondary structure
Secondary structure is one of the main classification feature used by the prediction
methods and its significance is highlighted in many studies (Ferrer-Costa et al., 2002, Khan
and Vihinen, 2007, Sitbon and Pietrokovski, 2007). Any change in the primary sequence may
alter the secondary and tertiary structure conferring an impact on the protein’s function.
Mutations in these structural components leads to destabilization of protein structure and they
harbor almost 80% of the disease causing mutations (Khan and Vihinen, 2007). The intensity
of casualty depends on the native and mutant amino acid, structural element and other
environmental features. For instance, secondary structure is composed of alpha helix, beta
strands and turns stabilized by hydrogen bonds. These individual elements have their own
preferences of amino acids and have distinct shape, flexibility and charge distribution. Any
unusual amino acid change that may subsidize essential features may be considered
damaging such as a mutation to a critical residue in a tight hairpin turn would result in loss of
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hydrogen bonds or absence of tight turn formation subsequently leading to structural
alterations (Khan and Vihinen, 2007). A normalized distribution pattern of amino acids in
each secondary structure element is given in the table below (Sitbon and Pietrokovski, 2007)
(Table 3.2).
Table 3.2: Distribution of amino acids in the secondary structure elements
Secondary Structure Element Amino Acid
Helix E, A, L, M, Q, K, R
Strands V, I, Y, C, W, F, T
Turns G, N, P, S, D
Helix Breakers P, G, Y, S
3.3.3.3 Stability
Stability is very significant for a protein to function normally. It is estimated that 83%
of disease-causing mutations affect protein function by disrupting stability. The major
stabilizing forces are hydrogen bonds and hydrophobic interactions. The stability of a protein
can be affected by loss of hydrogen bonds or salt bridge, reduced hydrophobic interaction,
over packing, buried charged or polar residue, disruption of metal binding, breakage of a
disulfide bond, electrostatic repulsion, backbone strain (Gly->X) and/or destabilization of a
protein multimer (Wang and Moult, 2001). For instance, L195F substitution in the
hydrophobic core of the protein leads to Porphyria, as a result of rearrangement of side-
chains (Steward et al., 2003). It is estimated that 83% of disease causing mutations affect
protein function by disrupting stability. The major stabilizing forces are hydrogen bonds and
hydrophobic interactions.
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3.3.3.4 Functional annotation
Substitutions at functional sites may have critical consequences for protein function
resulting in an organismal phenotype. These sites involve a catalytic residue or a residue
involved in ligand binding or binding to partner molecules. Substitutions at these sites are not
tolerated generally and can lead to a disease. Most mutations of this type are loss of function
mutations. Factor IX is required for control of coagulation and clot formation at the site of
injury. The catalytic domain of factor IX involves serine-histidine-aspartic acid triad.
Mutation of the catalytic serine (Ser) to arginine (Arg) results in the loss of enzyme activity
and a severe haemophilia phenotype (Koeberl et al., 1990). Some of the AAS can lead to
gain-of-function mutations. For example, missense mutations of R132 in IDH1
(OMIM*147700), an enzyme of the energy-producing TCA cycle alter the catalytic activity
of the enzyme resulting in different by-products and reduced production of NADPH.
Some methods include annotations as part of their prediction strategy (Sunyaev et al.,
2000, Sunyaev et al., 2001, Wang and Moult, 2001, Ferrer-Costa et al., 2002, Ferrer-Costa et
al., 2004). Sources of annotation include Uniprot, which contains annotation of residues in
the protein sequences such as if they are—located in the active site; or involved in ligand
binding; or part of a disulfide bridge; or involved in other protein-protein interactions
(Consortium, 2013). If the position of amino acid substitution is annotated at active site, then
the prediction is found to be deleterious.
      


Performance of prediction systems for variants in complex diseases3.4
Based on the features explained above, prediction methods score the pathogenicity of
substitutions. Although, they have proven to be an invaluable resource in helping to discard
passenger from driver mutations in the context of cancer, and in recognizing deleterious
mutations in a restricted benchmark set of Mendelian diseases, their usefulness and reliability
in the more subtle context of complex disease is unknown (Ng and Henikoff, 2006). Variants
involved in Mendelian diseases are likely to occur in conserved regions conferring major
alterations to the stability of the protein (Ng and Henikoff, 2006). On the contrary, variants
involved in complex diseases tend to occur in surface of proteins and in regions of less
conservation, and are most likely to be neglected by the current predictions programs (Ng and
Henikoff, 2006). Additionally, mutations can be segregated into loss-of-function (LOF) and
gain-of-function (GOF) mutations. Although most of the mutations identified so far are
LOFs, the number of identified GOF mutations is increasing and the performance of AAS
methods in relation to GOF is not usually discussed.
The aim of this study was to look at the prediction methods employed by current AAS
and how they might perform in not only distinguishing Mendelian mutations from harmless
variations, but in distinguishing polymorphisms associated with complex diseases from
neutral variants. Their performance was also evaluated in the case of GOF and loss-of-
function (LOF) scenarios. We also looked at how well the published benchmarks reflect the
true performance of the systems under these various scenarios by benchmarking several of
them against our own datasets. Three popular and widely used prediction programs—SIFT,
Polyphen and PANTHER were chosen. SIFT and Polyphen are widely recognized programs
and are incorporated in other tools and databases, whereas PANTHER claimed to
differentiate between GOF and LOF mutations. Hence, they were used to assess Mendelian
GOFs and GOFs associated with complex diseases. Their performances were compared by
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calculating sensitivity—the probability of identifying deleterious substitutions (TP/TP+FN),
where TP is the number of true positives and FN is the number of false negatives. Further,
these systems were then used to analyze GOFs in case of complex disease. 35 variants were
submitted to each of these prediction systems and their performance was assessed.
In conclusion, current prediction systems are more likely to correctly identify
pathogenic mutations of Mendelian inheritance and somatic mutations in cancer. They are
likely to make false predictions in calling variants of complex diseases.
This chapter is submitted for peer review in the Molecular Genetics & Genomic
Medicine journal—manuscript ID MGG3-2016-06-0068. A copy of this publication along
with the supplementary information is included here.
Reproduced with permission from Mohanasundaram, KA, Grover, MP, Crowley, TM,
Goscinski, A, & Wouters, MA. 2016. "In silico prediction of pathogenicity of missense
substitutions: the perspective for complex diseases".
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Abstract
Non-synonymous single nucleotide polymorphisms (nsSNPs) are single nucleotide
variations which occur in protein-coding regions of genes, substituting the wild-type amino
acid with a new one, thus altering the protein sequence. These substitutions may affect the
protein’s structure and function and are thus of great interest to the study of human diseases.
While cheap and quick sequencing of DNA, particularly exome sequencing, has allowed easy
identification of variations in the genes of individuals with a common phenotype,
distinguishing which variations cause the disease, and which are harmless, is not
straightforward. Here, we review computational methods for distinguishing pathogenic and
harmless variations. These amino acid substitution (AAS) methods can be classified roughly
as “site sensitivity” or “distance” methods. The techniques use bioinformatic and/or
physicochemical criteria derived from protein sequence and structure information to make
predictions. We look at their comparative performance on loss-of-function and gain-of-
function mutations; and discuss the employment of these methods for diseases of Mendelian
inheritance, cancer and also complex diseases, under both the rare variant and common
variant scenarios. Different methods are likely to be needed to understand complex diseases,
particularly under the common variant scenario, and we review efforts in this direction.
Keywords: non-synonymous SNPs, Mendelian diseases, complex disease, variants,
mutations, amino acid substitution methods, loss-of-function, gain-of-function
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1. Introduction
Genomes are not static entities but undergoing constant mutation in individuals, both
at the somatic and germline levels. Most of the variations introduced into a genome at the
molecular level have a neutral effect (Kimura, 1968, King and Jukes, 1969), but some can
effect a gene’s expression or its protein products. A non-synonymous or missense variation
occurs in the protein-coding region of a gene resulting in an amino acid change in the final
protein product. A non-synonymous variant which is common in the population may only
subtly alter protein function. When the change has more drastic phenotypic consequences, the
variant is generally termed a ‘mutation’. Most alterations that are deleterious will eventually
be eliminated through purifying negative selection. However, beneficial mutations can sweep
though the population and become fixed, thus contributing to species differentiation and
fitness.
In this review we confine our observations to non-synonymous single nucleotide
variations (nsSNPs). The human population is estimated to have 67,000-200,000 common
non-synonymous SNPs, and each person is thought to be heterozygous for 24,000-40,000
nsSNPs (Cargill et al., 1999, Halushka et al., 1999, Livingston et al., 2004). Understanding
how an individual’s genetic complement contributes to their susceptibility to disease is crucial
to the future of medicine and the development of therapeutics in precision medicine.
Most of the non-synonymous substitutions that have been mapped to phenotypes in
humans are recorded in two databases—Online Mendelian Inheritance in Man (OMIM)
(Hamosh et al., 2005) and The Human Gene Mutation database (HGMD) (Stenson et al.,
2014). HGMD professional (version 2014.4) includes 163,670 mutations, of which 72,633 are
single nucleotide variations (missense variations) that are either disease-associated or
functional polymorphisms (https://portal.biobase-international.com/hgmd/pro/stat1.php).
These databases mostly contain information about disorders caused by genetic changes that
 

follow Mendelian inheritance, which reflects historical progress in delineating these
relationships in medical research.
Based on the large variation between individuals and the fact that nsSNPs change the
protein machines that comprise and animate an organism, it is likely that non-synonymous
changes also play an important role in complex diseases. Complex diseases are polygenic
disorders caused by genetic and environmental factors. They generally do not follow
Mendelian rules of inheritance, although some rare familial forms or phenocopies of complex
diseases have been identified. To distinguish the genetic and environmental components of a
phenotype, the heritability of complex diseases is estimated by studies of identical twins. For
example, the heritability of Alzheimer’s disease (OMIM#104300) is estimated at 58-79%
from twin studies, but less than 25% of cases have detectable patterns of familial inheritance.
Patients with an early-onset form of the disease, constitute less than 5% of cases of
Alzheimer’s. In these rare early-onset subphenotypes, mutations in the genes PSEN1
(OMIM#607822), PSEN2 (OMIM#606899) and APP (included in OMIM#104300), which
are inherited in a Mendelian-dominant fashion, phenocopy the late-onset form (Gatz et al.,
2006). Salt-sensitive, low-renin hypertension is another example of an early-onset
subphenotype caused by rare mutations with Mendelian inheritance phenocopying the more
common complex form of the disease known as essential hypertension (OMIM#145500)
(Gordon, 1995).
Two models of complex disease have been proposed to explain the genetic
component—the common disease, rare variant (CDRV) hypothesis, and the common disease,
common variant (CDCV) hypothesis. The rare variant hypothesis posits that DNA variations
with minor allele frequencies less than 0.5% contribute to the disease (Bulmer, 1971,
Pritchard and Cox, 2002, Manolio et al., 2009, Schork et al., 2009). In the common variant
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hypothesis, it has been proposed that variations with minor allele frequencies of greater than
5% contribute to disease, based on the existing knowledgebase of diseases like Alzheimer’s.
Recently, progress has been made in identification of loci associated with complex
phenotypes using Genome-Wide Association Studies (GWAS). These population-based
studies compare the genomes of individuals with the phenotype of interest with a similar
number of matched controls. The original GWAS utilized high-throughput SNP chips with
500,000 SNPs with minor allele frequencies >5%, and thus assumed the CDCV model. Since
the publication of the first major study in 2007 (Wellcome Trust Case Control Consortium,
2007), GWAS have fuelled rapid growth in the identification of novel loci associated with
complex diseases. However, the cumulative heritability of the loci identified by these studies
is much lower than the heritability estimated by twin studies. This might suggest that the
original assumptions underlying GWAS were incorrect. For example, the rare variant model
(CDRV) may be more important than current data indicates; or allelic differences other than
SNPs, such as copy number variants, may encode a major genetic component of complex
diseases (Manolio et al., 2009). Alternately, the original assumptions underlying GWAS may
be correct and the failure of these experiments to yield the expected bounty derives from the
poor signal-to-noise ratio of this data (Ballouz et al., 2011, Ballouz et al., 2013). This is
supported by the success of meta-analyses which have identified further loci in much larger
study groups (Evangelou and Ioannidis, 2013).
Current data suggests that complex diseases are more genetically heterogeneous than
previously appreciated; and that only a handful of the responsible loci has been identified
while many more remain undiscovered (Manolio et al., 2009). The picture that is emerging is
that hundreds of genes may collectively contribute to the development of a complex
phenotype.
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1.1. Nature of variants at the nsSNP level
Once a locus is identified, the next problem is to find the causal SNP, or other
variation, in the region. The actual SNP identified by the GWAS may be the causal SNP, or it
may be simply be in linkage disequilibrium with the causal SNP.
Computational methods for distinguishing pathogenic SNPs from bystanders in
linkage disequilibrium, called amino acid substitution (AAS) methods, have been developed
over the last ten years. They have had some success in identifying pathogenic mutations in
cancer and in Mendelian diseases. Before applying these methods ad hoc to the study of
complex phenotypes, it is worth reflecting on the nature of the variants likely to be involved
in complex disease.
The term ‘mutant’ has historically been used for a novel or uncommon substitution,
whereas a ‘variant’ may be fixed in the population and therefore common. Such a binary
classification is artificial, and nsSNPs more likely constitute a spectrum between the two
extremes (Figure 3.1). Some examples serve to illustrate the difference. Somatic nsSNPs that
lead to cancer are more clearly mutations. ‘Limited’ mutations that result in embryonic or
early death before reproduction also clearly fall into the mutation category. Both of these
types of mutations are under negative selection. Mutations associated with rare Mendelian
diseases are also towards the left of the spectrum shown in Figure 3.1. These include the point
mutation in the haemoglobin β gene where the wild-type glutamic acid residue is substituted
by a valine (E6V), resulting in sickle cell anaemia in homozygotes (Wishner et al., 1975).
Heterozygotes for E6V have higher resistance to malaria. Diseases with more complicated
patterns of inheritance fall somewhere in the middle of the spectrum, until finally true variants
that are common in the population and functionally neutral, are encountered at the other end
of the spectrum. Somewhere in the middle are variants that are fixed in the population, but
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segregate with common complex diseases, with rare variants likely to be to the left in Figure
3.1 compared to common variants.
Figure 3.1: The spectrum of different types of nsSNPS and their likely impact on protein function.
Most of the rare mutations and cancer mutations fall to the left most extreme, where the nsSNP has a
large impact on protein function. Most of the variants fall to the right of the spectrum.
An early study of the most deleterious nsSNPs showed they affect protein stability, not
functionality. The nsSNPs studied were mostly associated with diseases of Mendelian
inheritance (Wang and Moult, 2001). Later studies have shown that while Mendelian
mutations are more likely to abrogate function, they can be segregated into loss-of-function
(LOF) and gain-of-function (GOF) mutations. The majority of Mendelian mutations
characterized to date are LOF mutations associated with decreased stability of the protein
product. Increasingly, GOF mutations are being characterized (Supplementary Figure 3.1).
One reason that GOF mutations were discovered later and are currently thought to be less
prevalent in Mendelian diseases is that they are more difficult to detect with standard assays
of protein function. For this reason some GOF mutations were originally thought to be LOF
mutations because the assay was designed to detect a specific aspect of protein function
whereas the actual function is more complex and not completely captured by a single assay.
GOF mutations are generally appreciated first at the phenotypic level, and further assays may
need to be developed at the molecular or in vitro level to appreciate the nature of the change.
GOF mutations may be hypermorphic, where the activity of the wild-type protein is
increased through some mechanism; or neomorphic, where the protein develops some new
activity. Hypermorphic GOF mutations can be associated with duplication of the gene. For
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example, it has been shown that patients with Axenfeld-Rieger malformation due to FOXC1
duplications have a more severe prognosis for glaucoma development than patients with
FOXC1 mutations (Strungaru et al., 2007). GOF mutations may also be associated with
premature termination of the protein sequence. For example, heterozygous mutations in
ASXL1, the obligate regulatory subunit of a deubiquitinase complex result in premature
truncations and is often associated with myeloid leukemias and Bohring-Opitz sybdrome. It
has been shown that the truncated ASLX1 with its catalytic subunit BAP1 results in enhanced
activity of the complex resulting in a GOF mutation (Balasubramani et al., 2015). Although
many null mutations, where a stop codon is substituted for that of amino acid, result in loss of
protein and haploinsufficiency ie a LOF phenotype—if the protein is successfully produced,
the presence of some of the domains without modifier domains can result in a GOF
phenotype.
Here we confine our discussion to more subtle GOF mutations resulting from nsSNPs.
A GOF phenotype may arise by disrupting an interaction with an inhibitory or modifier
protein or domain, resulting in constitutive activity of the protein. An example is the T337S
mutation in NLRC4 which results in autoinflammation with infantile enterocolitis (Boisson et
al 2015). An example of a suite of neomorphic GOF nsSNPs are missense mutations of R132
in IDH1 (OMIM*147700), an enzyme of the energy-producing TCA cycle. Mutations of
R132 alter the catalytic activity of the enzyme, resulting in different by-products and reduced
production of NADPH. Most enzymes of the TCA cycle catalyse reactions in both directions.
Wild-type IDH acts as a ratchet in the TCA cycle, catalysing production of isocitrate from α-
ketoglutarate (α-KG) by reduction of NADP+ to NADPH—one of the few irreversible
reactions in the TCA cycle. Mutant IDH preferentially catalyses a reverse reaction to produce
the novel metabolite 2-hydroxyglutarate (2HG) from α-KG via conversion of NADPH to
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NADP+ (Dang et al., 2009). In the case of multifunctional proteins, the distinction between
neomorphic and hypermorphic phenotypes may be blurred.
1.1.1. Nature of variants in complex disease
Several studies suggest that human genetic variants involved in complex diseases are
likely to be associated with more subtle alterations to protein function that defy classification
as ‘good’ or ‘bad’.
One study showed that SNPs associated with different patterns of inheritance occur in
different regions of protein sequence and structure. nsSNPs associated with Mendelian
diseases mostly occur in highly conserved regions of the protein; whereas most nsSNPs,
which would include neutral and mild functional variants, occur on the surface of proteins,
which is known to be less conserved than residues buried in the interior (Ng and Henikoff,
2006). This is an important difference because, as will be discussed below, conservation is
one of the important variables on which many pathogenic prediction programs are predicated.
An evolutionary study of nsSNPs based on the ratio of non-synonymous substitutions
in codons to synonymous substitutions (Ka/Ks ratios) showed that nsSNPs associated with
Mendelian diseases are under negative selection, whereas nsSNPs associated with complex
diseases are under greater positive selection. When substitution scores from hidden Markov
models (HMMs) of the protein families in question were also considered, nsSNPs associated
with complex phenotypes were indistinguishable from “normal” human variation with these
metrics (Thomas and Kejariwal, 2004).
As for the E6V allele of β-haemoglobin in the context of malaria, and the ∆F508 allele
of CFTR in the context of tuberculosis (Poolman and Galvani, 2007), mutations associated
with complex diseases may confer fitness on an individual in some situations and leave them
susceptible to disease in others.
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Polymorphic variants likely relate to two slightly different functional states. In this
sense variants associated with complex disease are likely to resemble subtle GOF mutations.
For example, some proteins that bind to multiple protein partners employ disordered regions
of the polypeptide sequence that fluctuate through a restricted set of multiple conformational
states, enabling them to bind promiscuously, but exclusively, with a specific set of protein
partners. TP53 is such a protein. LOF mutations in TP53 lead to loss of its tumor suppressor
function. GOF mutations in TP53 cause it to act as an oncogene (Oren and Rotter, 2010). But
because TP53 binds multiple partners, individual GOF mutations may alter the protein’s
function in different ways. In other words, while LOF mutations generally reduce protein
function, GOF mutations selectively “enhance” one of the protein’s functions, usually at the
expense of its other functions. In its simplest form this “enhancement” may render a
switchable protein constitutively active. In more complicated scenarios, such as TP53, which
competitively binds multiple protein partners, one of the protein’s functions may be enhanced
by increasing its affinity for one of its protein partners. Each binding partner ‘selects’ a
specific state of the disordered region during the binding process. The time a disordered
region of a protein spends in each state may influence which of its binding partners is
successful in competitive binding of such regions. Different polymorphisms may favour one
interaction over another (Mello and Attardi, 2013).
Alternatively, the full differential consequences of a variant may only be apparent in a
specific epistatic context. For example, several diseases are associated with methionine
variants of genes which may undergo a reversible post-translational oxidative modification.
These include the V129M variant of the ‘prion’ protein PRP and the V358M variant of α1-
antitrypsin SERPINA1. Unlike valine, methionine is susceptible to oxidation. Thus smokers
with the V358M variant are more susceptible to chronic obstructive pulmonary disease
(COPD, emphysema) and individuals with the V129M variant of PRP are more susceptible to
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Creutzfeldt-Jakob disease (CJD). Variants of the genes which reverse oxidative modifications
of methionine by reduction (MSRA, MSRB2) can potentially act as modifiers of these
diseases in the context of oxidative stress. For example, the c.1A>G variant in MSRA
encoded by rs10903323 is associated with CAD and rheumatoid arthritis (Gu et al., 2013,
Zhang et al., 2013).
This means that calling functional variants may be a far more difficult game for
complex diseases than for Mendelian diseases, or for cancer.
2. Methods of AAS Prediction
A bevvy of AAS prediction methods have been developed over the last ten years,
driven by the onslaught of high-throughput methods of sequencing (Ng and Henikoff, 2006,
Tavtigian et al., 2008). All these methods performed well when applied to the datasets on
which they were developed, but as will be discussed later in benchmarking (Section 2.4),
because there is no gold standard in knowledge discovery, these datasets are biased or
selective for various reasons. Thus methods of benchmarking need to be continually revised
as the field advances. These AAS methods are reviewed here in the light of our improved
understanding of the nature of the variants.
Typically, binary classification of AAS methods as “sequence-based” or “structure-
based”, based on the type of input information, is often used. Earlier studies of nsSNPs that
mapped to disease suggested two variables are paramount—the site of the substitution, and
the difference between the wild-type and the amino acid substituted. Here, we have
reclassified AAS methods based on these two important variables (Figure 3.2).
Methods that assess the site of substitution generally rely on bioinformatic information
in the form of multiple sequence alignments, but some methods that use structures to assess
site sensitivity also exist. Distance methods infer the difference between the wild-type and the
variant using sequence or structure. Hybrid methods that combine these approaches also exist.
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The general approach of these methods is described below. For details the reader is referred to
more extensive reviews such as Tavtigian et al. (2008), and Thusberg & Vihinen (2009).
Figure 3.2: Types of automated AAS assessment methods classified based on the variables taken
into consideration for identifying the pathogenic nsSNP. Some well-known examples are shown
on the right.
2.1. Site-sensitivity methods
Many site-sensitivity methods are purely informatic approaches with the underlying
assumption that well-conserved sites are more refractory or sensitive to substitution. These
methods can be either sequence-based or structure-based.
Sequence-based methods characterize site-sensitivity based on the primary sequence
of proteins alone. Typically, a multiple sequence alignment is built to determine the
conservation of the substituted site. A metric is then employed to measure the variation across
the site. The metrics employed can be sequence conservation or physico-chemical properties
of the amino acids at that position of the alignment. For example, SIFT uses blocks of
conserved regions in proteins (Ng and Henikoff, 2003); PANTHER uses a library of hidden
Markov models (HMM) (Thomas et al., 2003); Polyphen and SNAP use a position-
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independent count (PSIC) score (Bromberg and Rost, 2007, Adzhubei et al., 2010); PhD-SNP
and SNPs&GO calculate the sequence profile by using the BLAST algorithm (Capriotti et al.,
2006, Capriotti et al., 2013). The SNP receives a maximal score for pathogenicity if it falls in
the most highly conserved region, and lower scores in less conserved regions (Table 3.3).
Structure-based methods use the structural features of the protein around the site of the
substitution - for example, whether a residue is buried in the interior of the protein or not (Ng
and Henikoff, 2006). Other features which have been considered include stability, solvent
accessibility, difference in free energy, carbon-β density, crystallographic β-factor,
hydrophobicity and volume (Ng and Henikoff, 2006).
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2.1.1. Problems and pitfalls associated with site-sensitivity methods
One potential pitfall with site-sensitivity methods is that many of them rely on
accurate sequence alignments to make predictions. Sequence alignments cannot be reliably
generated in an automated fashion. Although many programs will do a reasonably good job
with most sets of sequences, the result is highly dependent on the input. Manual realignment
of a single problem sequence or subset of such sequences is often required. It is up to the user
to ensure that the alignment is accurate.
The difficulty in aligning protein sequences arises from their biochemistry. Proteins
consist of a linear polypeptide chain of amino acids, i.e. a sequence of amino acids. However
this linear sequence folds into a three-dimensional structure that partly consists of globular
structures called domains, and partly looser structures that link domains together in various
ways. These linkers may be—rigid like stalks, or—loose like tethers; and they may span
membranes, or be decorated with chemical modifications. These modifications include
signalling molecules such as phosphates; carbohydrates—which may acts as bumpers, fending
off interactions with other proteins; and lipids—which may anchor a loose part of the protein
in a membrane. In general, globular domains are more easily aligned than linker regions.
However, even within globular domains, misalignments can occur, particularly when one of
the sequences contains an inserted sequence of ten amino acids or more in length (Tavtigian et
al., 2008): an occurrence that is relatively common, and is often due to insertion of
retrotransposon elements in the genome. The issues encountered in sequence alignment arise
from the underlying multiple alignment algorithm (double dynamic programming). To avoid
gross errors, alignments can be cross-checked against pairwise alignments which do not suffer
from the same algorithmic limitation.
Suspect sequences that are likely to be incorrectly aligned and thus are suitable
templates for cross-checks are often shorter or longer than other sequences in the alignment.
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Aside from the common systematic error of misalignment, large enough numbers of
sufficiently diverse sequences must be used in the sequence alignment to reduce the
uncertainty in the result, which is typically not quoted in the output of these programs. Other
considerations that affect the accuracy of the sequence alignment relate to the number and
type of sequences used in the alignment. Most experts in the field agree that only orthologous,
and not paralogous, sequences should be included in the alignment.
How valid is the assumption that pathogenicity is inversely related to sequence
conservation? As active sites, binding sites and allosteric sites are more highly conserved than
other regions of proteins, site-sensitivity methods are likely to call mutations in these
important functional sites correctly. However, other important functional sites such as post-
translational modification sites and disordered regions are less likely to be conserved and may
not be called correctly. For this reason, evolutionary conservation methods such as SIFT
exclude disordered regions because they are not highly conserved and tend to have more false
positives in their predictions (Saunders and Baker, 2002). However, approximately 20-25% of
disease-causing mutations has been mapped to disordered regions (Vacic et al., 2012).
In particular, it has been shown that nsSNPs causing Mendelian diseases occur at
highly conserved positions but those in complex diseases shows a dramatically different
pattern, indistinguishable from normal variation (Thomas and Kejariwal, 2004). This suggests
that AAS methods designed for Mendelian diseases will not necessarily work well for
complex diseases.
2.2. Methods that calculate distance between the wild-type and variant/mutant
Distance-based methods calculate the distance, or difference, between the wild-type
and substituted amino acid. They may be sequence-based, structure-based, or use a
combination of sequence and structure-based information. For example, Bongo, a structure-
based prediction method, identifies key residues in the protein structure and calculates the
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difference in residue-residue interactions between the wild-type and mutant protein. Purely
distance-based methods are very rare, as most methods tend to use site-sensitivity combined
with the difference calculated between the wild-type and mutant. These ‘hybrid’ methods are
described below (section 2.3).
2.2.1. Problems associated with distance-based methods
Sequence-based methods mostly use generic metrics such as substitution matrices (eg
BLOSUM, GRANTHAM) to estimate the effect of a substitution. Thus the context of the
substitution is generally not taken into consideration. An exception is PHD which uses a
window-based method to incorporate the effect of adjacent residues in the calculation (Rost
and Sander, 1993).
Structure-based distance methods are intended to provide more insight into the amino
acid substitutions that influence the protein’s function, such as whether the affected residue
lies on the interior or the exterior of the protein structure (Ng and Henikoff, 2006). While
these methods do take the properties of an amino acid into account in a general way, the
specific function of a particular amino acid is not addressed. For example, mutation of a
lysine that forms a salt bridge may have quite a different effect on protein function than
mutation of a lysine which is ubiquitinated. These differences are likely to be particularly
relevant for GOF mutations. For example, replacement of a phosphorylatable serine by an
aspartate can mimic phosphorylation, and result in a switchable wild-type protein being
converted to a protein that is permanently in an “on” state i.e. constitutively active, whereas
the effect of this substitution on a serine that is not phosphorylatable may be negligible.
2.3. Hybrid methods
Methods that use both distance and site-sensitivity as a measure to distinguish nsSNPs
can be termed hybrid methods. These methods may use different metrics for the site-
sensitivity and distance calculations.
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One of the best known of these methods is Align-GVGD (Tavtigian et al., 2006),
which is a sequence-based hybrid method. This method utilizes a physico-chemical score
derived from the Grantham matrix to score both the site-sensitivity, termed the variation; and
the distance, termed the deviation - hence the name GVGD. In the site-sensitivity calculation,
the variation in the Grantham score is calculated based on the amino acids observed at the
substituted position of the sequence alignment. In the distance calculation, the difference of
the Grantham score between the wild-type and the variant is calculated.
One example of a structure-based hybrid method is SNPs3D (Yue et al., 2006). This
method employs a support vector machine (SVM) method which builds a MSA for site-
sensitivity, and uses 15 structural predictors for calculating the distance between the wild-type
and the mutant. It uses an SVM-profile for the site-sensitivity calculation and an SVM-
stability model for the distance calculation.
2.4. Benchmarking
AAS tools have been benchmarked in several different ways. Firstly, it should be
noted that all of these systems have been benchmarked on the existing knowledgebase, which
largely consists of mutations characterized for Mendelian diseases. The performance of AAS
tools on complex diseases is largely unknown but will be explored in section 2.4.1.
Two approaches are generally adopted to benchmarking. One approach is to use
mutations annotated in major mutation databases such as HGMD, OMIM and Uniprot
(Hamosh et al., 2005, Magrane and Consortium, 2011, Stenson et al., 2014). These are also
known as general mutation databases (GMDs). Another method relies on several well-studied
genes with multiple mutations which have been curated in locus-specific databases (LSDBs)
(Cotton et al., 2008, Tavtigian et al., 2008).
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2.4.1. Problems with general mutation databases
A problem with GMDs is they contain many errors (Cotton et al., 2008). The
information they contain is generally gleaned manually from the medical literature by
curators. Aside from curator input error, problems with non-standard nomenclature can result
in the wrong amino-acid being annotated (Cotton et al., 2008).
2.4.2. Problems with using LSDBs
As LSDBs are manually curated by research groups specializing in the gene of interest
they are usually more accurate than general mutation databases. They also give more specific
information about the phenotype associated with the variant, as well as the behaviour of the
variant in functional assays (Cotton et al., 2008).
A problem with this approach is that the genes which have been used for
benchmarking AAS methods against LSDBs are not representative of genes in general.
Although over 700 LSDBs exist (Cotton et al., 2008), only a handful have been used for the
purpose of benchmarking these methods. The reasons for this selective approach are not clear.
Most of the chosen genes are tumor suppressors in cancer (Table 3.4). Because many of the
mutations which arise in cancer are somatic rather the germline, these genes are very
mutation-dense which may be one reason for their choice. However many other genes, such
as keratins, have been extensively annotated in LSDBs. Why these genes have been
overlooked in the benchmarking process is not clear. Genes which have been used that are not
tumor suppressors include the enzyme tyrosinase (TYR), in which multiple mutations result in
the easily identified phenotype of albinism (Chan et al., 2007); and MECP2, a transcriptional
repressor in the brain. As MECP2 is on the X chromosome, the disease-causing alleles are
dominant, resulting in mental retardation in females (Amir et al., 1999), again an easily
identified phenotype.
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Most of the mutations in the genes studied were loss-of-function (LOF) mutations. For
LOF mutations, the protein generated from the mutant allele has a lower or negligible
function compared to the wild-type. An exception to this is TP53, in which both LOF and
GOF mutations have been characterized, but these were not distinguished in the benchmark.
Even within the limited set of genes with specific functions that result in LOF scenarios the
tools did not behave consistently. For example, the tools behaved quite differently on the
tumor suppressors versus the enzyme.
Within the limited set of tumor suppressors, the AAS programs were quite successful
in distinguishing harmless variants from pathogenic mutations. For example, a total of 92
variants in the CDKN2A tumor suppressor gene was studied in two sets. The first set included
31 germline variants in which 25 were associated with familial melanoma or a related
syndrome, and six were neutral variants. The second set had 80 variants (including 19 variants
from the first set), in which 41 showed wild-type activity and 39 had loss of function (Chan et
al., 2007). The results also agreed with functional assays for cell cycle arrest, cdk binding and
protein stability.
The focus on a small set of genes of limited function is of concern because the general
class of a gene’s function may also be important in calling a variant. Cancer is a good
example. In addition to the tumor suppressors, another group of genes that are mutated in
cancer, oncogenes, are involved in growth and proliferation. These genes are usually
associated with GOF scenarios. As discussed in section 1.1, GOF scenarios can arise from
nsSNPs when there is an amino acid substitution that disrupts an interaction with an inhibitory
protein or modifying domain. GOF phenotypes can also arise if these proteins contain
molecular switches which are transiently activated during growth and proliferation in the
wild-type gene. Mutations that change the protein activation status can accelerate growth and
proliferation.
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Table 3.4: Comparative performance of methods on mutations in genes from LSDBs
Gene Function Molecular
phenotype
Method Ref
SS Distance Hybrid
CDKN2 Tumor
suppressor
LOF ** *** * C
MLH1 Tumor
suppressor
LOF *** * ** C
MSH2 Tumor
suppressor
LOF *** ** * C
MECP2 Transcriptio
nal repressor
LOF ** *** * C
TYR Enzyme LOF *** ** * C
BRCA1 Tumor
suppressor
LOF ** * *** G
BRCA2 Tumor
suppressor
LOF ** * *** G
TP53 Tumor
suppressor
LOF+GOF *** ** ** H
The performance of methods is rated according to the overall predictive score. Data summarised from Chan et al.
(2007) – C, Goldgar et al. (2004) – G respectively and Hicks et al. (2011) – H: Site sensitivity (SS) – SIFT and
MSA and mathematical model as described in Abkevich et al. (2004); Distance – BLOSUM 62 and Grantham
matrix score (GMS); Hybrid – Align-GVGD & Polyphen and conservation, GMS, co-occurrence and
cosegregation.
2.4.3. Comparative performance of AAS methods on GOFs Vs LOFs
Existing prediction systems have primarily been benchmarked on the existing
knowledgebase which is heavily biased towards either diseases of Mendelian inheritance or
somatic mutations of cancer. In cancer, two different types of somatic mutations are
distinguished: Loss-of-function mutations (LOFs) and Gain-of-function mutations (GOFs),
which have very different mutation patterns and phenotypic consequences. Mendelian
mutations, which generally involve loss of function or stability, behave as LOFs. In previous
benchmarks of AAS systems, these two types of mutations were not distinguished and we
were interested to discover if the performance of AAS methods was different on LOFs and
GOFs.
In order to assess the tools in the light of some of the variables of importance
discussed above, we assessed the performance of three of the most popular AAS methods on a
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list of 158 LOFs and 99 GOFs from different genes (Supplementary Table 3.1). The methods
used were: SIFT and PANTHER—sequence-based site-sensitivity methods; and Polyphen2—
a sequence and structure-based site-sensitivity method. Of these methods, PANTHER is the
only method which attempts to distinguish LOFs and GOFs. We compared the performance
of these three methods by calculating the sensitivity, the probability of identifying deleterious
substitutions (TP/TP+FN), where TP is the number of true positives returned by the method,
and FN is the number of false negatives. The errors in these calculations were estimated as
fluctuations (Table 3.5). When compared with the benchmarks provided by the authors, both
Polyphen and SIFT performed as expected on LOFs (Chan et al., 2007). For example, the
sensitivity of SIFT on LOFs in our dataset was 0.81, slightly lower than the value of 0.83
quoted by Chan et al. (2007) in their benchmark. But for GOFs, SIFT’s performance was poor
(0.48 in this study Vs 0.83 in Chan et al). Polyphen’s performance was just a little below the
predicted sensitivity in the previous study for LOFs (0.81 in this study Vs 0.83 in Chan et al.
(2007)), and its performance for GOFs was even lower (0.74), but it still outperformed SIFT
on GOFs. To within the error PANTHER’s performance was the same for LOFs and GOFs
(0.6) within the errors expected. However it predicted fewer true positives than Polyphen2 for
both types of mutations. Although PANTHER did not perform as well as SIFT on LOFs, it
predicted GOF mutations better than SIFT.
Table 3.5: Comparative performance of AAS methods on GOFs and LOFs
SIFT POLYPHEN PANTHER
LOF GOF LOF GOF LOF GOF
TP (AFFECT) 128 48 142 74 86 41
FN (TOL) 30 50 16 25 58 25
Sensitivity 0.81±0.07 0.48±0.11 0.8±0.07 0.74±0.10 0.59±0.05 0.62±0.15
The performance of SIFT, Polyphen and PANTHER on LOFs and GOF. The list of LOFs and GOFs are
summarised in the Supplementary Table 3.1 & 3.2.
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We found most systems were far better in predicting LOFs than GOFs, with SIFT’s
performance on LOFs being indistinguishable from random guessing. This result in not
unexpected given they were designed and, in some instances, trained on data from Mendelian
diseases. PANTHER, which specifically aims to distinguish LOFs and GOFs as part of its
prediction method, was the only method with consistent performance across the two types,
although it was significantly less able to predict LOFs than the other systems tested.
We also hypothesised that complex diseases might more closely resemble cancer in
having variations that could either enable or disable organismal biology, but in a more subtle
fashion than in somatic mutations in cancer. Rather than having a major effect on a single
gene, as is the case in diseases of Mendelian inheritance, variations in complex disease are
likely to have an effect at higher levels, for example, in the dynamic range of signalling
pathways. Combinations of alleles that alter the output of signalling pathways in either a LOF
or GOF manner may predispose to disease. If this is the case, it will be important to
distinguish LOFs and GOFs since it will be the cumulative effect of multiple variations that
will determine whether an individual is predisposed to the disease. For example, if LOFs and
GOFs are scored negatively and positively respectively. The scores for the allelic
complement of a pathway of interest in a healthy patient who has some disease-associated
SNPs might “cancel” each other out, while the allelic complement in another patient might
cumulatively contribute to a higher risk. The number of cumulative disease-associated SNPs
may also contribute to the age of onset of a disease.
Given that variants involved in complex disease are likely to be subtle GOF mutations,
the performance of these systems in calling pathogenic variants in complex disease is also
likely to be poor. Although sufficient data does not exist to test this hypothesis rigorously, we
used all three programs to call pathogenic mutations in the PCSK9 gene linked to
hypertension (Supplementary Table 3.1 & 3.2). Of the 35 variants submitted, SIFT predicted
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16 were pathogenic (S=0.48±0.15) while Polyphen2 predicted 24 (S=0.68±0.14) and
PANTHER predicted 16 (S=0.55±0.15). In both cases, the performance of SIFT and
Polyphen2 on mutations involved in a complex disease was slightly worse than on Mendelian
GOF mutations, in line with expectations. In the case of PANTHER, nine variants were not
predicted as these did not align well in the alignment and hence of the 26 variants it was able
to call, PANTHER predicted 16 were pathogenic (~0.61). In line with its performance on
other benchmarks ie its performance was more robust regardless of whether the nsSNPs were
Mendelian or complex, LOF or GOF.
Thus, the performance of the three systems tested on complex diseases was either the
same as (SIFT) or worse (Polyphen/PANTHER) than the performance of the same system on
GOFs. In the case of SIFT, this was no better than random guessing. Without further data, it
is not possible to ascribe the poor performance of the AAS systems in the context of complex
diseases to any particular failure but possible differences between the variants in complex
disease and those in Mendelian disease could be the prevalence of more GOF variations in
the data, or may be due to a threshold effect ie the systems can tell the difference between
gross mutations found in Mendelian diseases and neutral variants but cannot distinguish more
subtle variations implicated in complex disease and neutral variants.
In summary, current sequence-based AAS methods are more likely to correctly
identify pathogenic mutations in phenotypes of Mendelian inheritance and somatic mutations
in cancer that involve loss of function (tumor suppressors). In particular, it is likely that
harmful mutations in complex diseases will be missed by the current suite of programs. The
genes that have been selected for benchmarking these tools, highlight the best they are
capable of. They are likely to be blunt instruments in distinguishing variants that are involved
with complex diseases. Although it is likely that the current suite of programs can be
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improved, in light of the variables mentioned above, further data mining is required to better
elucidate the molecular basis of disease-causing mutations.
3. Future directions for complex diseases
Although GWAS investigating the genetic basis of complex diseases have been
published over the last eight years (Wellcome Trust Case Control Consortium, 2007). Very
few authors have sought to address how applicable these AAS methods are to predicting
causal variants in complex diseases. More insights may be obtained by drilling down into the
data rather than taking a “one size fits all” approach.
Context is clearly important in determining the pathogenicity of a variant. Current
structure-based methods tend to call mutations to interior residues as pathogenic and surface
mutations as neutral (Ng and Henikoff, 2006). For example, the β-globin E6V mutation is
incorrectly predicted to be benign by Polyphen. This is because the structures of most proteins
are solved in homogeneous solutions whereas proteins in vivo interact with numerous binding
partners. However, unless the protein is solved in complex with the relevant binding partner,
no conclusions can be drawn about whether the variant will influence interaction with other
proteins. Mutations to particular amino acids may have differential effects depending on the
environment and context.
Unfortunately, past attempts to include context have not been successful in these
generic tools. For example, inclusion of sequence annotations does not significantly improve
prediction results, as methods which include annotations as part of their prediction scheme
perform the same way as evolutionary information-based methods. For example, the use of
Swiss-Prot annotation reduced the false negative rate by 1.6% but increases the false positive
rate by 2.1% (Ng and Henikoff, 2006). Other tools that incorporate annotation include
SNPeffect (Reumers et al., 2006) and PON-P (Olatubosun et al., 2012), which use multiple
bioinformatic tools to predict the effects of a SNP. SNPeffect analyses structure and
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dynamics, functional sites and cellular processing using tools such as FoldX, Phobius, Tango,
Catalytic Site Atlas and Psort II; whereas PON-P integrates the results from AAS methods
such as Polyphen, SIFT, PhD-SNP and SNAP and outputs the final prediction. To assess if
these context assessment tools were any better than standard AAS methods, we used PON-P
to analyse our GOF and LOF mutations and the set of mutations for complex phenotypes. For
LOFs the sensitivity was 0.58±0.07 compared to 0.48±0.1 for GOFs, while the performance
on complex nsSNPs was 0.24±0.20. In other words, as originally concluded by Ng &
Henikoff, these methods are still no better than standard AAS methods. This is likely due to
the sparsity of these annotations which are likely to improve in time, but they currently do not
represent better solutions to pathogenicity prediction.
More general methods for including protein context are needed. In an approach which
differentiated mutations in intracellular, extracellular and transmembrane (TM) regions of G-
coupled receptors, a huge family of signalling proteins, disease-causing mutations were
overrepresented in TM regions (Balasubramanian et al. 2005). The study on G-coupled
protein receptors as mentioned above, showed that inclusion of the context specification in the
prediction method increased the accuracy score from ~70% to ~89% (Balasubramanian et al.
2005).
As regions involved in protein-protein interactions have been flagged as important for
complex diseases, non-globular protein contexts such as disordered regions may be especially
important contexts for mutations in complex diseases. Methods that specifically address
protein-protein interactions are needed. Similarly, many mutations in coiled-coil regions have
been recorded and methods which include this important protein-protein interaction context
are required. As a step in this direction, we have recently searched for differences between
disease mutations and polymorphisms using in silico modelling (Mohanasundaram et al.
2016).
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Ultimately all predictions of the effects of nsSNPs must be underpinned by functional
assays. Computational studies of the likely functional consequences of nsSNPs can reduce the
amount of time and money spent on individual experiments and help design experiments and
functional assays to further explore the molecular impact of nsSNPs.
4. Conclusions
Most existing AAS methods attempt to call whether an amino acid variation is
pathogenic or not. In the context of LOF mutations in cancer and rare Mendelian diseases,
they often allow genetic researchers to distinguish between pathogenic mutations and
harmless bystanders. Current AAS methods perform less well when confronted with GOF
mutations. These methods are essentially untested in calling variants in complex disease and
should be use with caution in this context.
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Discussion3.7
3.7.1 Categorization of Amino acid methods
Critical view on AAS methods has been one-dimensional, with most of the reviews
and research directed towards the binary classification of these systems—structure or
sequence based. This classification tends to be superficial as it is based on the input features
considered to evaluate the pathogenicity and not the underlying assumption. Hence
algorithmic classification of existing amino acid substitution methods as explained in this
chapter is more intuitive. For example, in a binary classification, prominent methods such as
SIFT and Polyphen would fall in two different categories—sequence-based and structure-
based respectively. In the current binary classification, both these methods fall in the site-
sensitivity category. It is because both these methods investigate the parameter “site” and
check if the substitution would be tolerated at that particular position. While SIFT uses
evolutionary information to calculate its prediction score, Polyphen uses structural properties.
Algorithmic sorting of AAS methods resulted in majority of the methods grouped under
either site-sensitivity or hybrid methods. This indicates that purely distance-based methods
may not provide compelling results when used alone. This categorization is critical in this
field because researchers tend to use more than one method to predict pathogenicity of an
nsSNP. This sort of review would help them in choosing appropriate method for their
analysis.
3.7.2 Performance of AAS methods
Most of the systems successfully distinguished Mendelian mutations from harmless
variants but were far less successful at distinguishing variants in implicated in complex
disease from supposedly neutral variants. One of the reasons is the discrepancy of datasets
these prediction systems are built upon. AAS methods use two categories of variants—
variants of Mendelian inheritance and neutral variants. These neutral variants come from
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databases such as Uniprot, dbSNP and HGMD, laboratory mutagenesis experiments and
proteins where many variations have been characterized. Incidences of false positives and
false negatives in these cases are high (Ng and Henikoff, 2006). Whether the so called neutral
variants stored in databases are actually neutral or a polymorphism is not known. Another
group of neutral variants come from mutagenesis experiments. These variants identified from
laboratory experiments could have an effect on protein function and may require appropriate
environmental conditions to reveal phenotypic effects (Ng and Henikoff, 2006). Therefore
standard and accurate sets of neutral variants are required for building prediction models.
Additionally, methods are required to be trained on common variants in addition to
rare and neutral variants. This will escalate the performance of current prediction systems.
However, the amount of data relevant to common variants associated with diseases in
published databases is minimum to negligible. As there is no central database available for
such information, researchers are required to search many scattered resources (Mooney,
2005). This may be one of the reasons that these variants are neglected as it requires
significant time and tools to pool all the information together.
Furthermore, most of the systems are benchmarked against tumor suppressor genes
and genes that are extensively studied. As these data come from published resources, there is
high probability of these datasets to be part of their training and test data. This greatly
influences the overall performance of the prediction and might become a source of evaluation
errors. Because, if a predictor were evaluated using a dataset whose correct answers the
method had previously been provided with, this may yield unfair over-estimation of the
prediction capability (Izarzugaza et al., 2012). Therefore, it is highly important for these
systems to use a dataset that is not part of their training dataset for their benchmarking
process.
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Conclusion3.8
Current prediction systems were reviewed in three different aspects—underlying
algorithm, datasets used for benchmarking and their performance in case of GOF and LOF
scenarios. The majority of the methods employ bioinformatic or physico-chemical approach
to call pathogenic variants and tend to ignore the functional role of variants, which is critical
for assessing variants in case of complex diseases. This was clearly indicated by the
performance of three important prediction programs—SIFT, Polyphen and PANTHER in
GOF and LOF scenarios. Systems that included annotation as part of their prediction
performed the same way as other standard methods. Therefore, it was hypothesized that
context of the variations may be important in determining the pathogenicity of a variant as
shown previously by Balasubramanian et al. (2005).
Results also implied that a balanced dataset is vital to increase the veracity of current
systems. This includes training data, test data and the benchmarking data. In particular,
training data should include information on common variants.
Most existing AAS methods are untested and not applicable in calling variants in
complex diseases. They do not consider context of the resident protein and are more likely to
make false predictions. In case of rare Mendelian diseases and cancer mutations, these
systems are often able to distinguish between pathogenic mutations and harmless bystanders.
Current AAS methods perform less well when confronted with GOF mutations, thus
indicating the necessity of more sophisticated tools.
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Chapter 4: Analysis of variations in functional domain
Introduction4.1
Current prediction systems are predicated on data from Mendelian diseases. So
extrapolation of these data to complex diseases is not useful. For example, Reumers et al.
(2009) studied a set of 39 structural properties including protein stability, aggregation
propensities, H-bonds, Van der Waals contribution etc. and demonstrated that none of these
properties can solely differentiate the two datasets of disease associated mutations and
polymorphisms. To highlight the difference between disease mutations and polymorphisms, a
context-specific analysis evaluating variations in less conserved functional sites/motifs such
as disordered regions, post-translational modifications (PTM), coiled-coil regions and signal
peptides is required.
Existing informatic approaches ignore less conserved regions such as disordered
regions, although mutations in disordered regions have been mapped to diseases. Disordered
regions are associated with important biological functions such as post-translational
modifications, molecular recognition and assembly, binding to other proteins, RNA and DNA
(Dunker et al., 2002, Tompa, 2002, Iakoucheva et al., 2004, Dyson and Wright, 2005,
Radivojac et al., 2010). They are irregular structures that do not fold into regular three-
dimensional structure. They are usually more than 30 residues long found in ~40% of
proteins (Pentony et al., 2010). They differ from regular protein structures in amino acid
composition, sequence complexity, hydrophobicity, aromaticity, charge, flexibility, and type
and rate of amino acid substitutions over evolutionary time (Uversky et al., 2008).
In spite of their low conservation rate, they are known to be involved in number of
human diseases such as cancer, cardiovascular disease, amyloidoses, neurodegenerative
diseases, and diabetes (Uversky et al., 2008). A study by Vacic & Iakoucheva (2012)
demonstrated that about 20-25% disease mutations were mapped to dis-ordered regions.
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These disease mutations were enriched in domains and functions associated with DNA
binding motifs (homeobox, zinc finger, basic motif), transmembrane domains, sites of post-
translational modifications, disulfide bond formation, and triple helical regions, which are
often found in cytoskeletal and coiled-coil proteins (Vacic and Iakoucheva, 2012).
The site-sensitivity sequence based method SIFT disregards disordered regions and
tends to have more false positives when variants in such contexts are analyzed (Saunders and
Baker, 2002). Both the predictors SIFT and Polyphen had their sensitivity reduced by 10%
when mutations in disordered regions were analyzed (Vacic et al., 2012).
Some of the current prediction programs include protein annotations to determine the
pathogenicity of a variation along with other features. However, they are not extensive
enough to improve the prediction results, because they do not evaluate the functional role of
variants. This may also be due to the sparsity of these annotations. However, a study by Ng &
Henikoff (2006) showed that use of Swiss-Prot annotation reduces the false negative rate by
1.6% but increases the false positive rate by 2.1%.
4.1.1 Analysis of mutations in coiled-coil regions
Given the importance and role of considering contexts in improving the performance
of prediction systems, mores studies should be directed towards this analysis. As a step in this
direction, role of variations in the oligomerization domain “coiled-coil” was analyzed in this
chapter. Coiled-coil domains were chosen because they are abundant and, like dis-ordered
regions, they are actively involved in protein-protein interactions, making variants likely
candidates for disease states. Additionally, large scale analysis of mutations in coiled-coils
has never been studied unlike disordered regions and subcellular localizations.
Mutations in coiled-coil regions are often associated with both monogenic and
polygenic disorders. Mutations in intermediate filament proteins (proteins with a large α-
helical rod domain flanked by non-helical segments such as keratin, lamin) cause a variety of
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rare but frequently devastating diseases that include monogenic disorders such as severe skin
fragility, myopathies, neurodegeneration and premature ageing (Magin et al., 2004) and
polygenic disorders like liver and inflammatory disease. Mutations in other proteins are
associated with developmental phenotypes like primary ciliary dyskinesia (PCD), where
coiled-coils are required for correct left-right patterning of cilia (Becker-Heck et al., 2011).
For the analysis, proteins annotated with coiled-coil domains were retrieved from
Uniprot (Magrane and Consortium, 2011). Two sets of variations were used for this study –
DM and PY from two popular databases—Uniprot (Magrane and Consortium, 2011) and
Human Gene Mutations Database (Cooper et al., 2006). Only missense mutations and
polymorphisms present in the coiled-coil regions were analyzed. In order to compare the
stability of the coiled-coil between wild-type and the variant protein sequences, a specialized
tool called Multicoil was used (Kim et al., 1997). The probability of the protein forming a
coiled-coil is referred to as the oligomerization score. 841 DMs in 51 proteins and 1,275 PYs
in 401 proteins were used for this study.
The impact of these two variants on the coiled-coils was analyzed in various structural
parameters including stability, oligomerization state and the discontinuity. Statistical tests for
each analysis were performed to analyze the difference between DMs and PYs.
Results indicated that coiled-coil regions were more frequently associated with
pleiotropy than other proteins in general. A clear distinction was seen between the amino acid
frequencies of DM and PY in coiled-coil proteins and those that in all proteins in Uniprot and
between the DM and PY in the coiled-coil regions themselves. This shows that context is
important in assessing the impact of variants and in distinguishing disease mutations and
polymorphisms. In general, disease mutations were inclined to be more destabilizing than
polymorphisms.
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This chapter is provisionally accepted for publication—manuscript ID humu-2016-
0180 in the peer reviewed journal Human Mutation – Variants, Informatics and Disease. A
copy of this publication along with the supplementary information is included here.
Reproduced with permission from Mohanasundaram, KA, Grover, MP, Crowley, TM,
Goscinski, A, & Wouters, MA. 2016. "Mapping the genotype-phenotype associations of
nsSNPs in coiled-coil oligomerization domains in the human proteome".
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Abstract
We assessed the impact of disease mutations versus polymorphisms in coiled-coil
domains in Uniprot by modelling the structural and functional impact of variants in silico
with the coiled-coil prediction program Multicoil. The structural impact of variants was
evaluated with respect to three main metrics: the oligomerization score—to determine if the
variant is stabilising or destabilising; the oligomerization state, and the register-specific score.
The functional impact was queried indirectly in several ways. Firstly, we examined
marginally stable coiled-coils that were either stabilized or destabilized by the variant.
Secondly, we looked for variants that altered the register of the wild-type coiled-coil near
wild-type irregularities of likely functional importance, such as skips and stammers. Thirdly,
we searched for variants that altered the oligomerization state of the coiled-coil. Disease
mutations tended to be more destabilizing than polymorphisms; but interestingly,
polymorphisms were more frequently associated with predicted changes in the
oligomerization state. The functional impact was also queried by testing the association of
coiled-coil variants with multiple phenotypes i.e. pleiotropy. Mutations in coiled-coil regions
of proteins cause 155 different phenotypes and are more frequently associated with
pleiotropy than proteins in general; and importantly, the coiled-coil region itself often
encodes the pleiotropy.
Keywords: single nucleotide polymorphisms, coiled-coil domain, disease mutations, lamin
A, complex diseases, point mutation, missense mutation, pleiotropy
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1. Introduction
The completion of human genome sequencing and breakthroughs in genotyping
technologies have extensively progressed research investigating the molecular basis of
disease. A primary goal of human genetics is to identify causal variants underlying inherited
diseases and their associated phenotypes.
Recent advances in population-based discovery techniques such as genome-wide
association studies (GWAS) are yielding novel genetic loci for complex diseases by testing a
large number of SNP markers for disease association in cases versus matched controls.
GWAS conducted for almost 1,128 traits in 1,961 different studies have successfully
identified new loci associated with diverse phenotypes, with almost 13,849 SNPs and 16,933
loci now recorded in the National Human Genome Research Institute (NHGRI) catalogue
(Welter et al., 2014). However, GWAS are less powerful in deciphering complex diseases
than originally anticipated. In pioneering studies in this area, only a handful of SNPs reached
statistical significance for each phenotype, individually contributing a low risk (Wellcome
Trust Case Control Consortium, 2007). Cumulatively, the SNPs identified do not account for
the heritability of the phenotypes estimated through twin studies (Manolio et al., 2009),
suggesting that complex diseases are more heterogeneous than previously appreciated. Any
hope that GWAS would provide a magic wand to “crack” complex diseases has given way to
a more realistic appreciation that they have significantly advanced the field but much remains
to be accomplished.
Due to its high throughput nature and its underlying complexity, our ability to
interpret this GWAS data has not kept pace with its generation (Manolio et al., 2009, Ballouz
et al., 2011). The significant SNPs identified in GWAS may not be causal but merely in
linkage disequilibrium with the causal SNP (Goldstein, 2009). However, they do allow
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accurate identification of an involved locus. With the advent of exome sequencing, the reach
of high-throughput genetic analysis has extended from the gene level down to the nucleotide
level. The output of these systems consists of multiple variants within the exome examined.
Computational prioritisation of coding SNPs, in accordance with their functional significance
within the large sets of candidate genes scanned, can help differentiate causal SNPs from
harmless variants.
Understanding the effect of mutations and variations on protein function is not
straightforward. While several tools for assessing amino acid substitutions (AAS) have been
developed to distinguish pathogenic mutations from harmless genetic variations; many of
these knowledge-based systems are predicated on data from Mendelian diseases, reflecting
historical progress in delineating the genotype-phenotype relationship. Similarly, in cancer
research there is a need to distinguish harmful driver mutations from passenger mutations that
have little to no effect on the course of the disease. AAS methods have proved their value in
calling the pathogenicity of the somatic mutations that occur, particularly in tumor suppressor
genes in cancer (Chan et al., 2007). However, predictions by these AAS methods may not
translate well to interpretation of disease-associated variants in complex diseases, where the
variants have small contributions to the disease and their effects may be quite subtle
(Mohanasundaram et al., submitted to Human Mutation).
Furthermore, even if these methods are useful in predicting if a SNP is pathogenic,
they are not helpful in defining the cause of its pathogenicity, as many of them only give a
binary output or a score predicting the impact of the substitution. With the number of SNPs
reported increasing every day, it is important to elucidate how a SNP affects the protein’s
function, particularly in a way that can be tested.
Several studies suggest mutations to particular amino acids may have differential
effects depending on their context. In an approach which differentiated mutations in
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intracellular, extracellular and transmembrane (TM) regions of G-coupled receptors—a huge
family of signalling proteins, disease-causing mutations were overrepresented in TM regions
(Balasubramanian et al., 2005). These regions are responsible for transducing the signal
across the membrane, and may interact with components of the lipid membrane, as well as
other proteins embedded in it. This study on G-coupled receptors showed that consideration
of the context increased the accuracy of the prediction method from ~70% to ~89%
(Balasubramanian et al. 2005). Similarly, in a study of disease-causing mutations in
disordered regions, the authors noted that these regions are specifically excluded from
consideration by AAS prediction programs like SIFT (Ng and Henikoff, 2003) because of the
atypical behaviour of mutations in these regions (Vacic and Iakoucheva, 2012), again
suggesting that context is important.
In this work, we adopted a bioinformatic approach to ask whether harmless
polymorphisms are distinguishable from those likely to be pertinent to the phenotype in
question in the specific context of coiled-coil domains. Coiled-coils are twisted rope-like
structures present in many protein complexes. We chose coiled-coil domains because, like
disordered regions, they are involved in important protein-protein interactions. In addition,
they are very common structural subunits in proteins.
1.1. The nature of coiled-coils
Coiled-coil regions are found in over 2,000 genes of the human genome (Yip et al.,
2008) such that 0.9% of all protein residues form coiled-coils (Kim et al., 1997). Originally
characterised at the molecular level in fibrous proteins such as keratin, coiled-coils consist of
a twisted rope-like structure composed of bundles of α-helices (Crick, 1953, Pauling and
Corey, 1953). In proteins, the α-helices forming coiled-coils are most often found in pairs—
for example in intermediate filaments such as keratin; or to a lesser extent in trios— in
proteins such as fibrinogen; but structures with tetramers and pentamers have been observed
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(Moutevelis and Woolfson, 2009). Compound structures consisting of higher order
composites of multimers also form (Moutevelis and Woolfson, 2009). Coiled-coils have been
described in many other proteins containing rod-shaped domains such as intracellular
transport proteins (Burkhard et al., 2001); as well as cytoskeletal, nuclear, muscle, cell
surface, extracellular, plasma, bacterial and viral proteins (Kammerer, 1997).
Most coiled-coils are left-handed ie the α-helices twist around each other in a specific
direction. The sequence of each helix is comprised of tandem heptad repeats of amino acid
residues ie 7-residue repeats. Right-handed coiled-coils have also been observed in protein
structures, but are rare (Mason and Arndt, 2004). Because the α-helices themselves are chiral,
right-handed coiled-coils are formed by helices with 11-residue repeats, and will not be
considered further here.
For the purpose of classification, sequential residues in the heptad of a left-handed
coiled-coil are designated by a label from a to g, referred to as the “register”. Studies show
registers a & d are hydrophobic in character, while b, c, e, f and g are hydrophilic (Lupas,
1996). Specific interaction between helical elements is maintained by electrostatic
interactions imposed by polar residues at positions e & g (Mason and Arndt, 2004). Steric
effects also influence the register of the monomers through a distinctive packing of amino
acid side-chains between helices described as ‘knobs into holes’, where the sidechain of a
residue from one helix (the knob) packs into a space surrounded by four side chains in the 2nd
helix of the dimer (Crick, 1953). Hydrophobic packing and hydrophobicity within the
interface are contributing factors to the overall stability of a coiled-coil (Adamson et al.,
1993). These interactions are mediated by registers a & d. The orientation of the involved
helices may be either parallel or antiparallel, but is determined by packing specific to the type
of protein eg dimers of intermediate filaments are always parallel.
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The functions of coiled-coils are diverse. Proteins consist largely of globular domains,
but the polypeptide chain also contains linking regions that are less compact. These linkers
may be loose “disordered regions” which are dynamic in vivo; or more structural linkers,
such as coiled-coil regions, which may form stalks upon which globular domains rest,
anchored to the cell surface, or spacers between globular domains in soluble proteins. Within
proteins, coiled-coil regions act as major oligomerization domains, mediating dimerization
and other protein-protein interactions (Mason and Arndt, 2004, Lupas and Gruber, 2005).
Many transcription factors such as the basic region-leucine zipper (b/ZIP), b/HLH/ZIP, and
HTH-ZIP families, dimerize via coiled-coils domains and bind to different DNA sequences
based on the coiled-coil interaction specificity (Mason and Arndt, 2004). Thus, coiled-coils
act as molecular velcro: their long rod-like structures promote assembly to form mechanically
rigid structures such as hair, scales and feathers (keratin); the cellular skeleton (intermediate
filaments); extracellular matrices (laminin) and molecular stalks (nonfimbrial adhesins, viral
fusion proteins) (Rose et al., 2005, Parry et al., 2008). They provide scaffolds for regulatory
complexes, tethering factors (Gillingham and Munro, 2003); and a protective surface for
pathogens (Lupas, 1996).
1.2. Mutations in coiled-coil regions
Mutations in coiled-coil regions are associated with multiple diseases: their nature
depending upon the family of proteins and their functions. Mutations in intermediate filament
proteins—proteins with a large α-helical rod domain flanked by non-helical segments, which
have important structural roles, cause a variety of rare, but frequently devastating diseases.
Many of these mutations are documented in the human intermediate filament database
(Szeverenyi et al., 2008). Intermediate filaments such as keratin and lamin encode
phenotypes including monogenic disorders such as—severe skin fragility eg. epidermolysis
bullosa simplex (EBS, MIM:131900); myopathies, such as dilated cardiomyopathy 1A,
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caused by mutations in the lamin A/C gene (CMD1A, MIM:115200); neuro-degeneration—
encompassing Mendelian diseases such as Charcot-Marie-Tooth disease type 2B1 (CMT2B1,
MIM:605588), and complex disorders such as amyotrophic lateral sclerosis (ALS,
MIM:105400); premature ageing—which includes Mendelian disorders such as Hutchinson-
Gilford progeria (HGPS, MIM:176670) and atypical Werner syndrome (Orphanet:79474)
(Magin et al., 2004); and polygenic disorders like liver and inflammatory disease. Mutations
in other coiled-coil proteins are associated with developmental phenotypes like primary
ciliary dyskinesia (PCD, Orphanet: 244)—a genetically heterogeneous and autosomal
recessive disorder of cilia where correct left-right patterning of the embryo is disrupted
(Becker-Heck et al., 2011).
Coiled-coils have also been implicated in the disease aetiology of polyQ proteins
which contain multiple glutamate (Q) residues. In polyQ diseases such as Huntington disease
(MIM:143100), polyQ regions found in wild-type proteins are expanded at the nucleotide
level by CAG repeats; while CAA codons, which also encode glutamate, are rarely observed.
The generation of CAG repeats has been proposed to occur via DNA slippage and hairpin
formation during DNA replication (Strand et al., 1993). Coiled-coil regions are
overrepresented in nine polyQ proteins: including huntingtin and 3 ataxins; and their
interactomes. The coiled-coil regions tend to flank or overlap the polyQ region in the protein
sequence. The coiled-coil propensity of wild-type polyQ regions is not high, but tends to
increase strongly upon polyQ expansion (Fiumara et al., 2010), suggesting stabilization of the
naturally dynamic structures in a coiled-coil state may be important to the phenotype. Given
the role of coiled-coil regions as protein-protein interaction regions, stabilization of the coiled
coil state of the sequence may encourage interactions with a cognate protein partner.
Defects in coiled-coil proteins have also been associated with cancer. However, these
defects relate to wholesale reorganisation of genes and genomic regions rather than point
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mutations. For example, tyrosine kinases, which are typically activated by dimerization, are
constitutively activated by fusion with coiled-coil regions, creating oncogenes (Lupas and
Gruber, 2005). Amplification of genomic regions containing transforming acidic coiled-coil
(TACC) proteins, which stabilize centrosomal microtubules, can transform cells into cancer
cells. However as these changes do not involve point mutation to the coiled-coil region itself,
they will not be considered further here.
The location of disease mutations within the coiled-coil region also impacts the
phenotype at the protein and protein family level (Letai et al., 1992, McWhirter et al., 1993,
Liovic et al., 2001, Lo Giudice et al., 2006, Worman and Bonne, 2007, Fiumara et al., 2010,
Nishie et al., 2012). For example, Letai et al. (1992) showed that the effects of mutations in
the rod domain of keratins are more severe at the end of the domain than the internal
segments. The conserved end was more fragile, even to small perturbations, leading to a loss
of intermediate filament stability and disruption of normal cellular interactions. Substitution
of the wild-type amino acid with ‘helix-breaking’ proline residues in the central rod region
had less severe effects than those at the ends.
Some interesting phenotypic effects, in particular, highlight the deficiencies of current
in silico prediction tools which rely on simple informatic methods. In some cases, specific
mutations in coiled-coil domains are related to more than one phenotype, as is the case for
laminopathies, where multiple diseases arise from mutations in the lamin gene (Worman and
Bonne, 2007); and also in keratins (Corden and McLean, 1996). In these cases the epistatic
context of the mutation may be important. When changes in coiled-coil regions are subtle, in
vitro experiments may not always be able to mimic the cellular environment sufficiently well,
and the defect may only become apparent at the phenotype level. For example, the protein
may function normally until it is put under tension. Further insight into the effect of
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mutations in the coiled-coil region may be obtained with more detailed computational
studies.
Here, we performed a genome-wide study of variations observed in coiled-coil
regions of the human genome, comparing mutations that segregate with disease phenotypes
versus polymorphisms, to generate a genotype-phenotype correlation for coiled-coil domains.
We used bioinformatic tools that predict the presence of coiled-coil regions in proteins and
observed the effect of amino acid mutations and polymorphisms on stability and other
properties of the coiled-coil.
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2. Materials and Methods
We mined Uniprot (Magrane and Consortium, 2011) for proteins with coiled-coil
domains. Mutations were extracted from two online databases—Uniprot (Magrane and
Consortium, 2011) and The Human Gene Mutation Database (HGMD) (Cooper et al., 2006).
2.1. Protein Dataset
Coiled-coil proteins were obtained from Uniprot, a protein knowledgebase (release
2012_7). Two datasets of proteins were retrieved from this repository. The first set consisted
of proteins annotated with coiled-coil domains (CCP_UNIPROT). These were retrieved by
querying Uniprot with the keyword “Coiled-coil” (KW-0175), with the search restricted to
proteins from Homo sapiens (taxon identifier 9606). We downloaded the list of protein
identifiers for 2,387 coiled-coil proteins (CCP_UNIPROT) as well as the corresponding fasta
sequences and the gff file: a file containing annotations such as domains, natural variants, etc
for each protein. This file was used to retrieve the co-ordinates of the annotated coiled-coil
domain.
Because we were particularly interested in proteins containing variants, a second set
of proteins was derived from Hums_var.txt (release 2012_7) at
http://www.Uniprot.org/docs/humsavar, which lists all the variants annotated in Uniprot.
Proteins in the previous list CCP_UNIPROT were removed from this list. The remaining
10,956 proteins were analysed with the coiled-coil prediction program as described below in
detail. Proteins from a list of ~10,000 proteins with at least one predicted coiled-coil domain
formed the second dataset (CCP_VAR), which contained 524 proteins.
Both the datasets, CCP_UNIPROT and CC_VAR were combined, resulting in 2,911
unique protein entries (COILED_PROTEINS).
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2.2. Mutation Dataset
For the mutation dataset, we compiled the variation dataset from two repositories—
Uniprot and The Human Gene Mutation Database (HGMD) (Cooper et al., 2006). In both
databases, multiple variations of different types are listed for each gene along with any
associated disease. As the study is predominantly based on SNPs, variations associated with
single amino acid substitutions (missense mutations) were fetched. Two different mutation
variation datasets were used: disease mutations (DMs) and polymorphic variants (PYs).
The initial variation dataset, retrieved from the file Hums_var.txt in Uniprot,
contained a total of 66,720 missense variations in 12,392 proteins. The list of protein
identifiers from the COILED_PROTEINS set was compared with the identifiers in
Hums_var.txt, to include variations only from proteins with coiled-coil domains (1,958
proteins). Variations in this reduced list were categorised into three separate datasets:
polymorphisms (CC_PY, 6,802 PYs in 1,871 proteins), disease mutations (CC_DM, 2,767
DMs in 235 proteins) and unclassified (variations not yet classified as DMs or PYs—732 in
232 proteins). Only the DMs and PYs were included in our study. DMs in Uniprot are linked
with an Online Mendelian Inheritance in Man (OMIM) identifier (Hamosh et al., 2005),
whereas PYs have a Single Nucleotide Polymorphism Database (dbSNP) identifier
(Smigielski et al., 2000).
In addition, the online server of HGMD professional (version 2013.3 – 27th
September 2013) was used to retrieve variations to supplement the Uniprot set. In contrast to
Uniprot, HGMD includes all types of variations such as missense, nonsense, splice variants,
indels, gross deletions/insertions/duplicates, complex rearrangements and repeat variations,
totalling ~144,500 variations; of which missense and nonsense mutations constitute about
80,000. HGMD accepts many identifiers as input including Entrez gene names, OMIM or
dbSNP identifiers, HUGO gene IDs or symbols, chromosomal co-ordinates, HGMD
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accession or variant call format (VCF) identifiers. To submit the coiled-coil proteins retrieved
from Uniprot to HGMD, the Uniprot protein identifiers were converted to Entrez gene
identifiers with the ID mapping option in the Uniprot database (2,911 entries mapped to gene
ids). Since the inputs were gene ids, it was necessary to check in which isoform of the protein
the mutation variation was present. Sequences of all the protein isoforms were extracted and
the position of the variation was compared to this sequence to determine the exact isoform.
Gene entries were submitted to HGMD in batches of 500. Some gene entries were either not
present in HGMD (1,799); or had no missense mutations, even if they were reported in
HGMD (176). In total, we extracted 5,899 DMs in 485 proteins and 6,562 PYs in 305
proteins from HGMD.
The datasets from Uniprot and HGMD were compared to remove duplicates, and a
list of unique entries generated comprising 6,866 DMs in 540 proteins and 12,108 PYs in
1,948 proteins. These entries were then subjected to coiled-coil prediction analysis, and only
variations within the coiled-coil regions were considered further.
2.3. Coiled-coil Prediction
To identify coiled-coil regions and compare differences between the stability of the
wild-type and variant protein sequences, the popular coiled-coil prediction method Multicoil
was used. Multicoil utilizes a position-specific score matrix method to assign a likelihood-
like score of coiled-coil formation to each position of the input sequence. This score can be
decomposed into dimer and trimer probabilities that give an indication of the likely
oligomerization state of the sequence. (Kim et al., 1997).
2.3.1. Multicoil prediction: choice of threshold
Multicoil (Kim et al., 1997) was downloaded from
http://groups.csail.mit.edu/cb/multicoil/ and run on a linux server. Multicoil accepts single or
multiple protein sequences in fasta format. We submitted 157 disease-associated protein
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sequences in a single file. Multicoil predicts coiled-coils based on a threshold which can be
varied between 0 and 1. In order to choose an appropriate bound value for accurate prediction
of coiled-coil domains corresponding to the coiled-coil domains annotated in Uniprot,
Multicoil analysis was run for all bound values from 0 to 1 with a 0.1 step for all 157 wild-
type protein sequences for which disease mutations have been identified. This list of proteins
was extracted from the CC_DM list, which is annotated with coiled-coil domains in Uniprot
as well as with disease mutations. The regions predicted by Multicoil for each bound value
were compared with the annotated coiled-coil regions in Uniprot. The co-ordinates of the
coiled-coil regions annotated in Uniprot and those predicted by Multicoil were compared by
computing the residue difference between the start and stop sites. The best summed
correspondence occurred between an upper bound of 0.3 (∑∆Upper= 65aas) and a lower bound
of 0.2 (∑∆Lower=54aas). Thus the value of 0.25 was chosen as the threshold for coiled-coil
prediction instead of the default of 0.5. Using the chosen threshold of 0.25, not all proteins
annotated with coiled-coil domains in Uniprot were predicted to have coiled-coil regions by
Multicoil and vice versa (Supplementary 4.1A & 4.1B).
2.3.2. Multicoil prediction: extraction of disease mutant set
The 540 human proteins with 6,866 disease mutations (CC_DM) were analysed with
Multicoil. The co-ordinates of the predicted coiled-coil regions for each protein were
compared with the co-ordinates of each mutation to determine if the mutation lay within the
coiled-coil domain and only those proteins were considered for further analysis. Proteins with
polymorphisms (CC_PY) (1,948 proteins with 12,108 polymorphisms) were analysed
similarly. This resulted in 841 DMs in 51 proteins (CC_DM_MULT) and 1,275 PYs in 401
proteins (CC_PY_MULT). The output (.out) files for both the wild-type and mutations were
imported into Excel (Microsoft Corp) for comparison.
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2.4. Association of coiled-coil regions with Pfam domains
To assess representation of important functional domains that form coiled-coils in the
genome, proteins in CC_UNIPROT were analysed against the Pfam library of domains (Finn
et al., 2014). We were interested in noting which Pfam domains were co-incident with coiled-
coil regions of the genome, and which domains often occur as accessory domains to coiled-
coil regions. The fasta sequence was retrieved for each of the proteins from in CC_UNIPROT
and was submitted online to Pfam as a single file. Using the retrieved file, the co-ordinates of
the domain were compared with co-ordinates of the coiled-coil region annotated in Uniprot
for each protein. These resulting Pfam domains were categorized into two groups—the
coiled-coil group and the accessory group. The Pfam-coiled-coil group are domains which
are contiguous with the coiled-coil region. Pfam-accessory domains are found in proteins
with coiled-coil regions, but located outside the coiled-coil region. Similarly, proteins in
CC_VAR were also analysed and compared with the previous list to check the proteins with
coiled-coil domains not annotated in Uniprot. The results are shown in section 3.1.
Since we were particularly interested in the effect of variations in coiled-coils, we
filtered the results described above against the CC_DM_MULT (841 DMs in 51 proteins)
and CC_PY_MULT (1,275 PYs in 401 proteins) datasets to obtain domains harbouring
variations. The results are shown in section 3.2.
2.5. Tests of Pleiotropy
Based on the many instances of pleiotropy associated with DMs in coiled-coils, we
tested whether coiled-coil regions are more often associated with multiple phenotypes
compared to other proteins in the genome. 12,392 proteins with DMs extracted from
Hums_var.txt as described in section 2.2 were used. For each protein in Uniprot with variants
within the coiled-coil region, the phenotypes associated with the proteins were noted.
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We first checked whether multiple phenotypes were more likely to be associated with
proteins containing coiled-coils or not. The proteins in the dataset were partitioned in two
ways: firstly, on whether they did or did not contain a coiled-coil region; and secondly on
whether they exhibited pleiotropy, i.e. were associated with multiple phenotypes, or not. For
this test we did not require that the DM was inside the coiled-coil region. Fisher’s exact test
was performed on the resulting punnet.
In a second test, we wished to determine whether pleiotropy was a property of the
coiled-coil region itself. Proteins within the coiled-coil group with multiple mutations were
bi-partitioned based on: whether the multiple mutations resulted in pleiotropy; and the
location of the mutations—either within the coiled-coil region, or outside it. Fisher’s exact
test was performed on the resulting punnet. The results are shown in section 3.3.
2.6. Comparison of amino acid frequencies
To check if amino acid variations are context-dependent, we compared the
frequencies of variations in the coiled-coil domain versus global variations in the human
exome. For coiled-coils, variations from the CC_DM_MULT and CC_PY_MULT datasets
were used. For the rest of the human exome, 23,103 DMs and 37,046 PYs from Hums_var.txt
from Uniprot were used. In one test, we compared the observed frequencies of wild-type and
variant residues between DMs and PYs in coiled-coil regions versus the global frequencies of
these variations in the Uniprot database (CC-DM Vs Uniprot DM and CC-PY Vs Uniprot
PY). In another test, we compared relative frequencies of wild-type and variant residues
between the two groups. Relative frequency was calculated as the ratio of observed frequency
to the neutral frequency of an amino acid. The neutral frequency for each amino acid was
calculated as the summation of frequencies of each codon for that particular amino acid as a
function of the 64 possible codons, multiplied by the correction factor of 1.049 to account for
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the fact that only 61 codons code for amino acids. The frequency of each codon was
calculated by multiplying the frequencies of each DNA base comprising the codon.
A chi-squared test of significance was then performed to analyse the significant
variations between two groups. Coiled-coil frequencies were used as the observed frequency
and global frequencies as the expected frequency. Results are depicted in section 3.4.
Furthermore, we also compared the frequencies of variations in each register to check
if variations were register-dependent. In order to compare two unequal distributions, we
normalised the number of PY to number of DM. In one test we compared the normalised
registers as pairs (DM vs PY); while in a second test, we compared variations in each register
to the mean across all registers. We performed chi-squared tests to check if the distribution
and the deviations from the mean were significant. The results are shown in section 3.4.
2.7. Effect of variants on coiled-coils
To model the effect of variants on coiled-coil structures, Multicoil residue-wise scores
were compared for wild-type and variant sequences for proteins in the CC_DM and CC_PY
lists. Both local and more dispersed effects of the variation were considered. Initially,
pairwise-comparison of the oligomerization scores at the position of the variant was
performed between the wild-type and variant, determining the nature (stabilising or
destabilising) and size of the effect. To determine whether the effect of the variation was
widespread, we then analysed the difference between the Multicoil output for wild-type and
the variant residues over a range of window lengths, from seven residues to a maximum
length of 35 residues, centred on the residue of interest. We performed a normalised chi-
squared test as represented below to test the difference between these distributions.
χ2 = Σi(√P/DDi − √D/PPi)2/(Di + Pi) Eq. (1)
where, Di = Number of DMs, Pi = Number of PYs, D ≡ ΣiDi, P ≡ ΣiPi
The results are shown in section 3.5.
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The effect of destabilizing variants were further by distinguishing disruptive and
“mildly” destabilizing variants using the Multicoil prediction scores. As the threshold for
coiled-coil prediction used was 0.25, we classified any variations that resulted in the
probability of coiled-coil formation falling below 0.25 at the point of introduction in the
sequence as disruptive. We also calculated the probability of the two types of variation in
coiled-coil regions of varying stability using a bi-state classifier: positions where the
likelihood of coiled-coil stability of the wild-type residue was between —0.25 ≤ P < 0.8 were
designated semi-stable, whereas positions with P ≥ 0.8 were designated stable. We then
performed a chi-squared statistical test to determine if the PY and DM distributions were
different. Finally we investigated whether the two types of variants had differing effects on
changes of the stability of the coiled-coil with respect to the wild-type residue when
transitions between the three different stability states were considered: specifically stable
regions becoming semi-stable or unstable and semi-stable regions becoming unstable. A
normalised chi-square test was performed to compare the distributions and the results are
shown in section 3.5.2.
The effect of the variant on the oligomerization state was also noted. As Multicoil
predicts the oligomerization state as dimer or trimer for each position in the coiled-coil
sequence, the decomposition of the score was used to assess whether any variants were
predicted to change the oligomerization state of the coils by comparing wild-type
oligomerization scores to variant scores. The results are shown in 3.5.3.
We then investigated the effect of variations on register, both in regular coiled-coil
sequences and in sequences with conserved deviations from the heptad repeat. As Multicoil
predicts the likelihood of the register for every residue in the heptad repeat, we compared the
wild-type register with the variant register. We noted any differences and analysed the results
in two different tests. In the first test, we calculated the number of wild-type and variant
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registers that were altered. In the second test, we compared the registry changes as pairs,
performing a chi-squared test of significance to analyse the results. The results are shown in
section 3.6. Although coiled-coils are easily identified by their signature heptad repeat, some
irregularities shifting the register are highly conserved in native coiled-coils (refer to section
3.6.1 for more details). We looked for such irregularities in the wild-type coiled-coils and
compared the registers of the wild-type sequence with the variants. We classified the
resulting changes based on whether the wild-type irregularity was preserved or changed in
type or location. We also noted if variants introduced novel irregularities into wild-type
sequences with regular heptad repeats. All the results are shown in 3.6.1.
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3. Results
In this study, we analysed the structural and functional impact of disease mutations
(DMs) versus polymorphisms (PYs) in coiled-coil domains.
We evaluated the structural impact of variants with respect to three main metrics: the
oligomerization score—to determine if the variant is stabilising or destabilising; the
oligomerization state, specifically the likelihood of forming dimers or trimers; and the
register-specific score. Scores predicted by the coiled-coil prediction program Multicoil were
primarily used to compare the differences between wild-type and variant protein sequences.
The functional impact was queried indirectly in several ways. Firstly, we examined
marginally stable coiled-coils that were either stabilized or destabilized by the variant.
Secondly, we looked for variants that altered the register of the wild-type coiled-coil,
particularly in association with wild-type irregularities of the coiled-coil such as skips and
stammers, which may be of functional importance. Thirdly, we searched for variants that
altered the oligomerization state of the coiled-coil with respect to the wild-type. The
functional impact was also queried more directly by testing the association of coiled-coil
variants with multiple phenotypes ie pleiotropy.
3.1. Prevalence of coiled-coil proteins and domains
The 2,387 proteins annotated with coiled-coil domains retrieved from Uniprot
constitute about ~7% of the human genome and ~12% of the total human proteome when
different isoforms are included, as represented in Swiss-Prot (Magrane and Consortium,
2011). This value is in rough agreement with a previous estimate of 8-11% of all proteins in
humans (Liu and Rost, 2001, Peckham and Knight, 2009). Within these proteins, ~18% of the
amino acid residues form coiled-coil regions.
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A Pfam analysis was performed to determine which Pfam domains contain coiled-coil
regions, or are associated with them (Finn et al., 2014). We refer to these domains as the
‘coiled-coil group’ and ‘accessory group’ respectively. About 84% of the proteins with
annotated coiled-coil domains contained parsable Pfam domains, constituting a total of 1,059
unique Pfam domains. The remaining 16% of coiled-coil proteins contained no parsable Pfam
domains.
Approximately 45% of the unique Pfam domains were coincident with annotated
coiled-coil regions (Supplementary Table 4.1). The most highly represented Pfam domains in
this coiled-coil group were: the intermediate filament family (PF00038.16), CCDC144C
coiled-coil regions (PF14915.1), B-box zinc fingers (zf-B_box PF00643), putative golgin
subfamily A member 2-like protein 5 domains (GOLGA2L5 PF15070) and the microtubule-
binding stalk domains of the dynein motor (MT PF12777) (Figure 4.1A). Together these
constitute 17% of the counted domains, with 472 Pfam domains constituting the remaining
83%. Thus the recognizable Pfam domains which comprise the coiled-coil regions in the
human genome are highly diverse.
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Figure 4.1: Identity of Pfam domains in coiled-coil proteins (Finn et al., 2014) in proteins containing coiled-coil
regions: showing (A) the coiled-coil group in which the coiled-coil domain is contiguous with the named Pfam
domain; and (B) the accessory group in which the named Pfam domains is outside the coiled-coil region.
Groups found in more than 2% of proteins are represented individually, while the rest are combined in the
‘Others’ category. In total 4,509 parsable Pfam domains were found in coiled-coil proteins, of which 1,059 are
unique.
From a total of 1,059 unique domains, the remaining 581 Pfam parsable domains
(55%) formed the accessory group. The most highly represented Pfam domains in this group
were—the WD domain G-beta repeat (WD40: PF00400.27), a repeat of unknown function
(DUF1220: PF06758), the fibronectin type III domain (fn3: PF00041), and SPla and the
Ryanodine Receptor domain (SPRY domain: PF00622). Again, the accessory domains
associated with coiled-coil regions were highly diverse (Figure 4.1B), consistent with their
role as generic interaction domains.
3.2. Variations in coiled-coils by domain
Disease mutations mapped to a very limited set of Pfam domains. About 79% of the
DMs considered in our study were present in 10 unique Pfam domains contiguous with
coiled-coil regions which are listed in Table 4.1. The largest numbers of DMs were found in
Intermediate Filament (PF00038.16) and Myosin Tail (PF01576.14) domains. This is partly
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explained by the large number of these domains in the genome, as reflected by the
normalised values. This likely reflects the attention given to documenting and understanding
defects in these important structural proteins.
Table 4.1: Variants in coiled-coil Pfam domains
Domain Pfam Id No. of variants in coiled-coils Normalised Value
DM PY DM PY
Filament PF00038.16 441 175 3.47 1.38
Myosin_tail_1 PF01576.14 222 158 8.22 5.85
Tropomyosin PF00261.15 55 4 1.83 0.13
SMC_N PF02463.14 6 7 0.33 0.39
Dynamin_N PF00350.18 0 4 0.00 0.09
BBS2_N PF14781.1 1 0 0.14 0.00
AAA_11 PF13086.1 2 0 0.07 0.00
BBS2_C PF14782.1 1 0 0.14 0.00
BAR PF03114.13 1 0 0.03 0.00
Nsp1_C PF05064.8 1 0 0.20 0.00
CC2-LZ PF16516 8 0 2.00 0.00
Other - 180PY in 77D - -
Σ 738 528 - -
D-Domain; *Normalisation: Total number of variants/Total number of domains of that type in the genome.
PYs were annotated in 82 coiled-coil Pfam domains. Intermediate Filament and
Myosin tail domains was also prominent in this group.
3.3. Coiled-coils are associated with pleiotropy
In some cases, mutations in the same protein cause different phenotypes, a
phenomenon known as pleiotropy. DMs in coiled-coil regions of proteins cause 155 different
phenotypes as currently annotated in Uniprot and HGMD. These are listed in Supplementary
Table 4.2. Lamin A, an intermediate filament protein that has a structural role in the nucleus,
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is the best known of these pleiotropic proteins. Mutations within the protein-coding region of
lamin A may result in one of 58 phenotypes (Supplementary Table 4.3). Some instances of
pleiotropy occur in different domains of the same protein and thus can be explained by
abrogation of the function of the particular domain. For instance, most of the mutations of
lamin A associated with lipodystrophy phenotypes occur in the C-terminal immunoglobin-
like tail domain (Worman and Bonne, 2007). Of the 58 phenotypes associated with lamin A
to date, 31 phenotypes are associated with mutations of the coiled-coil region known as the
rod domain (bolded in Supplementary Table 4.3).
In a few cases, the same mutation is associated with two different phenotypes. For
example, a mutation in Keratin 17 (Uniprot Id: Q04695 with point mutation p.Arg94Cys), is
associated with either Type 2 Congenital Pachonychia (MIM: 167210) or Steatocystoma
Multiplex (MIM: 184500) (Covello et al., 1998). These are listed in Supplementary Table
4.4. The differential phenotypes of this single mutation may be associated with a different
epistatic context, or environmental effects.
Based on the many instances of pleiotropy associated with DMs in coiled-coils, we
tested whether coiled-coil regions are more often associated with multiple phenotypes
compared to other proteins in the genome. 12,392 proteins with DMs in Uniprot were
extracted and partitioned in two ways: firstly, on whether they did or did not contain a coiled-
coil region; and secondly on whether they exhibited pleiotropy, i.e. were associated with
multiple phenotypes, or not. For this test we did not require that the DM was inside the
coiled-coil region. The results are shown in Table 4.2A. The coiled-coil group with annotated
variations, consisting of 106 proteins or ~4% of the coiled-coil containing proteins in the
human genome as represented in Uniprot, were associated with 246 different phenotypes. 332
other human proteins in Uniprot, associated with 857 phenotypes in total, were also
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pleiotropic. This test revealed that proteins containing coiled-coils are more frequently
associated with pleiotropy than other proteins (Fisher’s exact test p < 1.1x10-07).
In a second test, we wished to determine whether pleiotropy was a property of the
coiled-coil region itself. Proteins within the coiled-coil group with multiple mutations were
bipartitioned based on: whether the multiple mutations resulted in pleiotropy; and the
location of the mutations – either within the coiled-coil region, or outside it (Table 4.2B). To
be in category A, two variations encoding different phenotypes were required within the
coiled-coil region. Variations encoding multiple phenotypes outside the coiled-coil region are
represented in category B. If mutations causing two phenotypes partitioned within and
without the coiled-coil region, the protein was deemed “not pleiotropic” for this test
(Category C). Of the 106 coiled-coil containing proteins exhibiting pleiotropy, 18 had
mutations within the coiled-coil domain that manifested as at least two phenotypes, being
associated with 54 phenotypes in total (Supplementary Table 4.4). This test demonstrated that
variations within coiled-coil regions of the protein are much more frequently associated with
pleiotropy than those outside the coiled-coil region (Fisher’s exact test p < 2.5x10-14).
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Table 4.2A: Association of coiled-coil proteins with pleiotropy
Proteins Pleiotropy No-pleiotropy
Coiled-coil proteins 106 2,805
Other proteins 332 16,958
Total 438 19,763
Table 4.2B: Association of coiled-coils with pleiotropy
Coiled-coil Proteins Pleiotropy No-pleiotropy
Variations Inside cc region 18 (A) 31 (C)
Variations Outside cc region 88 (B) 2,774 (D)
Total 106 2,805
Two things can be concluded from these tests. Firstly, that coiled-coil proteins are
more frequently associated with pleiotropy than proteins in general; and secondly, that the
coiled-coil region itself often encodes the pleiotropy.
Pleiotropy in the coiled-coil protein lamin A was previously suggested to be largely
domain-based i.e. the mutations in different domains abrogate specific functions of mosaic
proteins (proteins containing domains of different types, of distinct evolutionary origin,
arising by gene fusion) (Worman and Bonne, 2007). The results here suggest there is a
second type of pleiotropy associated with the coiled-coil region itself. As coiled-coils mediate
protein-protein interactions, the association of proteins engaging in multiple protein-protein
interactions (PPI) with pleiotropy suggested by a recent bioinformatic study of genetic
deletants in S. cerevisiae is interesting (He and Zhang, 2006). Our results suggest a possible
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molecular mechanism for this observation in coiled-coils. It seems likely that pleiotropy
associated with coiled-coil regions arises from their promiscuity. For example, mutation ‘x’
may abrogate interaction with protein partner ‘A’ but not partner ‘B’, while a nearby
mutation ‘y’ may do the opposite. This is supported by observations in the yeast study in
which 15 proteins were identified exhibiting different phenotypes with different interacting
partners. This important observation will be discussed further in the conclusions.
3.4. Amino acid substitutions are context dependent
At the molecular level, we wished to determine whether variants in coiled-coil regions
differ from variants in the human exome in general; and within these variants, whether DMs
differ to PYs.
The most common wild-type amino acids with annotated variations in coiled-coil
regions were typically arginine (DM~24%, PY~24%), glutamic acid (DM~15%, PY~11%) or
leucine (DM~14%, PY~4%) (Figure 4.2A). Variants of these three amino acids accounted for
almost 53% of all coiled-coil DMs, and 40% of all PYs (Figure 4.2A). This compares to the
combined frequency of variation of these wild-type residues in Uniprot as a whole of 16%
(DM) and 14% (PY) respectively. Variations of wild-type arginine and glutamic acid residues
are equally prevalent as DMs and PYs in coiled-coil regions but changes to leucine largely
segregate with DM but not PY. The high rate of arginine mutation in general has been
attributed to its six codons (Steward et al., 2003, Vacic et al., 2012). As the neutral frequency
of arginine is ~11%, this is likely an important determinant for Uniprot in general, where the
variation frequency is ~17% for DM and ~13% for PY, but does not fully account for the
much higher frequencies of variation in coiled-coils (Figure 4.2C). Note also that serine and
leucine are also encoded by six codons and thus have similar neutral frequencies, but are not
so enriched amongst variations of coiled-coil residues. In addition, in contrast to Ser and Leu,
which have frequencies in vertebrates which are close to their neutral frequencies, Arg is
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underutilised in vertebrates, suggesting a selective pressure against its presence in proteins.
This selective pressure probably arises from its bulky nature and its charge, both of which are
generally undesirable in the interior of folded proteins. In contrast, because of the more
extended structures of coiled-coils, wild-type arginine residues are more tolerated and likely
introduce novel properties into coiled-coil structures.
Wild-type residues that were significantly less likely to be changed by variations in
coiled-coils compared to Uniprot were Cys, Gly and Pro. This was partly due to their very
low frequencies in coiled-coils as demonstrated by their position near the x-axis in Figure
4.2A. (Cys < 1% for DM & PY in coiled-coils Vs 6% for DM & 2% for PY in Uniprot; Gly <
1% for DM & 3% in PY in coiled-coils Vs 13% for DM & 6% for PY in Uniprot; Pro 0% for
DM & PY in coiled-coils Vs 5% for DM & 7% for PY in Uniprot). The structural properties
of the polypeptide backbone are unusual for both glycine and proline among the twenty
amino acids: a glycine residue has more conformational freedom than any amino acid, while
the imide ring of proline, which restricts its conformational freedom, excludes it from
adopting canonical -helical backbone φ, ψ dihedral angles. It is known that proline is a helix
breaker and affects the helical conformation to a greater extent (Chou and Fasman, 1974).
The frequencies of amino acids introduced as variations are shown in Figure 4.2B.
Lys and Pro mutations were introduced more frequently in coiled-coils compared to Uniprot
(Lys ~12% for DM & 7% for PY in coiled-coils Vs ~4% for DM & PY in Uniprot; Pro ~18%
for DM but only 2% for PY in coiled-coil Vs 8% for DM & 4% in Uniprot).Arg, on the other
hand, was significantly underrepresented (3% for DM in coiled-coils Vs 11% for Uniprot).
Introduced Lys and Pro residues accounted for almost 30% of the DMs but only 9% of all
PYs. Introduced Pro & Lys residues were more often annotated as DMs whereas Trp & Gln
were more frequently annotated as PYs. These observations were robust when the likelihood
of neutral variation was taken into account (Figure 4.2D).
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Figure 4.2: Frequencies of modified wild-type amino acids (left panels) and amino acid variants (right panels)
introduced into coiled-coils (Y-axis) compared to Uniprot (X-axis) . The upper panels show the observed
frequencies whereas the lower panels show frequencies relative to neutral frequencies, as described in the
methods. A null effect is represented by the diagonal. Amino acids below the diagonal line are underrepresented
in coiled-coils compared to Uniprot, while those above the diagonal are overrepresented. Amino acids that are
significantly different are depicted with solid symbols and labelled.
Because coiled-coils consist of repetitive heptad motifs, the position of the variation
may be also non-random. To recap, the heptad repeat is composed of residues in the major
register, labelled—a, d, e & g, which are principally involved in interactions between
individual chains of the coiled-coil (Figure 4.3); and the residues in the minor register,
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labelled—b, c & f, which may be involved in formation of higher-order oligomers of coiled-
coils such as the homo-super-oligomers formed by intermediate filaments, or the hetero-
oligomers formed in complexes such as SNARES. We compared the frequency of variants in
each register for DMs and PYs. DMs were less likely to occur in the minor registers c & f
(p<0.0001) compared to their mean occurrence, and more likely to occur in the interaction
registers a & g (p<0.0001). PYs are less likely to occur in the hydrophobic interaction
registers a & d (p<0.001), but on the whole were more evenly distributed across all seven
registers than DMs. The differences between DMs and PYs were significant in registers a, c,
d & f (p<0.0001, ** in Figure 4.3). This suggests that disease mutations tend to impact direct
interactions between the coiled-coil chains.
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Figure 4.3: Left panel: Interaction of registers of the
heptad repeats between -helical elements of a
dimeric coiled-coil. The hydrophobic interactions
between registers a & d and the ionic interactions
between e & g are also observed in trimeric coiled-
coils. Right panel: Distribution of variants within the
coiled-coil heptad repeat, comparing polymorphisms
(PY) with disease mutations (DM) and the
distribution of each within the heptad. Compared as
pairs, the number of DMs is significantly different
(P<0.0001) to number of PYs in registers a, c, d and f
with DMs exceeding the number of PY in the hydrophobic registers a and d (**) and PYs exceeding DMs in the
minor registers c and f. In addition, the mean frequency of each variant type was calculated and compared to the
frequency in each register. There were significantly fewer PY (*) in the hydrophobic registers a and d
(Pc<0.001) compared to PYs in other sites. For DMs, there were significantly more mutations (&) in registers a
and g (Pc<0.0001) and significantly fewer mutations (*) in register c and f (Pc<0.0001) compared to other sites.
3.5. Modelling of position-specific effects of variants
To investigate the effect of missense variants in coiled-coils, and in particular the
differential effect of DMs vs PYs, we used the coiled-coil prediction program Multicoil. For
each position in the amino acid sequence, the probability of the residues forming a coiled-
coil, referred to as the oligomerization score or the coiled-coil probability score, was
calculated for both the variant and the wild-type. Because of the repetitive nature of the
coiled-coil heptad repeat, the introduction of a missense mutation may not only affect the
probability of coiled-coil formation at the point of its introduction, but may affect the
likelihood of coiled-coil formation at adjacent residues. The oligomerization scores of the
DM and PY sequences were compared with the wild-type sequence to analyse the effect of
the variant on the coiled-coil structure.
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3.5.1. Effect of variants on stability of coiled-coils
We used several metrics to examine the difference between the oligomerization scores
(OS) of wild-type and variant sequences. At the immediate point of introduction we defined a
local (de)stabilisation score as:-
∆OSloc = OSWT residue-OSvariant Eq. (2)
Based on the predicted oligomerization score, a variant can be classified as stabilising
or destabilising to the structure depending on whether its score is below (destabilizing) or
above (stabilizing) the wild-type residue score. Thus ∆OSloc is positive for destabilising
variations and negative for stabilising variations.
∆OSloc is plotted as a function of OSWT residue normalised to the window length in
Figure 4.4 in order to compare the effects at the point of variation (Figure 4.4A) and over
larger window lengths (Figures 4.4B&C). Within each subfigure the distributions of PY and
DM are also compared. At the immediate point of introduction of the variant (Figure 4.4A)
DMs are generally associated with a larger effect on the coiled-coil structure than the
polymorphic variants. The mean |∆OS|loc was 0.17±0.07 for DM and 0.06±0.02 for PY,
which was significantly different (t-test, two-tailed p < 3.2499x10-27), although there was
little difference in the range of ∆OSloc (DMs: -0.265 < ∆OSloc < 0.997, n=841; PYs: -0.339 <
∆OSloc < 0.996, n=1275). We also partitioned the two variant distributions (DM & PY) into
stabilising and destabilising. The mean value of destabilizing mutations for DMs was
0.23±0.27 compared to 0.12±0.14 for PYs (significantly different at p < 1.667x10-24), again
demonstrating that DMs tended to be more destabilising.
We also assessed longer-range effects of DMs and PYs by summing the effects of the
variant on the coiled-coil probability score over various window lengths centred on the
variant. When longer range effects are taken into account, DMs are more frequently
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destabilising compared to PYs, and PYs are more frequently stabilising. The mean |∆OS|loc7
was 0.13±0.02 for DMs, 0.08±0.01 for PYs and |∆OS|loc35 was 0.12±0.02 for DM, 0.06±0.004
for PYs. Both of these differences are significantly different (t-test, two-tailed p < 2.6429x10-
16 for |∆OS|loc7; p < 2.9914x10-27 for |∆OS|loc35).
The distribution for DMs was skewed towards destabilising mutations whereas the
distribution for PYs was more symmetric about zero (no effect) (Figure 4.4). At the point of
introduction (Figure 4.4A), 33% of polymorphisms are locally stabilizing with an average
increase in stability close to 5%. A secondary peak on the right-hand tail of the mutant
distribution, corresponding to a change in coiled-coil probability from 100% to 0 (completely
destabilising), is entirely due to proline mutants (n=150). The distributions over window
lengths of 7 and 35 respectively are shown in Figure 4.4B&C. A normalised χ2 test of the
difference between the two distributions was highly significant for all three scenarios (χ2loc
=147.98, χ2loc7 = 128.55, χ2loc35 = 163.75, df =13, p<0.0001) (See Methods for more details).
One caveat, when interpreting the differences between the distributions, is that some
polymorphisms could potentially be uncharacterized mutations.
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Figure 4.4: Effect of variations on coiled-coil
stability, comparing 828 disease mutations against
1,275 polymorphisms. A: Local effect at the point of
introduction on coiled-coil stability. The distributed
effect on coiled-coil stability over larger window
lengths is shown in B for seven residues and C for 35
residues. Polymorphisms, are, in general, less
deleterious to coiled-coil stability and may even be
stabilising (negative % difference). The PY
distributions have a sharper peak than the DM
distributions, which tails off more rapidly on the
destabilising side (RHS).
3.5.2. Gross effects on Stability
Destabilising variations may be mild, or may sufficiently destabilise the coiled-coil to
disrupt its structure. We predicted how many of the destabilizing transitions likely resulted in
disruption of the coiled-coil by calculating when introduction of a variation resulted in the
oligomerization score dropping below the threshold of 0.25, at which point the sequence has
lost its ability to stably form a coiled-coil structure. Thus, the effect of variants were
classified as C->S (coil->stabilising) transitions; C->DS (coil->destabilising) transitions,
     

when there is mild destabilisation to the order and formation of the coiled-coil structure; and
C->NC (coil->disruptive) transitions, when there is absence of coiled-coil formation for the
variant sequence.
The results are shown in Figure 4.5. DMs in coiled-coil regions cause destabilising
transitions (C->NC) significantly more frequently than PYs (DM=33%; n=274 Vs PY=16%
n=203, p<0.0001). In contrast, the rates of C->DS transitions show a slight depletion in DM
(44%; n=371) compared to PY (51%; n=639). We also observed that polymorphisms show
more C->S transitions than the disease mutations (PY 32%; n=433 and DM 23%; n=197). In
order to compare the two distributions, the number of PY variants were normalised to the
number of DMs. A normalized χ2 test of the difference between these two distributions was
highly significant (χ2 = 180.02, df =2 p<0.0001). These observations suggest that DMs in
coiled-coil regions are more likely to cause significant structural perturbation to the coiled-
coil structure than PYs.
Figure 4.5: Impact of variations on coiled-coil stability for disease mutations (left) and polymorphisms (right)
showing DM are more often associated with destabilising mutations (DS + NC: DM=77% vs PY=67%) of
higher impact.
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In summary, mutations (DMs) in coiled-coils generally have more deleterious effects
than polymorphisms (PYs): being generally more destabilising, longer range in their effects
and more frequently disruptive.
To investigate the effect of variations in regions of coiled-coil of varying stability, we
further classified the coiled-coil regions into stable, semi-stable and sub-stable coiled-coils.
Stable coiled-coils have definitive coiled-coil character, whereas semi-stable coiled-coils are
more labile. In this study, we defined a stable coiled-coil as P > 0.8, whereas the semi-stable
coiled-coil has 0.25 ≤ P < 0.8. Sub-stable coiled-coils are those with some sub-threshold
coiled-coil tendency, classified as those in which 0 < P < 0.25 in wild-type but P ≥ 0.25 in the
variant. An example is shown in Figure 4.6. Almost 55% of DMs and 67% of PYs were
observed in semi-stable coiled-coil regions (Supplementary Figure 4.2). When these raw
counts were normalised against the length of sequence found in each of these three states as
shown in Table 4.3, we found that both DMs and PYs were equally likely to occur in stable
or semi-stable regions.
Table 4.3: Frequency of variants in stable and dynamic regions
DM PY
Stable 40 per 100,000 residues 9 per 100,000 residues
Semi-stable 40 per 100,000 residues 10 per 100,000 residues
In addition to the magnitude of the coiled-coil probability change, its initial value may
be important in determining the effect of a variant. For instance, if the probability of forming
a coiled-coil is close to the threshold value for coiled-coil formation, a decrease in stability of
the coiled-coil introduced by a missense variant may be sufficient to completely destabilise
the surrounding coiled-coil. This is more likely to occur in semi-stable regions, where the
coiled-coil probability score is already less. Around 25% of the disease mutants converted
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semi-stable regions into unstable regions, whereas DMs only caused 7% of the stable regions
to become unstable. For PYs, 15% of the semi-stable and 0.6% of stable regions were
converted to unstable regions; again, demonstrating that PYs tend to be milder in their effects
on coiled-coils than DMs.
Figure 4.6: Regions of coiled-coils in the KRT1 gene encoding Keratin type II cytoskeletal I protein - Uniprot
ID P04264 as annotated in Uniprot (upper shaded panel) and predicted by Multicoil (lower panel). The
Multicoil prediction suggests highly stable regions of the coiled-coil between residues 231-272 and 389-473; a
semi-stable region between 273-332 and an unstable region that has potential coiled-coil forming ability
between residues 181-210. A stutter is located at residue 444 (red bar-lower bar in upper panel). Ten DMs – D1-
D10 and three PYs – P1-P3 encoded in the coiled-coil region are marked on the upper bar in the shaded panel.
3.5.3. Effects on oligomerization
Oligomerization is central to the structure and function of coiled-coils. Firstly, it
allows individually synthesised protein chains to form multimers, conferring strength on
structural proteins. For example, Intermediate Filament proteins are assembled from two
parallel polypeptide chains which may be homo-dimers assembled from the products of the
same gene e.g. desmin; or hetero-dimers transcribed from different genes, such as keratin.
These then form higher-order oligomers. Secondly, coil-coiled oligomerization may occur
post-translationally; allowing formation of transient complexes of proteins. This enables
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different functional units of a larger protein machine to be assembled in response to cellular
signalling. Alternatively, oligomerization may be part of a regular dynamic process such as
vesicular transport. SNARE complexes, which dock vesicles to membranes, tether via a
hetero-tetramer formed between helices protruding from both the vesicle and the membrane
(Harbury, 1998). Coiled-coils are found as dimers (2), trimers (3), tetramers (4), pentamers
(5) and higher order complexes. Lower order oligomerization states such as dimers and
trimers being the most prevalent (Woolfson, 2005). The CC+ relational database containing
712 proteins consists of 613 dimers, 69 trimers and 26 tetramers (Testa et al., 2009).
In order to better understand how mutations might influence the oligomerization state
of the coiled-coil structure, we compared the predicted oligomerization states of both DM
and PY sequences to the wild type protein sequence. Generally Multicoil reports the coiled-
coil probability as the sum of the dimer and trimer probabilities. For this calculation we
decomposed the overall probability into its component parts. In particular, we used an
oligomerization ratio to separate dimers and trimers defined as
ORD/T = (D or T) probability / (D+T) probability Eq. (3)
where OR=oligomerization ratio, D=Dimer and T=Trimer.
For example, if a coiled-coil sequence has a purely dimeric character ORD = 1. If, for
its variant sequence, 0.5 < ORD < 1, then the variation has introduced some trimeric character
to the sequence; and if ORD < 0.5 then the variant prefers to form a trimer instead of the
native dimer.
Variations that are predicted to change the oligomerization state (OLS) of their
coiled-coil segment were predicted to occur at a rate of 5-9% (Table 4.4). Interestingly,
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polymorphisms that changed the likely oligomerization state from dimer to trimer were the
most prevalent type of change.
Table 4.4: Variants affecting oligomerization state
Coiled-coil segment Entire sequence
OLS Change of OLS OLS Change of OLS
D T D -> T T -> D D T D -> T T -> D
DM 548 292 29 (5%) 15 (5%) 666 173 8 (1%) 3 (2%)
PY 555 720 48 (9%) 26(4%) 529 746 19 (4%) 10 (1%)
* D - Dimer; T – Trimer; OLS – Oligomerization state
The result was robust when the entire sequence rather than affected the coiled-coil
region alone was considered, with a change of oligomerization state observed in 5% of DMs
and 9% of PYs as shown in Table 4.4.
3.6. Effect of variations on other dynamics of coiled-coils
In addition to oligomerization, coiled-coils can also bend, although this occurs only at
select points along their length that have been dubbed “fragile”. As these points are
associated with bending of the coiled-coil rather than breakage, “flex” regions might be a
better term. Flex regions are associated with irregularities in the heptad repeat: either in
register, via the presence of irregularities such as skips, stammers or stutters, which will be
explained in more detail below; or in the hydropathic character of register residues, such that
the individual helices of the coiled-coil stick together less well, allowing internal “fraying”
(Tanizawa et al., 2009). For example in the rod region of the muscle protein myosin, the
average hydropathy (hav) in the hydrophobic registers a and d is ~+1, but at flex points the
average hav is <-1. Similarly, the average hydropathy in the hydrophilic registers (b-c, e-g) is
~-2 but at flexpoints hav >-0.5 (Tanizawa et al., 2009).
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Two types of inter-helical dynamic movements of coiled-coils, where the helices
move with respect to each other, have also been characterised: staggering and sliding (Xi et
al., 2012). In staggering, one helix shifts its registry, often by one heptad repeat, relative to
the other (O'Shea et al., 1991). These alternate conformations may be more likely to form in
coiled-coils with special sequence patterns (Kon et al., 2009, Carter et al., 2011, Croasdale et
al., 2011). The alternate conformation is often difficult to detect experimentally because it is
less stable than the native state, and likely only forms under special conditions, or in response
to a stimulus.
In sliding, the coiled-coil dynamically shifts its registry. A well characterised example
occurs in the antiparallel, two-stranded coiled-coil in the stalk domain of the motor protein
dynenin. The 15nm long coiled-coil stalk domain connects the ATPase and microtubule-
binding domains (Kon et al., 2009, Carter et al., 2011). The stalk transduces the force
generated by the ATPase domain, as well as co-ordinating interactions of the ATPase domain
with ATP, and the microtubule-binding domain with microtubules. Because of the nature of
coiled-coils, the sliding motion is accompanied by twisting of one helix with respect to the
other.
Registry shifts in coiled-coils may also be influenced by conformational changes in
isolated helices adjacent to a coiled-coil region, as has been shown to occur in the dynamic
extension of the coiled-coil in the HA2 chain of influenza haemagglutinin. At neutral pH, the
molecule forms a short coiled-coil structure when expressed in the presence of an N-terminal
region (HA1), which is proteolytically cleaved during further processing. Upon exposure to
acid pH in endosomes during the internalization process of the flu virus into host cells, a
conformational change occurs at the C-terminus of HA2, which involves bending and
unravelling of part of the C-terminal helix (residues 105-126). This conformational change
propagates along the remaining helical region resulting in extension of the coiled-coil region
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towards the N-terminus (residues 40-105) to form the fusogenic state of the viral entry
protein (Carr and Kim, 1993, Bullough et al., 1994). Thus coiled-coil regions can appear and
disappear in protein structures in regions of the polypeptide chain in response to
environmental changes and post-translational modifications.
As there is currently no way of predicting staggering in coiled-coils, we focussed on
sliding and other registry changes in this study. Anecdotal evidence on Intermediate
Filaments suggests that sliding occurs in less stable regions of coiled-coil. To check this, we
looked for registry changes in variant sequences compared to wild-type with respect to the
tri-state stability classifier described in section 3.5.2.
Of 849 DMs, 62 variants (7%) introduced registry changes, whereas only 52 PYs
(4%) resulted in registry changes (Table 4.5). DMs were significantly more likely to be in the
major registers a and g (p<0.0001). DM-induced conversions that were particularly dominant
involved switching between an interaction register and a hydrophobic register, with g -> a
and a -> e conversions being statistically significant (p<0.005), and g -> a showing a trend.
PY conversions were also non-random but more heterogeneous.
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Table 4.5: Registry changes for DMs and PYs
DM Register PY Register
WT a b c d e f g ∑ WT a b c d e f g ∑
a 3 1 3 8 1 16* a 1 1 1 1 1 5
b 2 1 1 4 2 10 b 4 5 9
c 1 2 3 c 4 1 5
d 2 1 1 4 1 9 d 3 1 1 9 14
e 1 1 1 1 4 e 6 4 1 1 12
f 0 f 2 1 4 1 8
g 9 2 9 20* g 2 4 1 1 8
∑ 12 5 6 14 12 10 3 62 11 7 8 5 7 11 12 61
* - Significant in wild-type at p<0.0001; Bolded – Significant when compared in pairs p<0.005.
3.6.1. Effects of variants on irregularities
Some irregularities, apparent as phase shifts of the coiled-coil register, are often
conserved between distant homologs, suggesting they have important functions in specific
proteins. The most common are skips – insertions of one residue e.g. ‘aabcdefg’ (a repeated);
stammers – deletions of four residues e.g. ‘afg’ (bcde missing); and stutters – deletions of
three residues e.g. ‘abfg’ (cde missing) (Brown et al., 1996). Examples are depicted in Figure
4.7. These irregularities cause local unwinding of the supercoil (skips & stutters) or
overwinding of the supercoil (stammers) (Parry et al., 2008). The structural effect may be
associated with dynamic behaviour of the coiled-coil, as implicated for the stutter region of
Intermediate Filaments (Arslan et al., 2011).
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Figure 4.7: Location of skips, stutters and stammers in the myosin rod domain represented in different myosin
families. Proteins shown are P11055 (MYH3), P35579 (MYH9) and P13535 (MYH8).
For example, one of the most studied proteins with irregularities is myosin where the
occurrence of skips influences the inter-molecular interaction between the myosin rods.
Within the coiled-coil of Myosin II rods, an irregular region is formed by a conserved 28
amino acid-residue -helical segment where the heptad repeat is interrupted at three to four
positions by the insertion of an extra residue corresponding to a skip. Non-muscle and
smooth muscle myosin rods have three skip residues. Skips in the myosin rod cause a registry
shift of the regular heptad repeat which results in under-winding between the helical
segments in this region forming a molecular hinge and enabling the rod to assume different
conformationally-stable states. The skips imbue unique properties on the coiled-coil which
govern sideways interactions between bundles of parallel rods in the higher-order oligomer
(Straussman et al., 2005). Each skip residue also has functional importance associated with
the rod position and molecular hinge in promoting end-to-end antiparallel packing of myosin
rods. Skips maintain a local relaxation of the super-helical pitch in the surrounding region,
causing the coiled-coil to form a non-close-packed structure. Their presence increases the
flexibility of the myosin rod required for formation of the long myosin tail. Each skip
provides a molecular hinge, providing C-terminal rod flexibility. Together, the skips affect
the structural properties of the entire region of the coiled-coil, not just the structure in their
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immediate vicinity. Any distortion to these structurally important elements may lead to a
mild or severe phenotype (Taylor et al., 2015).
Mutations at such functionally important sites of coiled-coils may be disastrous. For
example, Intermediate Filaments have two highly conserved regions – in Coil 1A and coil
2B. The coil 2B region spans a stutter within the heptad repeat, which is conserved in most
IFs (Weber and Geisler, 1985). The presence of this stutter has a global effect on the dimer
structure, creating a special hydrophobic core organisation, resulting in a parallel
arrangement for the two coils (under-wound) rather than the regular coiled-coil configuration
(Arslana et al., 2011). Distortion of the conserved stutter in disease mutants affects the
intermolecular interactions and rewinding of the coil into a continuous heptad repeat
(Strelkov et al., 2002). For example, a recessive mutation (E418K) in the stutter region of
Keratin intensified the disruption in the Keratin Intermediate Filament network caused by the
dominant mutation (E170K) (Yasukawa et al., 2002).
We searched for register phase shifts in variant protein sequences compared to the
wild-type. Initially, we searched the Multicoil predictions for irregularities in the wild-type
sequences, before limiting our analysis to sequences with characterised variants. Then, we
compared the registers of the Multicoil predictions for wild-type and variant sequences to
determine if the variant caused a register shift. We investigated in detail the changes caused
by variations for both DMs and PYs. In the case of DMs, we also studied the disease
associated with register phase shifts. Variants may introduce a new phase shift compared to
the wild-type or delete the normal phase shift resulting in a regular coiled coil.
The results are listed in Table 4.6. While most variants preserved the nature of the
conserved irregularity, as demonstrated by the diagonally dominant nature of these matrices,
PYs were more frequently associated with changes in the type of irregularity. However
within these, inter-conversion of skips and stutters which both result in under-winding of the
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coiled-coil, were more common than conversion between these under-winding irregularities
and the overwinding stammers. However, 17% of the variants either introduced a new phase
shift or deleted the regular phase shift, compared to the wild-type. PY variants of wild-type
sequences encoding skips had more diverse consequences. Some were associated with
deletion, whereas others caused a transition as shown in Table 4.6. DMs were more often
associated with local slippage of the irregularity within the primary sequence rather than an
interconversion of the type of irregularity: 40% showed a predicted 3 to 7 residue slippage of
the irregularity of the mutant structure towards the C-terminus of the sequence while 45% of
the sequences showed no locational difference (Figure 4.8). For PYs, the most common
locational change (42%) was a predicted 3- to 7-residue slippage of the irregularity of the PY
structure towards the C-terminus of the sequence, similar to DMs; 34% of PY sequences
showed no locational difference, while 9% of sequences were predicted to have a 3- to 7-
residue slippage of the irregularity of the PY structure towards the N-terminus of the
sequence; and the remaining 15% of variants had larger slippages. For both PYs and DMs
slippage of stutters were slightly more dispersed than skips or stammers. The effect of these
predicted slippages would be different for parallel and antiparallel coiled-coils, which is not
accounted for by Multicoil.
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Figure 4.8: Comparative location of irregularities in
variant sequences compared to the wild-type protein
sequence. Inter-conversions are represented by a
triangle, with the outline representing the wild-type
phase shift and the colour filled representing the
variant. Majority of the inter-conversions are
associated with PYs.
DMs causing changes to conserved skips were mostly found in the myosin family,
particularly myosin-6 and myosin-7, whereas PYs were distributed among different protein
families such as myosins, keratin, kinesin, GTP-binding protein, plectin, and desmoplakin.
The phenotypes associated with myosin mutants included some forms of Cardiomyopathy
(MIM 192600 & 613426), Optic Atrophy Type 1 (MIM 165500; in dynamin-like protein),
Cornelia de Lange syndrome Type 2 (CDLS2 in structural maintenance chromosome protein;
MIM 300590) and Disseminated Superficial Actinic Porokeratosis (MIM 175900) in
squamous cell carcinoma antigen. Most of these skip slippages propagated the skip by +1 or -
1 residues compared to the wild type. The distance between the site of mutation and the skips
varied from -24 to +24 residues, suggesting the mutations can affect the skip position over
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four turns of the involved -helices. All of the disease mutations were near semi-stable
regions in the coiled-coil; about half were near frayed ends (transition state).
Table 4.6: Phase shifts in irregularities of variants compared to the wild-type
DM PY
W
T
Skip Stam Stut Del Other ∑ Skip Stam Stut Del Other ∑
Skip 9 9 50 1 9 60
Stam 17 17 1 21 4 3 3 32
Stut 1 64 1 66 4 2 86 6 98
∑ 9 18 64 1 92 55 24 99 9 3 190
Stam – Stammers; Stut – Stutters; Del – Deletion; Other – 2 or 5 residue changes
DMs causing changes to conserved stammers were found in kinesin-like proteins and
desmoplakin. The associated phenotypes were Cardiomyopathy (MIM 107970) and
Congenital fibrosis of Extraocular Muscles Type 1 (MIM 135700). A comparison of the
location of the stammers in the wild-type and the mutants, showed shifts from -22 to +10
residues with the distance between the site of mutation and the position of the stammer in the
wild-type being as far as -18 and 21 residues.
Stutters in DMs were associated with phenotypes such as desmin-related myopathy
(MIM 125660), Epidermolysis bullosa simplex (MIM 131900) and Cardiomyopathy (MIM
107970).
Irregularities in DMs were mostly found in intermediate filament family members
such as lamin, myosins and keratins. It is known that irregularities are highly conserved in the
rod domains of these proteins (Weber and Geisler, 1985). The results showed that any
mutations in the vicinity of these conserved irregularities may lead to a major structural
perturbations such as displacement of the irregularity, or more rarely, changes in the type of
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irregularity, manifesting as a phenotype. Even though PYs more frequently changed the type
of irregularity, they were usually conserved in nature (ie interconversion of under-wound
skips and stutters), and were not associated with any clinical phenotype. However, further
experimental studies are required to understand how these irregularities affect the coiled-coil
formation.
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4. Discussion
Here we used a theoretical approach to investigate amino acid substitutions in coiled-
coils and their consequences, aiming to establish potential differences between mutations of
Mendelian diseases and polymorphisms that may be associated with complex diseases. While
Mendelian mutations compromise protein function and abrogate cellular pathways, harmful
variants in complex diseases are likely to alter protein function without directly
compromising it.
Significant differences were observed in the patterns of variations of DMs and PYs in
coiled-coil proteins. The amino acid frequencies of variations in coiled-coils were different to
those in all proteins in Uniprot and some significant differences between DM and PY variants
in the amino acids substituted and substituting in coiled-coils were also apparent. Register-
specific differences between DMs and PYs were also apparent with DMs favouring the major
registers that influence interactions between the -helices, particularly the hydrophobic
registers a and d; whereas PYs favoured the minor registers. These results show that context
is important in assessing the impact of variants and in distinguishing disease mutations and
polymorphisms. In general, disease mutations tended to be more destabilising while
polymorphisms caused more subtle effects, although they more frequently caused changes in
the oligomerization state as well as changes to irregularities in the heptad repeat that may
influence the dynamic behaviour of the coiled-coil.
One of the more interesting results of this study was the demonstration that mutations
in coiled-coils are a significant contributor to pleiotropy. Previously, He and Zhang
concluded, based on a bioinformatics study of pleiotropy in yeast, that genes exhibiting
pleiotropy are involved in more protein-protein interactions than those associated with a
single trait. Our work shows that pleiotropy in humans is associated more frequently with
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proteins containing coiled-coil regions than other proteins; and the coiled-coil regions
themselves are often implicated in pleiotropy. As coiled-coil regions are known to be
mediators of protein-proteins interactions, our work provides indirect support in humans for
the findings of He & Zhang (2006) on the importance of genes with a larger number of
protein-protein interactions in pleiotropy in yeast. However, the difference of what
constitutes pleiotropy in the two studies should be noted: we used human diseases recognized
as distinct phenotypes as traits, whereas He and Zhang used growth rate of single-gene yeast
deletants in different environmental conditions.
Our work also provides some insight into the molecular basis of pleiotropy arising
from multiple protein-protein interactions. This, and other work on coiled-coils suggests there
may be two origins of pleiotropy at the molecular level: a domain-based pleiotropy associated
with abrogation of a particular function in specific domains of mosaic proteins, as exhibited
by lipodystrophy phenotypes arising from mutations in lamin A; and an interaction-based
pleiotropy, as exhibited by the coiled-coil regions themselves, possibly associated with
altered interaction dynamics.
Previously two different molecular origins for pleiotropy have been proposed. Type I
pleiotropy arises from multiple molecular functions of a gene product, for which human
serum albumin (ALB) is generally cited as an example. This protein contains two distinct sites
within a single domain that perform different functions. Type II pleiotropy arises from
multiple morphological and physiological consequences of a single molecular function, for
which yeast HIS7 is generally cited as an example. HIS7 contains a single active site which
produces multiple metabolites. Different mutations to this site alter the suite of metabolites
produced by this protein.
How do the two types of pleiotropy associated with the coiled-coil proteins described
in this work align with these previous concepts? Both of the molecular mechanisms
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associated with coiled-coil proteins discussed here are examples of type I pleiotropy;
including the domain-based pleiotropy, manifested by the Lamin A gene (Worman and
Bonne, 2007); and the pleiotropy associated with the coiled-coil region itself. Thus we
propose, based on this study, two distinct molecular origins of type I pleiotropy: type 1A –
arising from distinct functions associated with different domains/subsites in a protein as
exemplified by ALB and LMNA; and type IB – arising from regions of the protein, such as
coiled-coils, which interact promiscuously with multiple binding partners, as supported by He
& Zhang’s experiments. Further experiments with the proteins listed in Supplementary Table
4.4 may elucidate whether pleiotropy can be attributed to this phenomenon.
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5. Conclusions
The advent of high throughput sequencing is allowing us to identify more sequence
variations in the human exome, but our understanding of the impact of these variations has
not advanced at the same rate, and seriously undermines the immediate utility of this data.
Much of the growing area of bioinformatics is being devoted to the generation and
normalisation of this data, leaving it to pile up in databases without further analysis. Better
use of this exome sequencing data in large scale studies such as this one will help elucidate
the genotype-phenotype relationship on a molecular basis. This work should contribute to a
better understanding of the role of polymorphisms in coiled-coils and a better understanding
of how polymorphisms may contribute to complex diseases.
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Bolded Phenotypes are associated with mutations of the coiled-coil region i.e. the rod domain
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Discussion4.4
Disease mutations more frequently affected stability of the structure as published in
previous studies (Wang and Moult, 2001). In coiled-coil regions, leucines (Leu) and glutamic
acid (Glu) were frequently mutated (29%). Both the amino acids are usually found in the core
positions of the coiled-coil structure. In particular, Leu are usually present in the registers a
or d both of which are required for stabilization of the coiled-coil structure. Also, Leu plays
an integral role in the formation of dimers (O'Shea et al., 1989, Woolfson and Alber, 1995).
As a matter of fact, dimers were more affected (65%) than trimers in DMs. DMs were also
more likely to occur in the hydrophobic registers a & d (32%). Furthermore, dimers are more
vulnerable to changes as they require specific structural determinants for their formation
(Woolfson, 2005). These results align well with the fact that mutations of Mendelian
inheritance affect residues that are important for structural stability and specificity.
On the contrary, polymorphisms were mostly found in interaction interfaces of the
coiled-coil such as in the minor registers b, c and f (48%). Also, they were observed more
frequently in trimers (56%). Variants affecting trimers may not have a huge impact on the
structure unless—the specific position has a significant function; and the variant is unfavored
in the coiled-coil structure. This is because trimers are the default oligomerization state for
the coiled-coil and do not require any strong determinants. So, they accommodate any
residues that favor the formation of coiled-coils. Also, they have a broader hydrophobic
interface to provide better shielding of the core which results in increased polar and ionic
interactions by the involvement of positions b and c (Woolfson, 2005). These facts suggest
that polymorphisms tend to have a subtle effect on the structure that may be difficult to assess
its effect on the protein.
This can be further explained by the nature of amino acid introduced in DMs and
PYs. While prolines (Pro), were more often annotated as DMs, tryptophan (Trp) was more
 
	
frequently annotated as PYs. Pro variants introduce a kink in the coiled-coil structure and are
generally avoided in coiled-coils, as they tend to destabilize the formation of coiled-coil. On
the contrary, aromatic residues such as Trp are not favoured in the hydrophobic positions
because of their bulky nature, but occur in the coiled-coil structure (Woolfson and Alber,
1995).
4.4.1 Segregation of prolines in DM and PY
Destabilization of the coiled-coil structure in disease mutants was largely due to the
number of Pro mutations as explained above; but there were instances of Pro variations in
polymorphisms. In such scenarios, the context of the protein determines if the variant is
pathogenic or not. For example, presence of Pro in coiled-coils in transmembrane proteins
such as channel-forming proteins or peptides results in reduction in stability and a larger
structural fluctuation than Pro in the more regular helical assembly. Decreased structural
stability significantly affects functions such as transportation to the cell surface (Chen et al.,
1993; Kreis and Lodish, 1986). For instance, presence of Pro residues in the glycoprotein
(gp) gp41 decreases stability of the coiled-coil and severely impairs the membrane fusion
activity of the wild protein (Chen et al., 1998). The envelope glycoprotein gp41 mediates the
process of membrane fusion that enables entry of the HIV-1 virus into the host cell. Likewise,
proline-containing gp41 LZ-like domain has reduced ability to block syncytium formation
due to the decreased affinity of the distorted peptide helix in the carboxyl-terminal helix of
the gp41 ectodomain (Wild et al., 1992).
Additionally, the effect of Pro depends on the cellular environment and its location in
the coiled-coil segment. Its effect has been shown to be smaller in membranous medium than
in aqueous buffer (Li et al., 1996). In type I keratin, introduced Pro mutations in the ends of
the rod domain led to loss of filament stability and cellular interactions and those in middle
had a slighter effect. But it should be noted that ends are conserved regions of the protein
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(Letai et al., 1992). Thus, context effects, and not just the property of amino acid, influence
the relative stabilities of the oligomers.
4.4.2 Association with pleiotropy
Phenotypes associated with coiled-coil domains exhibited two types of pleiotropy—
domain based and interaction based. Based on this study and the study by He & Zhang
(2006), it can be hypothesized that pleiotropy may be a property of proteins involved in
interactions. Furthermore, a study by Sivakumaran et al. (2011) showed abundant occurrence
of pleiotropy in case of complex diseases, where many genes interact with each other or with
the environment. Apart from pleiotropy, phenotypes such as BBS 2 and amyotropic lateral
sclerosis observed in coiled-coil regions showed incomplete penetrance, a property of
oligogenic and complex disease (Cooper et al., 2013). In BBS, at least 17 genes are
characterized towards the development of phenotype (Cooper et al., 2013). One of them is
the BBS gene, which holds coiled-coil domains. The outcome of the phenotype may vary
depending upon the interaction of mutations in different BBS genes, indicating a potential
role of coiled-coils in interactions.
Conclusion4.5
Results emphasized the differential effects of disease mutations and polymorphisms
in all functional impacts that were assessed—amino acid substitutions, stability,
oligomerization state and change of register. Mendelian mutations perturbed the structural
stability of the coiled-coils by inducing a variety number of unfavored residues such as Pro,
Gly and Cys into the coiled-coil structure when compared to polymorphisms (DM—29% Vs
PY—12%). Additionally, disease mutations were mostly prevalent in the registers—a, d, e &
g influencing the coiled-coil structure (DM—69% Vs PY—52%). Interestingly, PYs could
also have large effects, different to classical high-penetrance mutations, and thus may be
unrecognized Mendelian mutations. Some were involved in loss of stability (Pro PYs), while
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others affected features important for interactions and oligomerization such as inter-
conversion of oligomerization state and phase shifts. Unexpectedly, disease mutations were
less likely to induce these inter conversions.
A profound outcome of this study was association of pleiotropy with coiled-coils.
25% of pleiotropy found in Uniprot was attributed to coiled-coils. Pleiotropy is one of the
properties of complex diseases and deciphering the role of variants in these regions would
enable to deduce the mechanism of complex phenotypes.
The current set of prediction rules implied by AAS methods may not perform well in
a context-specific manner. For example, coiled-coils differ from other globular domains in
evolutionary pattern (Surkont and Pereira-Leal, 2015) and also substitutions between amino
acids with similar properties can change the intrinsic properties such as oligomerization state
of the coiled-coil (Harbury et al., 1993). For example, Asn16Gln mutation, despite chemical
similarity, destabilizes GCN4 allowing two peptide states—dimer and trimer. Also, Gonzalez
et al. (1996) demonstrated that by changing hydrophobic residues at a &d positions in GCN4
leucine zippers to other hydrophobic residues, different orders of oligomers ranging from
dimers to tetramers were formed.
Hence exhaustive analysis of variations such as demonstrated in this study is required
to encode the functional role of variants.
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Chapter 5: Analysis of fixed substitutions
Introduction5.1
Genomes are under constant pressure by variations introduced into them. The effect
of variation may be beneficial, neutral or damaging (Kimura, 1968, King and Jukes, 1969).
Most of the deleterious alterations will eventually be eliminated through purifying negative
selection. However, beneficial mutations can persist through the population and become
fixed. These fixed substitutions contribute to species differentiation and play an important
role in evolution. Accumulation of such substitutions may either lead to development of a
new gene function, enhancement of an existing gene function or loss of an already existing
function. For instance, humans being closely related to chimpanzees acquired many distinct
evolutionary, physiologically and biomedically important differences traits after the human-
chimpanzee divergence that occurred around ~ 5-7 million years ago (MYA) (Varki and
Altheide, 2005). Examples include beneficial mutations in the genes—FOXP2, contributing
to the development of central nervous system; and MYH17, resulting in increased size of the
brain (Enard et al., 2002, Stedman et al., 2004, Konopka et al., 2009). However, some (mal)
adaptations during this evolutionary process occurred making humans susceptible to diseases
like autoimmune diseases, Alzheimer’s disease pathology—formation of neurofibrillary
tangles, atherosclerotic strokes and rheumatoid arthritis (Varki and Altheide, 2005).
Functional studies of such fixed variations in genes will provide insights into the molecular
mechanisms underlying acquisition of various human-specific traits.
The evolutionary roles of such substitutions are usually analyzed in the conserved
regions of proteins, such as active sites and binding sites that imply major functional impact
on the protein (Saunders and Baker, 2002, Ng and Henikoff, 2003, Subramanian and Kumar,
2006). However other intrinsic protein sites such as disordered regions, post-translational
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modification sites (PTM), interfaces of protein-protein interactions are functionally important
(Wang et al., 2012).
5.1.1 Analysis of fixed mutations in post-translational modification sites
Post-translational modifications (PTMs) alter the biochemical properties of amino
acids and extend the functional repertoire of proteins. PTMs include reversible and
irreversible changes such as enzymatic cleavage of peptide bonds, covalent addition of
chemical groups, lipids, carbohydrates, or even entire proteins, to amino acid side chains; and
occurs typically after translation and polypeptide synthesis (Savas and Ozcelik, 2005). This
enables a protein to have more than 150 chemically different residues besides the primary 20
amino acids (Uversky et al., 2001).
Variants in PTM regions tend to add or remove molecular interaction sites, rewiring
protein networks that may imply potentially deleterious outcome on the phenotype.
Mutations in PTM regions are less emphasized as they are particularly enriched in disordered
sequences that are generally less constrained (Reimand et al., 2015). Variations in PTMs can
result in partial or complete loss of function (LOF) or gain of function (GOF) scenarios. In
case of ubiquitination, where a small ubiquitin molecule is attached to a lysine residue for the
protein to be degraded, variations either disrupt or introduce an ubiquitination site. It is
mainly observed in proteins associated with various human diseases such as cancer (p53,
BRCA1, BRCA2, AR), cystic fibrosis (CFTR), Alzheimer disease (APOE), muscular
dystrophy (LMNA) (Uversky et al., 2001). And in particular these substitutions happened
between physico-chemically different residues (Li et al., 2010). For instance, variation
T183A which resulted in a loss of N-linked glycosylation in the prion protein, was shown to
be related to the autosomal dominant spongiform encephalopathy (Uversky et al., 2001).
PTMs are specific to types of amino acids and they regulate different protein
functions. For instance, phosphorylation which mediates intracellular signaling is the most
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widely studied PTM and in involves residues such as Ser, threonine (Thr), and tyrosine (Tyr)
(Wouters et al., 2011, Reimand et al., 2015). Other PTMs include multiple modifications of
lysine (Lys) that undergo acetylation, methylation, hydroxylation, transglutamination and
ubiquitination that mediate diverse processes from epigenetics to protein fate and structural
processes (Begg et al., 2006). An emerging signaling pathway, which may be as important in
cellular signals as phosphorylation, is thiol-based redox signaling.
Modification of Cys and Methionine (Met) residues by reactive oxygen species (ROS)
and reactive nitrogen species (RONS) is collectively known as thiol-based redox signalling.
They were first characterized in plants and is now known to be functional in all three
kingdoms (Wouters et al., 2011). ROS include chemical oxidants such as hydrogen peroxide
(H2O2), superoxide anion (•O2–), singlet oxygen (O2), and hydroxyl radicals (•OH). Inside the
cells, ROS are constantly generated as harmful by products of neutrophil-mediated
phagocytosis (Hampton et al., 1998), cellular respiration (Cadenas and Davies, 2000), and
various NADPH oxidases (Suh et al., 1999). In order to maintain homeostasis when the
concentrations of ROS and RONS increases, cells use antioxidant enzymes such as
peroxidases and two redox regulated systems—thioredoxins (Trx) and glutaredoxins (Grx)
(Brandes et al., 2009, Wouters et al., 2011).
Cys residues form the central building block of thiol-based redox switches in redox-
regulated proteins. Many of the Cys oxidative modifications are readily reversible. Cys
residues undergo reversible thiol modifications in response to ROS and RONS and acquire a
variety of redox modifications such as sulfenylation (SOH), sulfinylation (SO2H, SO3H),
glutathionylation (-SSG), protein disulfide formation and nitrosylation, with distinct chemical
properties that contribute to signaling specificity, modulating protein function, activity, or
localization. They play important roles in many signal transduction cascades such as—
phosphatase and tensin homolog gene (PTEN) and protein-tyrosine phosphatase 1B (PTP1B)
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(Lee et al., 1998, Yu et al., 2005); gene transcription in p53 (Pognonec et al., 1992); and
immediate defense against oxidative stress conditions in Hsp33 and Hsf-1.
Regulation of thiol modifications involves one or more Cys and their activity depends
on the cellular context and the pKa. For example, a single Cys in a protein may allow
reversible GSH conjugation to occur, introducing a simple redox switch into the protein. If a
second Cys is introduced into the protein sequence, the potential for disulfide formation
exists. In favorable configurations and protein contexts, a bistable redox switch may be
formed (Wouters et al., 2010). How these redox active disulfides are introduced into the
proteins is not well characterized.
In order to study the evolution of these systems, protein substrates where the number
of redox-active Cys residues has changed throughout evolution were searched for and
selected. Specifically, cross-strand disulfides (CSDs), the most common type of forbidden
disulfide motif was chosen. Protein orthologs where the CSD is present, absent and found as
a single Cys were studied.
From a dataset of 29,261 disulfide-containing proteins, 195 unique protein clusters
containing 235 CSDs were retrieved (Haworth and Wouters, 2013). From this set of CSD-
containing proteins, three different proteins were selected for detailed study—CD4, ERO1
and AKT1 based on the evidence that these proteins were redox regulated and an
intermediate 1-Cys state existed. Evolutionary acquisition of CSD, physico-chemical
properties of the CSD and mechanism of reduction of the CSD was analyzed.
CSD acquisition in the proteins studies did not involve insertion of an entire
sequence fragment. Instead, the redox switch was introduced by stepwise mutation of two
residues in the native sequence to Cys. The advantages of acquisition of the CSD to protein
function were clearly demonstrated by the retention of the redox switch in higher organisms.
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and can be accessed at http://dx.doi.org/10.3389/fphar.2015.00001. A copy of this publication
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Cysteine is susceptible to a variety of modiﬁcations by reactive oxygen and nitrogen
oxide species, including glutathionylation; and when two cysteines are involved, disulﬁde
formation. Glutathione-cysteine adducts may be removed from proteins by glutaredoxin,
whereas disulﬁdes may be reduced by thioredoxin. Glutaredoxin is homologous to the
disulﬁde-reducing thioredoxin and shares similar binding modes of the protein substrate.
The evolution of these systems is not well characterized. When a single Cys is present
in a protein, conjugation of the redox buffer glutathione may induce conformational
changes, resulting in a simple redox switch that effects a signaling cascade. If a second
cysteine is introduced into the sequence, the potential for disulﬁde formation exists.
In favorable protein contexts, a bistable redox switch may be formed. Because of
glutaredoxin’s similarities to thioredoxin, the mutated protein may be immediately exapted
into the thioredoxin-dependent redox cycle upon addition of the second cysteine. Here we
searched for examples of protein substrates where the number of redox-active cysteine
residues has changed throughout evolution. We focused on cross-strand disulﬁdes (CSDs),
the most common type of forbidden disulﬁde. We searched for proteins where the CSD
is present, absent and also found as a single cysteine in protein orthologs. Three different
proteins were selected for detailed study—CD4, ERO1, and AKT. We created phylogenetic
trees, examining when the CSD residues were mutated during protein evolution. We posit
that the primordial cysteine is likely to be the cysteine of the CSD which undergoes
nucleophilic attack by thioredoxin. Thus, a redox-active disulﬁde may be introduced into
a protein structure by stepwise mutation of two residues in the native sequence to Cys.
By extension, evolutionary acquisition of structural disulﬁdes in proteins can potentially
occur via transition through a redox-active disulﬁde state.
Keywords: cross-strand disulﬁde, forbidden disulﬁde, redox-active disulﬁde, exaptation, disulﬁde evolution, CD4
evolution, AKT evolution, post-translational cysteine modiﬁcation
INTRODUCTION
Thiol-based redox signaling is the collective name for biochemi-
cal pathways that regulate cellular processes by post-translational
modiﬁcation of sulfur moieties in cysteine (Cys) and methio-
nine (Met) residues of proteins. These pathways are patholog-
ically dysregulated in diseases of oxidative stress which include
cancer, neurodegenerative diseases, heart disease and aging. A
better understanding of these pathways is essential to diagnosis,
treatment, and prevention of these diseases.
Cys residues are susceptible to a variety of modiﬁcations by
reactive oxygen and nitrogen oxide species (ROS, RNS). Cys can
be nitrosated, glutathionylated, and can form covalent bonds
with other Cys. RNS such as nitric oxide (•NO) can mediate
S-nitrosation to yield an S-nitrosothiol (RSNO). Other RNS, such
as peroxynitrite (ONOO–), can also mediate S-nitration to yield
S-nitrothiols (RSNO2). Sequential oxidation of Cys thiols yields
sulfenic (–SOH), sulﬁnic (–SO2H), or sulfonic (–SO3H) acid
derivatives. Reaction of protein thiols with low-molecular weight
thiols such as glutathione (GSH) can yield mixed disulﬁdes.
Alternatively, oxidation by ROS or RNS can result in a disulﬁde
bridge forming between two thiols, either within a protein chain
or between protein chains (Wouters et al., 2011).
Reduction of these systems is effected in a variety of ways. For
some disulﬁdes, autoreduction within a protein may be assisted
by mechanical stresses and the local electrostatic environment.
For example, arsenate reductase (ArsC), an enzyme involved in
detoxiﬁcation of arsenic, transfers electrons through a series of
Cys modiﬁcations, manifested largely as disulﬁde isomerizations,
as part of its catalytic cycle (Messens et al., 2002). Two of the three
disulﬁdes formed in the oxidized states of ArsC are autoreduced,
while the disulﬁde in the ﬁnal oxidized state is reduced by thiore-
doxin (Trx) (Messens et al., 2002; Wouters et al., 2010). In general,
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reduction of surface accessible disulﬁdes may be effected by the
GSH redox buffer (Ostergaard et al., 2001), or speciﬁc thiol oxi-
doreductases such as Trx. GSH-Cys adducts may be reduced by
glutaredoxins (Grxs), which are homologs to Trxs (Martin, 1995),
and share similar binding modes of the protein substrate with
Trxs.
It is now understood that a continuum of redox set points
within proteins control cellular processes in response to a range
of ROS ﬂuxes. Low ﬂuxes mediate homeostatic control of house-
keeping redox processes, while higher ﬂuxes mount stress and
adaptive responses before a threshold is reached, triggering apop-
tosis, or programmed cell death. Partial loss of control of these
processes is now believed to underlie aging (Humphries et al.,
2006). Even higher levels of ROS can cause cellular necrosis.
In addition to its roles in housekeeping and the stress response,
thiol-based redox regulation is also important in developmental
processes in plants and animals. In plants, thiol-based redox reg-
ulation is involved in seed germination (Buchanan, 1980). In ani-
mals, the early embryo forms under reducing conditions (Hartley,
1960), but the embryonic environment becomes more oxidizing
as the embryo grows (Hartley, 1960; Ibrahim et al., 2006). Redox-
regulated processes govern the formation of substructures during
embryo development by selective apoptosis.
The evolution of these systems is not well characterized.
Among prokaryotes, the well-studied GSH system of eukaryotic
redox regulation operates only in purple bacteria and cyanobac-
teria (Fahey, 2001; Mallick et al., 2002). In other prokaryotes,
different redox buffers are utilized, for example acetyl-coenzyme
A in gram positive bacteria (Hummel et al., 2005). It appears
that the role of GSH as a redox buffer is predated by its role
in detoxiﬁcation. Glutathione S-transferases (GSTs) label xeno-
biotics with GSH, allowing them to be removed from the cell
by speciﬁc transporters. GSTs are found in all classes of eukary-
ota and bacteria. Within GSTs, the GSH-conjugating site lies in a
Trx-like domain (Atkinson et al., 2009). These data suggest that
a common stress-related ancestor with a Trx-like fold may have
pre-dated the evolution of the thiol-oxidase function now most
commonly associated with the Trx-like fold.
In its role as a redox buffer, GSH is conjugated to reactive Cys
of endogenous proteins, inducing conformational changes in the
substrate proteins, and effecting a signaling cascade that evokes
biological responses (Wouters et al., 2011). Conformational
changes are generally small, involve the protein backbone, and are
often accompanied by a local increase in protein disorder (Mallis
et al., 2000; Wouters et al., 2011). Surface modiﬁcation of proteins
such as carbonic anhydrase by GSH results in signiﬁcant disorder
of the GSH distal to the covalent bond (Mallis et al., 2000). In
this disordered state, GSH may act as a ﬂipper, disrupting protein
interactions. Thus, introduction of a single Cys into a protein may
allow reversible GSH conjugation to occur, effectively introducing
a simple redox switch into the protein.
If a second Cys is introduced into the protein sequence, the
potential for disulﬁde formation exists. In favorable conﬁgura-
tions and protein contexts, a bistable redox switch may be formed
(Wouters et al., 2010). This has the potential to effect two dif-
ferent “active” states of the protein. For example, the protein may
interact with certain protein partners with the switch in one redox
state, and with other protein partners when the switch is in the
alternate redox state.
How are these redox-regulated sites introduced into proteins?
The introduction of potential disulﬁde-forming thiol pairs may
be facilitated by the fact that both Cys do not need to be intro-
duced into the protein chain simultaneously. This may seem
obvious in isolation but, in toto, a number of constraints must be
satisﬁed, and the likelihood of this occurring is greatly increased
if the process can occur in a stepwise manner. Incorporation of
a single Cys may make the protein immediately responsive to a
range of oxidative modiﬁcations, including nitrosation and glu-
tathionylation (Figure 1). In order for these modiﬁcations to be
effective, the context of the Cys within the protein must be suit-
able. To be modiﬁable, the Cys must have a low pKa, a property
that is largely determined by the electrostatic environment of the
protein context. In addition, in order for GSH to be reductively
removed from the Cys, Grx must be able to dock to the backbone
near the modiﬁed Cys. Thus, there are additional requirements
on the secondary structure and accessibility of the introduced Cys
residue. Introduction of a second Cys at a later stage may then
enable disulﬁde formation subject to further constraints. Because
Grxs are homologs to Trxs and share similar binding modes of
the protein substrate, the complete redox cycle may potentially be
immediately effected. So the similarity in the constraints of 1-Cys
and 2-Cys reduction facilitates this second Cys acquisition step,
but an additional constraint is that the second Cys must be the
resolving Cys and thus have a higher pKa than the existing Cys.
Anecdotally, a number of these 1-Cys/2-Cys homologs have
been described (Wouters et al., 2010). An example where one
protein is glutathionylated and a homolog forms disulﬁdes is the
Grx–Trx pair itself. Trx forms a disulﬁde between the Cys residues
of the CXXC motif as part of its reaction cycle. Grx contains
only the reactive N-terminal Cys of the CXXC motif which is glu-
tathionylated during its reaction cycle. Another pair of families is
the 1-Cys and 2-Cys peroxiredoxins (Prxs) (Copley et al., 2004).
When the resolving Cys is present, Prxs are reduced by Trx. When
it is not, they are reduced by Grx. In all the above examples, the
additional Cys is the resolving Cys, suggesting the reactive Cys
must come ﬁrst in order for the mutation to become ﬁxed in
the population. These examples demonstrate evolutionary exap-
tation from the Grx pathway to the Trx pathway, or vice versa,
does occur; and likely can be easily effected for other proteins.
The vast database of sequenced genomes of organisms is a
valuable resource which can be mined for information regarding
the evolution of these pathways, leading to a better understanding
of their function and control. Here we searched for examples of
protein substrates where the number of redox-active Cys residues
has changed throughout evolution.
We focused on cross-strand disulﬁdes (CSDs), a type of forbid-
den disulﬁde motif. Forbidden disulﬁdes are a group of canonical
disulﬁdes that disobey elucidated rules of protein stereochem-
istry (Wouters et al., 2010). CSDs are metastable disulﬁdes: their
intermediate disulﬁde torsional energies render than more easily
reduced than low energy structural disulﬁdes, but they are more
stable than high energy disulﬁdes (Wouters et al., 2007, 2011).
Their reduction is likely assisted by endogenous proteins. The
postulated role of CSDs as canonical redox switches is supported
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FIGURE 1 | Panels depict biochemical redox cycles of (A) single Cys and
(B) disulﬁde-forming pair of Cys residues and their evolution (white
central vertical panel). Incorporation of a single Cys (α) may make the
protein immediately responsive to a range of oxidative modiﬁcations,
including nitrosation and glutathionylation. Cys with lower pKas are more
susceptible to modiﬁcations. Introduction of a second Cys (β) at a later stage
may then enable disulﬁde formation, preventing overoxidation of the low pKA
“active” Cys and effectively forming a bistable redox switch. Because Grxs
are homologs to Trxs and share similar binding modes of the protein
substrate, the complete redox cycle may potentially be immediately effected.
These evolutionary modiﬁcations are reversible i.e., the resolving Cys may be
lost, returning the protein to the Grx pathway etc.
by anecdotal information underpinning a functional redox role
in speciﬁc examples (Haworth and Wouters, 2013). In particu-
lar, several CSDs are known Trx substrates (Maeda et al., 2005),
and we have postulated recently that CSDs are, in general, cognate
substrates of Trx (Haworth and Wouters, 2014).
Here, we focused speciﬁcally on protein orthologs where the
CSD is present, absent and also found as a single Cys. We pro-
vide a number of examples and speculate on the evolutionary
advantages of the changes.
MATERIALS AND METHODS
We mined the Protein databank (PDB) (Berman et al., 2000)
for proteins with CSDs, the most common type of forbidden
disulﬁde. In a dataset of 29,261 disulﬁde-containing proteins,
195 unique protein clusters containing 235 CSDs were retrieved
(Haworth and Wouters, 2013). These proteins were mapped to
Uniprot (Magrane and Consortium, 2011) using the PDB iden-
tiﬁers. For each protein sequence in this CSD set, sequences in
the corresponding 50% cluster of homologs from Uniprot were
retrieved and aligned.
SELECTION OF PROTEINS FOR STUDY
The proteins used in this study were chosen from the above
list based on two criteria—ﬁrstly, that there was good sequence
evidence (i.e. more than one ortholog) that an intermediate 1-Cys
state for the protein existed, and was retained in some species;
and secondly, that there was evidence that the protein was redox
regulated. From this set of CSD-containing proteins, three differ-
ent proteins were selected for detailed study—CD4, ERO1, and
AKT1. A fourth protein, DAPP1, satisﬁed the ﬁrst criterion, but
because we could ﬁnd no evidence supporting its redox activity,
it was not considered further. The corresponding identiﬁers for
the selected proteins in Uniprot were P01730 (CD4_HUMAN),
Q96HE7 (ERO1A_HUMAN), and P31749 (AKT1_HUMAN).
Data for the corresponding protein structures 4h8w, 3ahq, and
1unr was retrieved from PDBsum (De Beer et al., 2014).
MULTIPLE SEQUENCE ALIGNMENT AND TREE GENERATION
For each seed sequence, an initial alignment was performed
in Uniprot using the sequences in the 50% sequence identity
cluster (Clusterref_50) with the “Align” option. The raw mul-
tiple sequence alignment from Uniprot was loaded into Jalview
(2.8.1) (Waterhouse et al., 2009) for editing, visualization and
analysis. Masking was performed to remove ambiguous regions
of the alignment, and the initial tree was generated with the
Neighbor-joining method using the BLOSUM 62 substitution
matrix. Additional sequences were added to the alignment using
a combination of Blast searches (Altschul et al., 1990) of Uniprot,
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and joining of additional 50% sequence identity (ID) clusters to
provide further evolutionary depth when necessary. The gener-
ated tree in Newick format was loaded into the evolutionary tree
builder MEGA6 (Tamura et al., 2013) and the root chosen using
an outgroup from the accepted species tree (Murphy and Eizirik,
2009). The ﬁgure for the ﬁnal tree was created in MEGA6 and fur-
ther manipulated in Illustrator 6 (Adobe Systems). The number of
Cys residues in the CSD motif was mapped onto the phylograms
manually.
CD4
For CD4, the human cluster Uniref50_P01730 containing 42
sequences from 20 different species was initially retrieved.
Multiple sequences were excluded: including 15 partial sequences,
seven Refseq sequences, an uncharacterized protein, a testis cDNA
sequence and two surface antigen sequences; resulting in an ini-
tial alignment built on 16 sequences from seven different species.
Since the sequences in the cluster did not provide enough evolu-
tionary information, we extended our analysis using a Blast search
(Altschul et al., 1990) in Uniprot using P01730 as a template. The
results from the Blast search were again ﬁltered, excluding alter-
nate isoforms from the same species, resulting in an additional
125 CD4-like sequences being added to the alignment. Masking
was performed to remove alignment ambiguities near gaps. As the
alignment was ambiguous in the region of the CSD in ﬁshes, tur-
tle, duck, snakes, and frogs, these sequences were excluded from
further consideration. The ﬁnal tree was built on an alignment
of 51 sequences from 50 different species using residues homol-
ogous to 85–129, 150–230, 233, 236–244, 281–302, 307–348, and
351–373 of the human sequence. The disulﬁde of interest forms
between Cys residues at positions 154 and 184 of the human
sequence P01730 (130 and 159 in the PDB structure: 4h8w). The
complete phylogram is shown in Supplementary Figure 1. Further
analysis of sequence conservation was performed with Jalview on
sequence subsets. In one subset, the sequences of 16 primate and
three muroid sequences, where the disulﬁde was conserved, were
analyzed separately in the vicinity of the CSD. In two additional
subsets, separate pairwise alignments of human and galago CD4,
and mouse and Chinese hamster CD4 were performed as a part
of more detailed analyses (Supplementary Figure 2).
ERO1
For ERO1, the cluster Uniref50_Q96HE7 built on the human
sequence, containing 66 protein sequences from 37 species,
was used in the initial alignment. Most of the sequences were
ERO1A and ERO1B genes in higher animals. In order to retrieve
more evolutionary information, a Blast search was performed
in Uniprot using the human ERO1A protein Q96HE7 as the
template. This retrieved ERO1-like sequences from divergent
species including worms, beetles, lancelet, ﬁshes, fruit ﬂies, and
mosquitoes. The 50% identity cluster Uniref50_L7MC09 built
on the Rhipicephalus pulchellus sequence, with sequences from
lancelet (C3Z2H2), red ﬂour beetle and polychaete worms, was
incorporated, and an additional Blast search using the ERO1
protein of Capitella teleta (Polychaete worm) was performed.
The resulting alignment of 177 sequences was further reﬁned by
choosing a representative sequence for branches with very small
branch lengths. Masking was performed and a tree built from the
ﬁnal alignment containing 119 sequences using regions 33–58,
61–103, 108–115, 137–144, 157–160, 174–210, 239–270, 275–287,
295–324, 328–335, 338–363, 371–386, 390–393, 402–418, 433–
438, and 444–456 homologous to the human ERO1. A Newick
tree was generated in Jalview and loaded into MEGA6, where
the Black ﬂying fox sequence (Uniprot id: L5K102) was chosen
as the root. The two CSDs of interest are nested in the sequence
at positions 35 and 48 and 37 and 46 (PDB: 3ahq and Uniprot:
Q96HE7). A complete phylogram is shown in Supplementary
Figure 3.
AKT
For AKT, the Uniref50_P31751 cluster was retrieved with 121
sequences from 69 organisms. Of these, 54 sequences from 38
different organisms, from human to snake, were mapped to
Uniprot and the initial alignment was built. This was merged
with UniRef50_Q17941, a 50% sequence ID cluster built on
Caenorhabditis elegans AKT1 (Q17491) which mapped to 19
Uniprot sequences from 18 different organisms, mostly arthro-
pods; and the 50% cluster Uniref50_Q9XTG7 built on C. elegans
AKT2 with nine mapped sequences from sea squirt, C. vulgaris
and platyﬁsh. A Blast search was performed with the Honeybee
AKT1 (H9KF44) as the template. After removing the duplicates,
the resulting sequences were aligned in Uniprot and merged with
the previous alignment. After masking, the ﬁnal alignment was
built with 262 sequences with residues 28–45, 48–71, 76–113,
146–210, 215, 230–266, 269–302, and 335–427 homologous to
the human AKT1 protein P31749. A Newick tree was generated
and loaded into MEGA6. The land crab sequence was chosen as
the root. The disulﬁde of interest is formed between Cys 60 and
Cys 77 of the human AKT1 protein (PDB: 1unr and Uniprot:
P31749). The complete phylogram is shown in Supplementary
Figure 4.
PHYSICOCHEMICAL PROPERTIES OF CSDs
To further investigate the lability of the CSDs of interest we
calculated the torsional energies of the disulﬁde bonds; and,
where possible, the pKas of the two involved Cys. Torsional
energy calculations were performed using an online torsional
energy calculator1 based on input dihedrals, which uses a com-
bined quantum chemical (χ2,χ3,χ
′
2) and empirical calculation
(χ1,χ
′
1) described in detail elsewhere (Haworth et al., 2010).
Dihedral angles were calculated using Pymol2. Calculations of pKa
for individual Cys residues were performed with Propka3 which
gives an approximation of the pKa based on a solution of the
Boltzmann equation (Rostkowski et al., 2011). The only reduced
structure available was for AKT (PDB: 1unq).
RESULTS
We previously mined the PDB for proteins with CSDs, the most
common type of forbidden disulﬁde (Haworth and Wouters,
2014). Forbidden disulﬁdes are strained disulﬁdes that occupy
1http://www.sbinf.org/applications/pes.html
2http://www.pymol.org/
3http://propka.org
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recognizable contexts in primary and secondary structure of
proteins. The contexts were originally declared “forbidden” by
analyses that considered the geometric constraints of disulﬁde
formation and hydrogen bond formation in secondary struc-
ture (Richardson, 1981; Thornton, 1981). Later work has shown
that disulﬁdes in these strained contexts do occur, despite their
strain, which likely relates to their functional redox role in pro-
teins (Wouters et al., 2010; Haworth and Wouters, 2013). The
frequency of CSDs in solved protein structures is increasing,
likely due to better control of redox conditions during structure
solution (Wouters et al., 2010). Because CSDs can act as redox
switches, failure to control conditions carefully results in the
proteins adopting different structural states. This heterogeneity
adversely affects the crystallization process.
CSDs have been introduced into protein sequences extensively
throughout evolution, especially in molecules of the immune
system, particularly the adaptive immune system (Wouters et al.,
2007). In order to study this process in the selected proteins of
interest, we scanned homologs of proteins with CSDs for sets
where the disulﬁde was not completely conserved. Three proteins
were chosen where a CSD has been introduced relatively recently
in evolutionary history; and where the 1-Cys evolutionary inter-
mediate state was preserved in some species: CD4, ERO1, and
AKT. For each of these proteins, alignments of the homologs were
created from Uniprot clusters and Blast searches. Alignments
were masked and evolutionary trees created as described in detail
in the methods.
CD4
CD4 is a critical protein of the adaptive immune system, which
may be expressed on the surface of some lymphocytes, including
T helper cells, monocytes, macrophages, and dendritic cells. CD4
T helper cells signal to other immune cells, such as CD8 killer
cells, to alert them to the presence of infectious agents which must
be targeted. CD4 is a co-receptor for major histocompatibility
complex (MHC) class II molecules, and the primary cell sur-
face receptor for Simian immunodeﬁciency virus (SIV)/Human
immunodeﬁciency virus (HIV) (Dalgleish et al., 1984).
In CD4+ T cell antigen receptor-mediated signaling, the poly-
morphic regions of the MHC class II proteins engage the recep-
tor complex, whereas the non-polymorphic regions engage the
CD4 co-receptor (Parnes, 1989). The TCR/MHCII/CD4 super-
complex then recruits intracellular molecules such as LCK to
effect signaling.
The CD4 molecule is a single-pass transmembrane protein
with 4 extracellular immunoglobulin (Ig) domains and a short
cytoplasmic tail. The Ig domains comprise a duplication of a
pair of Ig variable (IgV) and Ig constant (IgC) domains arranged
in tandem (Figure 2B). Structurally, IgV domains are slightly
larger than IgC domains, having more strand elaborations on
the basic Ig domain fold (Halaby et al., 1999). Ig domains are
extremely common domains that are frequently involved in
redox regulation (Wouters et al., 2010; Haworth and Wouters,
2013). Ig domains and their antecedents, the ﬁbronectin type III
(FIII) domains are found in many proteins of both the innate
and adaptive immune system including cytokine receptors (FIII
domains); and Ig domain-containing MHC homologs such as
MICA and RAE-Iβ (Wouters et al., 2007). Ig domains consist of
two β sheets that form a sandwich, typically containing seven
to nine strands. The seven-stranded variety is labeled from A to
G. Additional strands in larger Ig domains (such as the variable
domains) are typically found between the C and D strands and
are labeled C′, C′′ etc. In general, Ig domains are distinguished
from FIII domains by an intersheet disulﬁde that links strand B
on one sheet to strand F on the other.
Three regions of CD4 have been implicated to date in impor-
tant protein-protein interactions (Figure 2B). The region of
human CD4 that interacts with MHC class II lies mainly within
the C′′ and D strands of domain 1 (D1), the N-terminal IgV
domain (Wang et al., 2001). A second region, located in the short
cytoplasmic tail, is a CXC motif that mediates the interaction with
lymphoid cell kinase (LCK or p56LCK) necessary for T cell acti-
vation (Laing et al., 2006). The third region, which contains the
CSD of CD4, is located in D2, the N-terminal IgC domain, joining
two β-hairpins. The CSD is formed by a disulﬁde bond between
Cys 130 and Cys 159 in the structure (PDB: 4h8w).
The CSD has been demonstrated to be reduced during the
process of T-cell signaling, and its reduction is also co-opted
during entry of the HIV viral envelope glycoprotein (gp120)
into the cell. During T-cell signaling, it must be reduced in
order for the TCR/MHCII/CD4 receptor complex to form: a
process that requires CD4 dimerization and domain swapping
(Cerutti et al., 2014). Reduction of the CD4 CSD is mediated
by Trx, Grx1, and PDI in vitro (Gallina et al., 2002; Matthias
et al., 2002; Auwerx et al., 2009). Further investigation of the
role of the CSD of CD4 in T-cell signaling has recently been
performed using four Cys mutants: C159A, a mutant of the
putative active Cys of the CSD; C16A/C84A, a double mutant
deleting the disulﬁde from D1; C130A/C159A, a CSD deletant;
and C16A/C84A/C130A/C159A, a D1 disulﬁde and CSD deletant
(Cerutti et al., 2014). Experiments with these mutants demon-
strated that CD4 binds gp120 of HIV as a reduced monomer; and
that CD4 requires reduction of either the D1 or the D2 disulﬁde to
bind gp120, but not both (Cerutti et al., 2014). A redox potential
of -241mV has been determined for the CSD by titration against
DTT (Matthias et al., 2010). The higher efﬁciency of Trx reduc-
tion of the CSD suggests the reduction is likely performed by Trx
in vivo (Cerutti et al., 2014).
The phylogenetic tree for CD4, built from 51 sequences from
50 species is shown in Figure 2A. CD4 is thought to have arisen
relatively recently in teleost ﬁsh following duplication of a two Ig
domain-containing ancestral gene, CD4REC (Laing et al., 2006).
In trout, CD4, CD4REC and the related protein lymphocyte-
activation gene 3 (LAG3) share many similar features (Figure 2B)
(Laing et al., 2006). The CSD is not present in D2 of trout CD4
which instead contains a disulﬁde between strands B and F (Laing
et al., 2006), typical of most Ig domains (Halaby et al., 1999).
The full alignment shows that between the divergence of bony
ﬁsh and chicken, the Cys on strand B was lost by mutation.
The homologous residue is a leucine (Leu) (143 in P01730 and
118 in PDB: 4h8w) in human CD4, and a single unpaired Cys
residue remains on strand F in D2 of the chicken sequence. It
seems likely this single Cys is a glutathionylation site in chicken.
Based on the phylogenetic tree, the acquisition of the second
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FIGURE 2 | Evolution of CD4 (A) phylogenetic tree in mammals. The
color of the branches indicates the number of Cys of the CSD motif in
D2. The CSD is found in species with red branches. Species with purple
branches have only the C-terminal Cys. The CSD was likely acquired in
primates (A–D) around 75 MYA, and independently in muroid rodents viz
mice, rats (O) and hamsters (P), after the divergence of squirrels (Q,
sciuridae), also around 75 MYA. Acquisition of the CSD in muroids was
accompanied by rapid evolution of the CD4 protein as evidenced by the
long branch lengths of this clade (upper red branches). The four major
clades of Eutherian mammals are Afrotheria (including elephants E);
Xenartha (none depicted); Laurasiatheria (F–L, shown in pink) and
Euarchontaglires (primates, A–D, green circle; glires, N–S yellow circle;
and treeshrews, M) (Murphy et al., 2001) Key: A, Lesser apes; B, Greater
apes; C, Marmoset (Platyrhines); D, Galago; E, African Elephant; F, Bats;
G, Panda/Mink/Ferret; H, Dog and cat; I, Pig; J, Dolphin, Whale and
Camel; K, Sheep, Bovine, Goat; L, Horse; M, Tree shrew; N, Rabbit; O,
Mouse and rat; P, Chinese hamster; Q, Squirrel/wood chuck; R, Guinea
pig; S, Mole rat; T, Wallaby and opossum; U, Platypus. (B) Evolution of
CD4 and related molecules showing important thiol-containing sites.
Molecules are depicted from the more ancestral forms of the molecule
(leftmost) to more recently evolved forms to the right. The CD4
homologs consist of two to four extracellular Ig domains, a single
transmembrane region and a short cytoplasmic tail. Three important
thiol-bearing functional sites have been identiﬁed: the CXC motif in the
cytoplasmic tail, the between-sheet disulﬁde in D1, and the cross-strand
disulﬁde (CSD) in D2. The CXC motif is present in all CD4 orthologs
(β–ε), but not in the CD4-like LAG3 molecule. The between-sheet
disulﬁde in D1 is present in CD4 and LAG3 (α–ζ). In some teleosts, such
as trout and fugu, the Cys on strand B is lost, leaving a single unpaired
Cys on strand F. D1 can be deﬁnitively identiﬁed in CD4REL because it
is distinctively encoded on two exons in molecules β–ε (Laing et al.,
2006). It is involved in interaction with MHC II molecules. Thiols in the
D2 site have evolved over time. Originally D2 contained Cys residues on
strands B and F, typical of Ig domains (α–γ). Around 250 MYA, the thiol
on strand B was lost (δ–ε). Around 75 MYA, a new thiol appeared on
strand C allowing the novel CSD to form upon oxidation (ζ). α–γ are
CD4-like proteins which evolved in a trout ancestor around 450 MYA.
Interacting proteins are shown in gray: all proteins bind MHC class II;
the CD4-related molecule LAG3 (α) binds MHC but not LCK. D3 and D4
contain glycosylation sites which may serve to fend off adventitious
interactions with other membrane proteins (Laing et al., 2006). Ig
domains are depicted as bisected hexagons with each half representing
one sheet: V-like domains are depicted in green; C-like domains in
magenta. A CXXC motif in LCK binds to the CXC motif of CD4 via Zn2+
(depicted as a blue diamond) (Lin et al., 1998). The extracellular and
cytoplasmic sides of the membrane are labeled on the right.
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Cys on strand C enabling CSD formation likely occurred inde-
pendently in two different clades, both within euarchontaglires,
one of four large clades of placental mammals (Murphy and
Eizirik, 2009). The tree in Figure 2A shows only mammals. The
CSD is found in primates, which emerged around 75 million
years ago (MYA); and was acquired independently in muroid
rodents (mice, rats, and hamsters), after the divergence of squir-
rels (sciuridae), also around 75 MYA (Murphy and Eizirik, 2009).
Acquisition of the CSD in both clades was accompanied by rapid
evolution of the sequence between the two Cys residues in D2,
as shown in the partial alignment in Figure 3 and in the full pair-
wise sequence alignments in the supplementary data (Figures S2b,
S2c). The pairwise identity for the entire CD4 molecule between
human and galago is 74%, and between rat and chinese ham-
ster is 66%; but the pairwise sequence identity over a 52-residue
window surrounding the CSD is 63% for the pairwise primate
sequences, and 44% for the pairwise muroid sequences. This
demonstrates that rapid remodeling of the sequence surround-
ing the CSD has occurred during the last 75 MYA in both the
primate and muroid clades. See further notes on this event in the
Discussion.
ERO1A (ENDOPLASMIC RETICULUM OXIDASE)
ERO1 is an essential oxidoreductase involved in disulﬁde for-
mation of nascent proteins in the endoplasmic reticulum (ER).
It acts by reoxidising protein disulﬁde isomerase (PDI), the
enzyme catalyzing disulﬁde formation. It has been extensively
studied in yeast (Frand and Kaiser, 1998). The protein contains
multiple redox-active disulﬁde bonds. In human ERO1, two
disulﬁde-forming Cys pairs, Cys 94/Cys 99 and Cys 394/Cys
397, constitute the redox-active enzymatic center. The ﬁrst pair
of thiols are regulated via isomerisation with a second pair of
redox-active thiols to form a pair of nested disulﬁdes between
non-consecutive Cys in the sequence (Cys 99–Cys 104, Cys
94–Cys 131) (Hansen et al., 2012).
Near the N-terminus of the sequence, two additional disulﬁdes
which form a nested pair, are the CSDs present in the structure
of human ERO1 (Figure 4B). In the human sequence, the two
CSDs are formed between Cys 35 & Cys 48 and Cys 37 & Cys 46.
These disulﬁdes are deemed to have a “structural role” because
they do not appear to be involved in thiol-disulﬁde exchange with
the enzymatic center (Inaba et al., 2010), nor are they conserved
across all ERO1 genes. However, the identity of these two disul-
ﬁdes as CSDs suggests a redox role, possibly as substrates of a
Trx-like enzyme (Haworth and Wouters, 2013). The role of the
Cys residues of the N-terminal thiol region (NTR) has not been
investigated by mutation but constructs of human ERO1A and
yeast ERO1 lacking the NTR are often used for functional assays
(Cabibbo et al., 2000; Sevier et al., 2007; Hansen et al., 2012). This
region may have a regulatory role.
FIGURE 3 | Multiple sequence alignment of CD4 in the region of the
CSD in species where both Cys are conserved (upper panel) and
measures of its conservation (lower panel) across two groups:
primates and muroids (purple), and primates only (green). For each
group, the conservation of the amino acid residue in each column, quality
(BLOSUM62 score based on observed substitutions) and consensus (most
common residue and its proportion for each column) as determined by
Jalview (Waterhouse et al., 2009) is shown. The sequence alignment of
CD4 showed less conservation in the vicinity of the CSD motif. In the
portion depicted, the average conservation across the primate + muroid
lineages is 6.2 for residues 53–80 (CSD region highlighted in yellow) and
7.9 within the primate group.
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FIGURE 4 | (A) Evolution of the ERO1 gene family. Branches are colored
according to the number of Cys present in the NTR of each species, as
shown in the legend. A single ERO1-like ancestral gene (pink background)
is present in eukaryotes from yeast to lamprey (J–P). With the exception
of plants (P), the majority of these genes have four Cys in the NTR (red
branches). ERO1 duplicated prior to the divergence of bony ﬁshes. ERO1A
(green background) genes retained the nested Cys motif, as does ERO1B
(yellow background) in early diverging species such as ﬁsh, sharks, and
amphibians (F, G). However, later diverging species such as birds, reptiles,
and mammals (H, I) have only two Cys, homologs to the inner pair of
CSD-forming Cys. Plants (P) have an additional Cys, C-terminal to the
nested Cys motif. Selective loss of Cys residues has resulted in a single
N-terminal Cys in some ERO1 genes (purple branches) such as in ERO1L
in tapeworm (O) and Silk moth (K), and ERO1B in the Japanese riceﬁsh.
Key to branches: A, Mammals; B, Birds; C, Frog and turtle; D, Shark and
Spotted gar; E, Fish; F, Fish; G, Shark, Frog and Coelacanth; H,
Birds/Snake/Chameleon; I, Mammals; J, Sea squirt/Oyster/Sea urchin; K,
Flies (Mosquito/Beetle/Bugs); L, Ants; M, Lancelet and Polychaete worm;
N, Worms; O, Tapeworms; P, Plants. (B) Line diagram of ERO1 showing
the disulﬁdes and NTR. The two CSDs are the two nested disulﬁdes in
the NTR region. The NTR region comprising residues 1–55 is typically
deleted in yeast functional assays. An equivalent region is typically deleted
in ERO1α (Hansen et al., 2012). Interestingly, this region is not generally
deleted in ERO1B (Pagani et al., 2000).
The phylogenetic tree for ERO1, built from 119 sequences
is shown in Figure 4A. Originally present as a single gene,
ERO1 duplicated prior to the divergence of bony ﬁshes. The
single gene in organisms predating bony ﬁshes is generally
termed ERO1-like (ERO1L) because it is clearly homologous
to yeast ERO1 but has diverged in some crucial aspects,
for example the yeast sequence has a long C-terminal tail.
Yeast ERO1 has diverged sufﬁciently from human ERO1 that
a meaningful sequence alignment over the full mask region
employed for the phylogenetic tree is not possible. Of the dupli-
cated daughters, ERO1A is ubiquitously expressed. This gene
is located on chromosome 14 in humans. The other daugh-
ter, ERO1B, expressed in secretory tissues such as the pan-
creas, is found on chromosome 1 in humans. In metazoan
ERO1L and ERO1A, the NTR has four Cys residues homol-
ogous to the CSD residues of human ERO1A, suggesting the
CSDs are conserved across the group. In ERO1B, the four
Cys are retained in the NTR of ﬁshes and sharks, but only
two Cys, homologous to those forming the inner CSD, are
present in ERO1B of amphibians and higher teleosts. The
presence of four Cys or two Cys in the NTR of ERO1B
homologs partitions with sea and land animals respectively.
Similar to ERO1B, in yeast ERO1, only the inner Cys pair is
present.
What is the signiﬁcance of Cys mutations in the NTR to the
function of ERO1 homologs? As proteins rich in disulﬁdes are
highly expressed in secretory organs, the cells in these tissues are
more susceptible to ER stress. Thus, ERO1B is likely to be under
increased demand for disulﬁde formation in the secretory tis-
sues where it is expressed compared to ERO1 homologs in other
tissues. In addition, the emergence of animals onto land likely
increased the importance of secretory organs in dealing with the
effects of dehydration. The fact that one of the CSDs is lost in the
NTR of ERO1B found in secretory tissues of land animals, sug-
gests its loss is associated with increased activity of ERO1B. This
suggests the NTR may have a role in inhibition of ERO1. The loss
of the outer CSD of ERO1B in land animals may have resulted
in decreased inhibition, allowing these organisms to cope with
Frontiers in Pharmacology | Experimental Pharmacology and Drug Discovery March 2015 | Volume 6 | Article 1 | 8
____________________________________________  171  __________________________________________________ 
Mohanasundaram et al. Role of GSH in evolution of thiol-based redox signaling
the greater demands for disulﬁde bond formation in their secre-
tory organs. The fact that NTR-deletants are typically used for
functional assays of ERO1A and yeast ERO1 is consistent with this
hypothesis.
AKT
Kinases of the AKT family are cytoplasmic proteins forming
essential components in growth factor signaling pathways,
activated downstream of the membrane-bound phospho-
inositol-3 kinase (PI3K). The AKT genes are serine/threonine-
protein kinases involved in regulating many processes such as
metabolism, proliferation, cell survival and growth, and angio-
genesis. AKT1 (RAC-α) is encoded on chromosome 14 of the
human genome. AKT2 (RAC-β), which acts in the insulin sig-
naling pathway, is encoded on chromosome 19. Both AKT1 and
AKT2 are activated by platelet-derived growth factor. AKT3 is
expressed in the brain.
The protein consists of three domains: an N-terminal
Pleckstrin homology (PH) domain, a protein kinase domain, and
a C-terminal AGC kinase domain. The PH domain is involved
in membrane targeting of AKT via binding of phospholipids.
The CSD is formed between Cys 60 and Cys 77 in the PH
domain (PDB: 1unr). Crystallographic evidence supports redox
activity of the disulﬁde (Fan et al., 2009). The reduced struc-
ture is PDB 1unq. It undergoes a morphing transition: a plastic
deformation involving a large-scale conformational rearrange-
ment of the polypeptide backbone which is likely regulated by
redox activity of the CSD (Fan et al., 2009). Cys 77 can be modi-
ﬁed by methylglyoxal to form an advanced glycation end product
(AGE). Methylglyoxal is a byproduct of several metabolic path-
ways including threonine metabolism, lipid peroxidation and
glycolysis.
Like CD4, AKT has multiple redox-regulated thiol sites. In
AKT2 a redox-regulated order/disorder transition, modulated by
reduction of the Cys 297/Cys 311 disulﬁde in the T loop, con-
trols exposure of a key phosphorylation site at Thr 309 (Huang
et al., 2003; Fan et al., 2009). Formation of the T loop disulﬁde is
proposed to inhibit kinase activity by recruiting the cognate phos-
phatase (Leslie, 2006). Grx reduces AKT, although it is not clear
whether it acts at the CSD, the T loop disulﬁde, or some other site
(Murata et al., 2003). Modiﬁcation of Cys 77 by methylglyoxal
results in activation of AKT1, promoting proliferation of vascular
smooth muscles (Chang et al., 2011). Overexpression of an AKT1
Cys77Ser mutant increased cell proliferation and DNA synthesis
which could not be augmented by methylglyoxal treatment like
the wild-type.
The phylogenetic tree for AKT built from 262 sequences is
shown in Figure 5. The AKT gene has triplicated from the original
ancestor: The original AKT-like (AKTL) gene is found in metazoa
ranging from C. elegans to lamprey. An initial duplication, occur-
ring after the divergence of lamprey, a jawless ﬁsh, was followed
shortly after by a second duplication. AKTL genes predominantly
have a single N-terminal Cys, for example all arthropods; but
orthologs exist with no Cys (clade Q—eye worm, pig round worm
and pinewood nematode worm; and the red ﬂour beetle within
clade W, Coleoptera); and a single C-terminal Cys (clade R-C. ele-
gans, pole worm and nematode worm, clade O—Sea squirt).
Clade N is the earliest metazoan with both Cys of the CSD. This
group includes the hemichordate acorn worm and a placazoan, a
basal form of invertebrate. Lamprey is the highest organism con-
taining a single AKT gene with both Cys of the CSD. Subsequent
to the divergence of lamprey the AKT gene underwent a trip-
lication, with all daughters: AKT1, AKT2, and AKT3, retaining
the CSD.
PHYSICOCHEMICAL PROPERTIES OF THE CSDs
The physicochemical properties of the CSDs of interest to this
study are listed in Table 1, along with those of three control
disulﬁdes. Two positive controls are barley α-amylase/subtilisin
inhibitor (BASI) Cys 144–Cys 148, a CSD which is a preferred
substrate of Trxh; and DsbD Cys 103–Cys 109, a CSD which is
the active site disulﬁde in the N-terminal domain of DsbD, which
is reduced in vivo by the Trx-like C-terminal domain of DsbD.
A negative control is BASI Cys 43–Cys 90 which is reduced by
Trxh, but is not a preferred substrate (Maeda et al., 2006). All
the CSDs adopt the right-handed staple conformation and have
medium torsional energies (10–17.5 kJ.mol−1) typical of CSDs,
except the outer disulﬁde of the ERO1 nested pair. This disulﬁde
between Cys 35 and Cys 48 adopts a much higher energy cis GGS′
conformation (Haworth et al., 2007). Its extremely high torsional
energy is consistent with an auto-reduction process; the Cys of
this disulﬁde could potentially isomerize with Cys 37 and Cys 46
or may even be mechanically reduced. The negative control in
BASI between Cys 43 and Cys 90 is a low energy disulﬁde in a
right-handed spiral conformation, typical of structural disulﬁdes
(Haworth et al., 2007). In summary, with the exception of the Cys
35–Cys 48 CSD of ERO1, all the CSDs in the proteins of interest
had conformations and torsional energies consistent with CSDs
which are preferred substrates of Trx-like enzymes.
Finally, we attempted to assess the likelihood that the reduced
form of the protein of interest was a likely target of ROS/RNS; and
which of the Cys was more likely to be modiﬁed. This was only
possible for the PH domain of AKT. The controls we used were
reduced forms of Trx-like enzymes and other proteins known to
be modiﬁed by GSH. The results are shown in Table 2. The pKas
of the active Cys in Grxs were generally between 7 and 8, while Cys
in proteins which are modiﬁed by GSH were between 10 and 11.
The values calculated for AKT were in the same range as GSH sub-
strates. From the point of view of pKa, both Cys are equally likely
to be attacked by ROS/RNS. However, other considerations may
be important in vivo such as solvent accessibility of the individual
Cys i.e., whether it is buried or accessible.
DISCUSSION
Disulﬁde bonds between Cys residues are generally thought to
confer extra rigidity and stability to their resident protein, form-
ing a type of proteinaceous spot weld. The conundrum of disul-
ﬁdes as structural stabilizers is how the two Cys residues could
have been introduced into the protein chain simultaneously. A
possible explanation is suggested by the emerging paradigm that
the disulﬁde proteome consists of two subproteomes: a structural
group and a redox-sensitive group (Yang et al., 2007). For struc-
tural disulﬁdes, both Cys are functionally required. However, a
single Cys residue can form a redox-sensitive site on a protein.
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FIGURE 5 | Evolution of AKT genes showing the presence of the CSD.
Colors of branches denote the number of Cys residues homologous to
those of the CSD present in each species. Reversion to a single C-terminal
Cys in the Chinese tree shrew is accompanied by rapid diversion of the
sequence from other mammalian sequences. Keys to branches A,
Mammals, birds, reptiles; B, Fishes; C, Sea lamprey; D, Mammals; E,
Snakes; F, Spotted gar, salmon, and ﬁshes; G, Frogs; H, Elephant ﬁsh; I,
Zebra ﬁsh; J, Mammals; K, Tasmanian devil, Opposum, Turtle, and Birds;
L, Frog and Coelacanth; M, Fishes; N, Acorn worm; O, Sea squirt; P,
Trichina worm; Q, Eye worm, Pig round worm, and Pinewood nematode
worm; R-C. elegans, pole worm and nematode worm; S-Y-Arthropods
including Lepidoptera (T) and Diptera (U,V).
Table 1 | Dihedral angles calculated for the disulﬁdes of interest in the proteins studied with the torsional energies and their respective
conformations.
Protein PDB code Disulf χ1 χ2 χ3 χ
′
2 χ
′
1 Torsion energy Conf. Motif
kJ/mol
AKT 1unr 60–77 −52.3 −120.5 105.2 −82.6 −50.9 13.9 Staple CSD
ERO1 3ahq 35–48 −54.3 −121.9 45.8 75.6 176.7 36.9 cis CSD
ERO1 3ahq 37–46 −61.3 −79.9 110.1 −102.8 −58.8 11.7 Staple CSD
CD4 4h8w 130–159 −67.0 −86.3 108.2 −91.1 −58.6 11.7 Staple CSD
+BASI 1ava 144–148 −63.2 −93.9 115.6 −78.1 −71.0 12.5 Staple CSD
−BASI 1ava 43–90 −60.1 −73.5 −89.3 −73.6 −67.0 1.6 Spiral –
+DsbD 1jpe 103–109 −51.0 −116.4 92.1 −77.8 −72.8 13.8 Staple CSD
Thus, a redox-active disulﬁde may be introduced into a pro-
tein structure by stepwise mutation of two residues in the native
sequence to Cys. By extension, evolutionary acquisition of struc-
tural disulﬁdes in proteins can potentially occur via transition
through a redox-active disulﬁde state.
Alternatively, a fully-ﬂedged disulﬁde of either type could be
acquired via a retrotransposon. Indeed, introduction of another
type of redox site, the four Cys zinc (Zn2+) binding site (Wouters
et al., 2010), into proteins appears to largely have been effected
by retrotransposons (Babu et al., 2006). A hallmark of this
type of acquisition is insertion of a sequence fragment. In the
case of Zn ﬁngers, the fragment is around 30 amino acids in
length.
The cases of CSD acquisition here clearly do not involve
insertion of a sequence fragment, as evidenced by the sequence
alignment. Instead, the redox switch was introduced by stepwise
mutation of two residues in the native sequence to Cys. The
advantages of acquisition of the CSD to protein function are
clearly demonstrated by the retention of the redox switch in
higher organisms. It is interesting to note that triplication of the
AKT gene occurred after acquisition of the CSD, and it remained
encoded in all daughter genes, suggesting it is integral to the
function of these genes. In some species or homologs, the CSD
acquisition process appears to have reversed. For example, in
ERO1B, one of the CSDs was lost in secretory tissues of land
animals.
Do the two Cys need to be acquired in a particular order dur-
ing the evolutionary process? In order to be glutathionylated,
a minimum requirement is that the Cys has a low pKa. When
two disulﬁde-forming Cys are present, the Cys with the lower
pKa is generally termed the “active” Cys (Figure 1), because it is
the one targeted by ROS/RNS. The second Cys, which prevents
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Table 2 | Calculated pKas for AKT and control proteins.
Protein Cys PDB pKa
ScGrx6 136 3l4n 7.42
StGrx2 9* 3ir4 7.11
HsGrx2 37 2ﬂs 8.01
HsCLIC1 24 1k0n 9.43
SpGST 10* 1f2e 11.56 ± 0.24
PmGST 10* 1pmt 11.07
BxGST 10 2dsa 17.29 ± 0.05
HsGSHR 58* 1dnc 9.52 ± 0.11
TttRNA methyltransferase 223 3g5s 10.09
Rncarbonic anhydrase 183* 1ﬂj 10.57
AKT 60 1unq 11.35
AKT 77 1unq 11.03
*Indicates the proteins where GSH was removed from Cys for calculation.
Standard error was calculated where required.
FIGURE 6 | Location of CSDs in the secondary structure of the proteins
studied according to PDB structures: CD4—4h8w, ERO1—3ahq, and
AKT—1unr. The Cys on the orange strand is the putative active Cys for
each protein. Trx/Grx must bind as an extra strand near the active Cys as
shown for AKT. In ERO1 and CD4, this site is protected by an additional
strand (strand G in both CD4 and ERO1), which must be displaced to allow
access by Trx. For CD4 to become accessible to Trx/Grx, one of the hairpins
must hinge open to allow Trx/Grx to dock in place of the strand as shown in
the hypothetical CD4∗ diagram.
overoxidation of the active Cys by disulﬁde formation, is termed
the “resolving Cys.” However, the pKas of the two Cys are not
easily discerned from a protein structure and are generally deter-
mined experimentally. In addition, the structural requirements
of Grx and Trx docking are such that the active Cys should be
on an edge strand (Figure 6). Thus, by the simplistic hypothe-
sis depicted in Figure 1, the low pKa Cys should be introduced
into the protein ﬁrst and be mutated from the protein last; and it
should be on an edge strand. How does this hypothesis stack up
with the three proteins studied here? The relevant information is
summarized in Table 3.
Table 3 | Contexts of CSD residues in proteins of interest.
Protein N-Cys Edge? C-Cys Edge? Environment
CD4 130 No 159 No Cell surface
ERO1 35 No 48 Yes ER
ERO1 37 No 46 Yes ER
AKT 60 Yes 77 No Cystosol
The table is based on PDB structures 1unr (AKT), 4h8w (CD4), and 3ahq (ERO1).
The most common 1-Cys residue in the sequence alignments is bolded. This is
likely to be the “active” Cys.
Of the three molecules, only AKT can dock Grx/Trx in the
manner suggested, as shown in Figure 6. However, of the three
molecules, AKT is the only cytosolic protein and thus would
be found in the reduced state under normal physiologic con-
ditions. Thus, consideration of the cellular compartment is an
additional complication. Oxidation of a cytosolic molecule, pro-
moting formation of the disulﬁde-bonded form, will only occur
under conditions of oxidative stress. Disulﬁde bond formation in
the pleckstrin-homology domain of AKT is likely associated with
membrane targeting of AKT under conditions of oxidative stress
(Fan et al., 2009). The likelihood that Cys 60 is the active Cys
of the AKT CSD is supported by studies which demonstrate its
modiﬁcation in experiments on growth factor signaling (Antico
Arciuch et al., 2009). On the other hand, CD4 and ERO1 exist
in oxidative environments where the disulﬁde bond would be
formed in the latent state: CD4 is cell surface protein of the blood
plasma; ERO1 is an ER-resident protein.
Only in the cytosolic protein AKT, where the disulﬁde is nor-
mally in the reduced state, is the protein readily accessible by Trx.
In CD4 and ERO1, the putative Trx-binding site is blocked by
an additional strand. In CD4, the additional strand G is formed
by residues 166–172 (PDB: 4h8w). In ERO1, strand G is formed
by residues 355–359. Protection by an additional strand may be
a general feature of CSDs in oxidative environments to prevent
adventitious reduction of the CSD.
Because the disulﬁdes in ERO1 and CD4 are latently oxi-
dized, it is likely that Trx is only given access to the site under
special conditions. For example, in CD4 the site becomes acces-
sible during T-cell signaling. It has been proposed that CD4
undergoes domain swapping to facilitate this reduction (Matthias
et al., 2002), a process that involves rearrangement of β strands.
We speculate on the nature of this process in CD4 below. The
latently oxidized states, are thus likely “occult” Trx-binding sites
which must be unmasked by conformational changes prior to Trx
binding and disulﬁde reduction (Wouters et al., 2010).
Several other proteins containing CSDs domain swap suggest-
ing a relationship between domain swapping and CSD reduction
(Wouters et al., 2010). GSH binding may also be related to domain
swapping: GSH binding to Cys 60 of glyoxalase I regulates domain
swapping in this protein (Saint-Jean et al., 1998).
EVOLUTION OF CD4
Several evolutionary studies of CD4 have examined the non-
synonymous/synonymous substitution rate (ω = dN/dS) in
order to determine which regions of the CD4 molecule are under
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positive selection. Non-synonymous changes are nucleotide
codon changes that alter the amino acid coded at the protein
level, while synonymous changes alter the nucleotide while
preserving the amino acid. These studies found that CD4 is
evolving rapidly under positive selection. In a pairwise com-
parison of human and mouse CD4, Ansari-Lari et al. (1998)
determined ω = 0.77, much higher than the average of ω = 0.12
determined for ∼13000 pairs of human/mouse orthologs. A
study of primate CD4 sequences identiﬁed positive selection
(ω > 1) throughout the molecule, but chieﬂy in the N-terminal
region corresponding to D1 and D2 (Zhang et al., 2008). The
sequence up to residue ∼153, which includes the ﬁrst Cys residue
of the CSD, has stronger selection than average for the molecule
(ω > ω−= 1.17).
Our study shows that the relatively rapid evolution of CD4 is
predominantly focused on acquisition and modiﬁcation of thiols
involved in redox signaling. CD4 is an interesting molecule from
the point of view of evolution of thiol-based redox signaling.
All three known protein-protein interaction sites contain impor-
tant cysteine residues. The primordial cysteine site: the CXC
motif found in the cytoplasmic tail, is not found in the ances-
tral gene LAG3. This motif mediates the interaction with p56LCK
necessary for T cell activation (Laing et al., 2006).
A second site is the CSD in D2, which is the subject of this
study. This is the primary recognition site for HIV gp120 and
a co-recognition site for MHCII molecules. The independent
acquisition of the CSD in two clades, primates and muroids,
at roughly the same epoch ∼75 MYA is interesting, and could
arise from an environmental change, for example in the oxy-
genation of the Earth’s atmosphere. This date is not long after
the KT extinction, the global event that wiped out the dinosaurs
around 80 MYA. Alternatively the dual acquisition might have a
biological origin e.g., challenge by a common parasite or infec-
tious agent. Mammals evolved during an interesting period of the
earth’s history with respect to continental drift. During the cre-
ataceous period, the super-continent Gondwana broke up. Given
the co-location of the two clades involved on the same continent,
the second “biological challenge” hypothesis seems attractive.
The pairwise sequence alignments show the CSD site has been
undergoing rapid evolution since its introduction in both clades
(Figure S2).
The third protein-protein interaction site bearing important
Cys residues is located in D1. Interestingly, in a process similar to
step 1 of the CSD evolution in D2, modiﬁcation of the canonical
Ig disulﬁde between strands B and F has also occurred in D1 of
some ﬁsh CD4 proteins (trout and fugu), which contain a distinct
unpaired Cys in strand F, but lack the second Cys in strand B that
forms a disulﬁde in mammalian and bird CD4 molecules.
Finally, LAG3 is very similar to CD4 but lacks the LCK bind-
ing site (Laing et al., 2006) (α in Figure 2B). Functionally LAG3
interacts with MHCII with higher afﬁnities than CD4, and may
have a role in impeding access to MHCII of CD4 (Workman
et al., 2002; Workman and Vignali, 2003). The two Ig-domain
molecule CD4REL (β in Figure 2B) appears to be a progenitor
of CD4 which is also found in the lamprey a vertebrate which
diverged earlier than ﬁsh. The lamprey genome does not contain a
CD4 ortholog (γ in Figure 2B). Trout contains both CD4REL and
CD4, but vertebrates that evolved later, such as the chicken, do not
appear to have a CD4REL-like molecule, retaining only CD4.
Thus, CD4 arose de novo in ﬁsh around 450 MYA around the
time its primary tissue of origin, the thymus, appeared in ani-
mals. Originally containing the important cytosolic CXC motif,
CD4 then underwent rapid evolution at two distinct protein-
protein interaction sites in D1 and D2, both bearing important
Cys residues.
Speculations on activation of CD4 by HIV gp120
Given the importance of CD4 CSD reduction in the entry of HIV
gp120 into the cell, it is worth speculating on the nature of this
process in the light of the hypothesis put forward here. Sheet 1
in D2 of CD4, which consists of residues 99–119 and 142–146,
can be considered as the “torso” of D2 from which two β-hairpin
“arms” are extended, comprising residues 127–140 (N-arm) and
residues 157–172 (C-arm). These “arms” are clasped together by
a series of hydrogen bonds and the disulﬁde formed between
Cys 130 and Cys 159 on strands C and F to form the second
sheet. In domain swapping, either one or both of these arms may
be exchanged with an adjacent CD4 molecule. This can only be
achieved by breakage of the C-F hydrogen bonds and reduction
of the CSD between Cys 130 and Cys 159. In its location on the
interior strands of the four-stranded sheet 2, the CSD is protected
from interaction with Trx and Grx. However, it may be accessi-
ble by GSH. In order to become accessible to Trx/Grx, one of the
hairpins must hinge open, to allow Trx/Grx to dock in place of the
strand. As Cys 159 is conserved in all CD4 molecules, it is likely
the “active Cys.” Thus, docking of Trx/Grx may be effected by
peeling away the C-terminal strand (G) from the molecule (CD4∗
in Figure 6). Thus, we propose this is a necessary “priming” step
for CD4 CSD reduction.
CONTEXT-DEPENDENCE OF Cys INCORPORATION IN PROTEIN
SEQUENCES
Early studies on protein sequences indicated Cys is more abun-
dant in more complex organisms (Fahey et al., 1977; Miseta and
Csutora, 2000). This has been conﬁrmed by more recent stud-
ies on whole genomes that have shown the abundance of Cys
in proteins has been increasing since divergence from the Last
Universal Common Ancestor (Woese, 1998; Brooks and Fresco,
2002); and this increase is a continuing panspecies phenomenon
which is evident within the last 10 million years (Jordan et al.,
2005). It seems likely that increased Cys abundance arises from
increased use of thiol-based redox signaling in more complex
organisms. Although the prevalence of Cys in proteins is increas-
ing, the abundance has not yet reached the neutral frequency (i.e.,
the frequency that would be expected based on the number of
Cys codons in the genetic code) (King and Jukes, 1969; Brooks
and Fresco, 2002). The failure of Cys to reach its equilibrium fre-
quency suggests that incorporation of additional Cys into proteins
may come at a cost: increased signaling and control may be gained
at the cost of deleterious effects of over-oxidation (Wouters et al.,
2010).
This study suggests that successful incorporation of Cys may
be limited to very select contexts in proteins, speciﬁcally those
where reduction of the Cys can be effected by enzymes of redox
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homeostasis. In this study, the successfully incorporated sites are
likely reduced by Trx-like enzymes. The disulﬁde bond in CD4 is
reduced by Trx (Aniksztejn et al., 1987; Matthias et al., 2002), and
the disulﬁde in AKT may be sensitive to Grx (Murata et al., 2003;
Wang et al., 2007).
If a Cys that is modiﬁable by GSH is in a place which cannot
be accessed by Grx, the protein will likely be targeted for removal
by the GSH detoxiﬁcation system. Thus, the mutation most likely
will have a deleterious effect on protein function by inducing a
state of haploinsufﬁciency. If the Cys is in a place where it may be
reduced by Grx, introduction of the Cys does not have a deleteri-
ous effect on protein function because it may be removed. If, in
addition, it is introduced in a place which modulates the protein’s
function in a way which is beneﬁcial to redox function, it may
become ﬁxed in the population. For example, if addition of GSH
temporarily prevents a protein interaction that would be delete-
rious under conditions of oxidative stress. Thus, only 1-Cys GSH
switches that are beneﬁcial to physiologic function are likely to be
retained in the population sufﬁciently long for random mutation
of a second Cys to occur; and this second mutation must also be
sufﬁciently beneﬁcial to be retained over the 1-Cys variant.
CONVERGENT ACQUISITION OF MODULAR REDOX SWITCHES
Before multiple genome sequences were complete, it was gener-
ally believed increased complexity of organisms correlated with
gene number. After completion of the ﬁrst genomes, the small
differences in gene number between simple unicellular eukaryotes
and mammals forced revision of how complexity is encoded. For
example, the yeast genome contains 5000 genes, yet the human
genome contains only ﬁve times more: 25,000. Additional com-
plexity at the organismal level is likely encoded at the molecular
level by noncoding DNA, as this is considerably different between
these organisms (Mattick, 2004).
However, increased complexity may also be encoded at the
protein level. It was previously recognized that concatenation
of existing domains through gene fusion, also known as pro-
tein domain mosaicism, encodes new functions in more complex
organisms (Patthy, 1985). Studies on the changing amino acid
content of proteins show that domains also are not static struc-
tures. Additional complexity added to protein domains in the
form of redox and other switches likely increases the signaling
capabilities of individual domains. In other words, nature is con-
tinually tinkering with these independent folding units: a domain
from archaea may not have the same sophisticated set of switches
as the homologous domain from a mammalian protein.
Thus, two modes of acquisition of increased protein complex-
ity have been demonstrated to date: protein domain mosaicism
(Patthy, 1985), and acquisition of allosteric control sites.
Previously, Babu et al. (2006) showed that Zn ﬁnger allosteric
control sites are added to protein sequences via retrotransposons.
Here we studied a novel method of acquisition of an allosteric
control site: formation of CSDs by stepwise acquisition of Cys
residues in appropriate contexts. Both these Cys-based sites, Zn
ﬁngers and CSDs, are known to be redox regulated.
In this study, we analyzed incorporation of disulﬁde-
based redox switches into three protein families. Successful
context-dependent stepwise evolution of the sites likely enabled
the proteins to utilize existing Trx-like enzymes to mediate suc-
cessful incorporation into cellular mechanisms of redox home-
ostasis. Thus, three non-homologous proteins have convergently
acquired the same modular redox switch: the CSD. CSDs are,
by far, the most common forbidden disulﬁde found in homol-
ogous sites of protein structures (Wouters et al., 2010). They have
evolved independently multiple times. CSDs have been postu-
lated to have special redox properties: speciﬁcally intermediate
torsional energies that enable them to be reduced in a con-
trolled process by other thiol sites in proteins. However, many
other forbidden disulﬁdes share this property, so this does not
explain why evolution of CSDs is favored over other forbid-
den disulﬁdes. Work by Maeda et al. (2005), which suggests
that a CSD in BASI is speciﬁcally recognized by Trx; and our
own bioinformatic work, which has identiﬁed multiple CSDs
which undergo redox reactions with the CXXC motif of Trx-like
enzymes, suggest that CSDs are cognate substrates of Trx-like
enzymes (Haworth and Wouters, 2013). Although Trxs recognize
multiple non-homologous substrates, solved protein structures of
disulﬁde-linked Trx-substrate reaction intermediate mimics have
provided evidence for recognition of structural motifs in tar-
get proteins by Trxs (Qin et al., 1995, 1996; Maeda et al., 2006;
Chartron et al., 2007).
Although BASI has nine disulﬁdes, only two are speciﬁcally
targeted by Trxh (Maeda et al., 2005). Cys 144–Cys 148 and Cys
43–Cys 90. Of these two, Cys 144–Cys 148, which is a CSD, is
much more efﬁciently reduced. The speciﬁcity of the reaction is
partly ensured by consistent docking of the substrate. In most
solved protein structure complexes, Trx-like molecules bind their
substrates as an antiparallel β-strand. The interaction between Trx
and its substrate is characterized by three distinctive hydrogen
bonds of a pattern typically found between pairs of antiparallel β-
strands. A similar pattern of hydrogen bonds is observed between
the N-terminal Trx-like domain of Escherichia coli DsbD in com-
plex with the C-terminal domain of DsbD which contains the
CSD (Cys 103–Cys 109) substrate (Rozhkova et al., 2004). This
suggests the evolution of CSDs is favored over other forbidden
disulﬁdes because they can be immediately exapted from the Grx
to the Trx redox homeostasis pathways.
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Supplementary Figure 1. Phylogram of 51 CD4 sequences 
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
Supplementary Figure 2. Pairwise alignment of CD4 sequences (a) in the region of the CSD 
between human & galago (upper panel) and mouse & Chinese hamster (lower panel).  
 (a) 
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Supplementary Figure 2 cont. Pairwise alignment of CD4 sequences (b) between human and 
galago over the full length sequence 
 (b) 
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(c) 
Supplementary Figure 2 cont. Pairwise alignment of CD4 sequences (b) between mouse and 
Chinese hamster over the full length sequence 
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Supplementary Figure 3 Phylogram of 119 ERO1 sequences
 TR|tr|B6T402|B6T402_MAIZE|B6T402_MAIZE
 TR|tr|C5XP64|C5XP64_SORBI|C5XP64_SORBI
 TR|tr|B8AR26|B8AR26_ORYSI|B8AR26_ORYSI
 TR|tr|V7B0U3|V7B0U3_PHAVU|V7B0U3_PHAVU
 TR|tr|B9I0F6|B9I0F6_POPTR|B9I0F6_POPTR
 TR|tr|M0TVD4|M0TVD4_MUSAM|M0TVD4_MUSAM
 TR|tr|Q0WSW0|Q0WSW0_ARATH|Q0WSW0_ARATH
 TR|tr|R0HZ01|R0HZ01_9BRAS|R0HZ01_9BRAS
 TR|tr|V4M9W8|V4M9W8_THESL|V4M9W8_THESL
 TR|tr|M4DHU7|M4DHU7_BRARP|M4DHU7_BRARP
 TR|tr|S8DWJ9|S8DWJ9_9LAMI|S8DWJ9_9LAMI
 TR|tr|A9SBX8|A9SBX8_PHYPA|A9SBX8_PHYPA
 TR|tr|A9UUU1|A9UUU1_MONBE|A9UUU1_MONBE
 TR|tr|R7YQS1|R7YQS1_CONA1|R7YQS1_CONA1
 TR|tr|E9C516|E9C516_CAPO3|E9C516_CAPO3
 TR|tr|I1GIZ9|I1GIZ9_AMPQE|I1GIZ9_AMPQE
 TR|tr|T2MA59|T2MA59_HYDVU|T2MA59_HYDVU
 TR|tr|C1LI61|C1LI61_SCHJA|C1LI61_SCHJA
 TR|tr|U6IFD3|U6IFD3_HYMMI|U6IFD3_HYMMI
 TR|tr|U6J885|U6J885_ECHGR|U6J885_ECHGR
 TR|tr|U6HFF2|U6HFF2_ECHMU|U6HFF2_ECHMU
 TR|tr|F1KZ40|F1KZ40_ASCSU|F1KZ40_ASCSU
 TR|tr|E1FI97|E1FI97_LOALO|E1FI97_LOALO
 SP|sp|Q7YTU4|ERO1_CAEEL|ERO1_CAEEL
 TR|tr|W2THQ4|W2THQ4_NECAM|W2THQ4_NECAM
 TR|tr|U6PNX3|U6PNX3_HAECO|U6PNX3_HAECO
 TR|tr|R7UCP7|R7UCP7_CAPTE|R7UCP7_CAPTE
 TR|tr|C3Z2H2|C3Z2H2_BRAFL|C3Z2H2_BRAFL
 TR|tr|E9H6Q2|E9H6Q2_DAPPU|E9H6Q2_DAPPU
 TR|tr|W4YG08|W4YG08_STRPU|W4YG08_STRPU
 TR|tr|V3ZG02|V3ZG02_LOTGI|V3ZG02_LOTGI
 TR|tr|K1QN22|K1QN22_CRAGI|K1QN22_CRAGI
 TR|tr|L7M109|L7M109_9ACAR|L7M109_9ACAR
 TR|tr|L7M871|L7M871_9ACAR|L7M871_9ACAR
 TR|tr|G3MQT0|G3MQT0_9ACAR|G3MQT0_9ACAR
 TR|tr|B8Y9B6|B8Y9B6_BOMMO|B8Y9B6_BOMMO
 TR|tr|U5ETA6|U5ETA6_9DIPT|U5ETA6_9DIPT
 TR|tr|Q7QCV3|Q7QCV3_ANOGA|Q7QCV3_ANOGA
 SP|sp|Q9V3A6|ERO1L_DROME|ERO1L_DROME
 TR|tr|D6W7V7|D6W7V7_TRICA|D6W7V7_TRICA
 TR|tr|N6TSI6|N6TSI6_DENPD|N6TSI6_DENPD
 TR|tr|T1HPH1|T1HPH1_RHOPR|T1HPH1_RHOPR
 TR|tr|E0VC42|E0VC42_PEDHC|E0VC42_PEDHC
 TR|tr|H9KE10|H9KE10_APIME|H9KE10_APIME
 TR|tr|E2A327|E2A327_CAMFO|E2A327_CAMFO
 TR|tr|E2BCF6|E2BCF6_HARSA|E2BCF6_HARSA
 TR|tr|W4WQW6|W4WQW6_ATTCE|W4WQW6_ATTCE
 TR|tr|F4WHH6|F4WHH6_ACREC|F4WHH6_ACREC
 TR|tr|F6V6R4|F6V6R4_CIOIN|F6V6R4_CIOIN
 TR|tr|H2TT03|H2TT03_TAKRU|H2TT03_TAKRU
 TR|tr|H2TT05|H2TT05_TAKRU|H2TT05_TAKRU
 TR|tr|H3C6T4|H3C6T4_TETNG|H3C6T4_TETNG
 TR|tr|I3KP09|I3KP09_ORENI|I3KP09_ORENI
 TR|tr|H2L719|H2L719_ORYLA|H2L719_ORYLA
 TR|tr|M3ZKX5|M3ZKX5_XIPMA|M3ZKX5_XIPMA
 TR|tr|W5LPX7|W5LPX7_ASTMX|W5LPX7_ASTMX
 TR|tr|F1QE51|F1QE51_DANRE|F1QE51_DANRE
 TR|tr|E7F2A8|E7F2A8_DANRE|E7F2A8_DANRE
 TR|tr|V9KT61|V9KT61_CALMI|V9KT61_CALMI
 TR|tr|H3AMX3|H3AMX3_LATCH|H3AMX3_LATCH
 TR|tr|F6ULN4|F6ULN4_XENTR|F6ULN4_XENTR
 TR|tr|J3SC59|J3SC59_CROAD|J3SC59_CROAD
 TR|tr|U3FX11|U3FX11_MICFL|U3FX11_MICFL
 TR|tr|G1KAL4|G1KAL4_ANOCA|G1KAL4_ANOCA
 TR|tr|E1C917|E1C917_CHICK|E1C917_CHICK
 TR|tr|F7CL82|F7CL82_MONDO|F7CL82_MONDO
 TR|tr|F1MW08|F1MW08_BOVIN|F1MW08_BOVIN
 TR|tr|M3W090|M3W090_FELCA|M3W090_FELCA
 TR|tr|G3HWE1|G3HWE1_CRIGR|G3HWE1_CRIGR
 SP|sp|Q8R2E9|ERO1B_MOUSE|ERO1B_MOUSE
 TR|tr|L5K2X2|L5K2X2_PTEAL|L5K2X2_PTEAL
 TR|tr|G5APM2|G5APM2_HETGA|G5APM2_HETGA
 TR|tr|K9J2V9|K9J2V9_DESRO|K9J2V9_DESRO
 TR|tr|F6PL51|F6PL51_CALJA|F6PL51_CALJA
 TR|tr|G1T433|G1T433_RABIT|G1T433_RABIT
 TR|tr|J9NT87|J9NT87_CANFA|J9NT87_CANFA
 TR|tr|G1QSI0|G1QSI0_NOMLE|G1QSI0_NOMLE
 TR|tr|H2R1J8|H2R1J8_PANTR|H2R1J8_PANTR
 TR|tr|B2RD00|B2RD00_HUMAN|B2RD00_HUMAN
 SP|sp|Q86YB8|ERO1B_HUMAN|ERO1B_HUMAN
 TR|tr|G3RN30|G3RN30_GORGO|G3RN30_GORGO
 TR|tr|H9FX92|H9FX92_MACMU|H9FX92_MACMU
 TR|tr|H9YWG1|H9YWG1_MACMU|H9YWG1_MACMU
 TR|tr|V9KCJ8|V9KCJ8_CALMI|V9KCJ8_CALMI
 TR|tr|W5N2H6|W5N2H6_LEPOC|W5N2H6_LEPOC
 TR|tr|E9QES5|E9QES5_DANRE|E9QES5_DANRE
 TR|tr|I3JJ71|I3JJ71_ORENI|I3JJ71_ORENI
 TR|tr|H2UPL0|H2UPL0_TAKRU|H2UPL0_TAKRU
 TR|tr|H3C7W4|H3C7W4_TETNG|H3C7W4_TETNG
 TR|tr|H3DN84|H3DN84_TETNG|H3DN84_TETNG
 SP|sp|B1H1F9|ERO1A_XENTR|ERO1A_XENTR
 SP|sp|Q6DD71|ERO1A_XENLA|ERO1A_XENLA
 TR|tr|K7G086|K7G086_PELSI|K7G086_PELSI
 TR|tr|H0ZSA4|H0ZSA4_TAEGU|H0ZSA4_TAEGU
 TR|tr|U3JMP2|U3JMP2_FICAL|U3JMP2_FICAL
 TR|tr|U3I177|U3I177_ANAPL|U3I177_ANAPL
 TR|tr|E1C0W7|E1C0W7_CHICK|E1C0W7_CHICK
 TR|tr|F7F941|F7F941_MONDO|F7F941_MONDO
 TR|tr|H0VA43|H0VA43_CAVPO|H0VA43_CAVPO
 TR|tr|Q4FJZ3|Q4FJZ3_MOUSE|Q4FJZ3_MOUSE
 SP|sp|Q8R180|ERO1A_MOUSE|ERO1A_MOUSE
 SP|sp|Q8R4A1|ERO1A_RAT|ERO1A_RAT
 TR|tr|S7MW57|S7MW57_MYOBR|S7MW57_MYOBR
 TR|tr|G1PS99|G1PS99_MYOLU|G1PS99_MYOLU
 TR|tr|H2Q8B5|H2Q8B5_PANTR|H2Q8B5_PANTR
 TR|tr|F6YZY7|F6YZY7_CALJA|F6YZY7_CALJA
 SP|sp|Q96HE7|ERO1A_HUMAN|ERO1A_HUMAN
 TR|tr|H2NL92|H2NL92_PONAB|H2NL92_PONAB
 TR|tr|H0X1Q6|H0X1Q6_OTOGA|H0X1Q6_OTOGA
 TR|tr|K9J152|K9J152_DESRO|K9J152_DESRO
 SP|sp|B6CVD7|ERO1A_PIG|ERO1A_PIG
 SP|sp|A5PJN2|ERO1A_BOVIN|ERO1A_BOVIN
 TR|tr|M3X8L8|M3X8L8_FELCA|M3X8L8_FELCA
 TR|tr|U6CSF8|U6CSF8_NEOVI|U6CSF8_NEOVI
 TR|tr|M1ESD2|M1ESD2_MUSPF|M1ESD2_MUSPF
 TR|tr|G1LEZ2|G1LEZ2_AILME|G1LEZ2_AILME
 TR|tr|E2RNW5|E2RNW5_CANFA|E2RNW5_CANFA
 TR|tr|G3STY7|G3STY7_LOXAF|G3STY7_LOXAF
 TR|tr|L5K102|L5K102_PTEAL|L5K102_PTEAL
5
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Supplementary Figure 4 Phylogram of 262 AKT sequences 
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Discussion5.4
Acquisition of CSDs in the three proteins studied was context-dependent. In CD4,
which is primarily found in the cell surface of proteins, CSD formation was likely to occur
independently in two different clades, both within the super order of mammals. However in
the cytosolic protein AKT, the two Cys of the CSD were retained in AKTL in higher animals
up to the lamphrey, and also in daughter genes—AKT1, AKT2, and AKT3 subsequent to
gene duplication. On the contrary, in case of the endoplasmic protein ERO1, two outer CSD
was lost in higher animals in ERO1B, after the duplication of ERO1 gene. Results suggested
that incorporation of Cys might be limited to selected contexts in proteins.
5.4.1 Reduction of CSD
Similar to acquisition of CSD disulfides, reduction of these CSDs was also context-
dependent. For example, in order for the CSD to be reduced, the active Cys should be on the
strand that is easily accessible by Trx/Grx like enzymes. Of all the three proteins considered
here, only the cytosolic protein AKT, where the disulfide is normally in the reduced state was
readily accessible by Trx. In CD4 and ERO1, the putative Trx-binding site was blocked by an
additional strand, which is required to be either dissolved or be modified, for Trx/Grx to act
upon active Cys. CD4 undergoes domain swapping a mechanism which involves exchange of
homologous subdomains between two or more identical proteins to generate an oligomer,
altering the protein’s function to ON, OFF, or intermediate states to achieve this reduction
(Matthias et al., 2002, Wouters et al., 2010). Many proteins with CSDs are more likely to
domain swap similar to CD4 and suggests a possible relationship between domain swapping
and CSD reduction (Wouters et al., 2010).
5.4.2 Role of oxidative reduction in diseases
Mechanism of domain swapping is critical for CSD reduction. For example, Trx-
driven dimerization of CD4, a process critical for the establishment of functional MHCII-
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TCR-CD4 antigen presentation complexes, is impaired when CD4 is bound to gp120 (Cerutti
et al., 2014). Domain swapping is effected differently in case of complex diseases and
Mendelian diseases. In complex diseases, increased oxidative or reductive stress may deluge
the redox homeostasis system, which may in turn affect the ratio of domain-swapped dimers
to monomers. In Mendelian diseases, adverse change in redox potential may be due to
mutations in the vicinity of a critical disulfide, and if it is involved in domain swapping, it
may impact the domain-swapped population (Wouters et al., 2010).
A well-known example is in the case of superoxide dismutase (SOD1) mutants which
are associated with familial lateral sclerosis (FALs), an age-dependent degenerative disorder
of motor neurons in the spinal cord, brain stem, and brain. SOD1 is found in the inter-
membrane space of mitochondria but largely localized in the cytosol. Copper carrier CCS
which inserts Cu and the formation of disulfide bonds, activates SOD1. The conserved
disulfide of SOD1 is essential for activity and it remains oxidized in the cytosol. Even though
the disulfide is intrachain, it is thought to play a critical role in stabilizing the SOD1
homodimer. In SOD1 maturation process, formation of disulfide is critical and is regulated by
physiological oxidative stress. 14 FALs mutants have the common property of being more
susceptible to disulfide reduction than wild-type protein (Tiwari and Hayward, 2005).
Toxicity associated with disulfide-linked multimerization of SOD1 mutants has recently been
implicated in the disease mechanism (Furukawa et al., 2006).
Effect of variations involving oxidative reduction may be associated with different
functional states, with the consequences being apparent in a specific epistatic context. As
discussed in section 5.1.1, Met residues undergo oxidative reduction similar to Cys residues
and several diseases are associated with methionine variants. These include the V129M
variant of the ‘prion’ protein PRP and the V358M variant of α1-antitrypsin SERPINA1.
Since Met is susceptible to oxidation unlike valine, smokers with the V358M variant are
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more susceptible to chronic obstructive pulmonary disease (COPD, emphysema) and
individuals with the V129M variant of PRP are more susceptible to Creutzfeldt-Jakob disease
(CJD).
Conclusion5.5
Here we report for the first time a novel method of acquisition of CSDs in a
stepwise manner via incorporation of disulfide-based redox switches into three protein
families. Successful context-dependent stepwise evolution of the sites enables the proteins to
potentially utilize existing Trx-like enzymes to mediate successful incorporation into cellular
mechanisms of redox homeostasis.
Results from this study indicated that the CD4 molecule, and in particular the
sequence including and flanking CSD, is under positive selection, similar to nsSNPs
associated with complex diseases (Thomas and Kejariwal, 2004). For example, pairwise
comparison of human and mouse CD4 molecules, suggested that they are under six times
more positive selection than the average comparison of human/mouse orthologs (ω =0.77 Vs
ω- =0.12), especially near the first Cys residue of the CSD, where ω > ω- =1.17, where
ω=Ka/Ks, the ratio of non-synonymous substitutions in codons to synonymous substitutions.
Identification of genes across species that are under positive selection enables
attribution of a likely functional role to an amino acid region. For example, orthologous
genes in different species have a common ancestor, but not necessarily the same function.
This functional difference can be used to identify which amino acid caused the functional
change. For example, AlcR is a transcriptional regulator whose activation depends on the
presence of an inducer in one Bordetella species but not in another species. Although the
AlcR genes are clearly orthologs in the genus, they behave differently in different species.
Supposedly the residue analysed was responsible for inducer dependence (Ng and Henikoff,
2006).
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Structural characterization of redox-sensitive Cys-based switches is still an area of
emerging research. A mechanistic understanding of these switches is important for
generalizing their behaviour. Although patterns are beginning to emerge, many more
structures need to be studied. Importantly, ageing and several major diseases including
neurodegenerative diseases such as Alzheimer’s disease, type II diabetes, cancer, and
cardiovascular disease have been associated with abnormal redox conditions (Wouters et al.,
2010). More research on these systems will undoubtedly improve our understanding of the
aetiology of these diseases and lead to better diagnosis and treatment.
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Chapter 6: Discussion
This work was undertaken to extend Gentrepid, our in-house candidate gene
prediction platform to enable identification of pathogenic nsSNPs. Firstly, I studied the
current methods of identification of disease-associated SNPs, identifying context, as an
important variable that is currently not considered. Therefore, I studied variants in relation to
two different contexts of proteins—dynamic variations in coiled-coil domains and fixed
substitutions in thiol-based redox signalling sites in proteins. Coiled-coil proteins were
chosen because they are extremely common structural elements in proteins that likely have
important roles in protein-protein interactions. Thiol-based redox signalling sites were chosen
because the involved Cys residues are under highly negative selection, but the sites where
they are incorporated show evidence of strong positive selection. Our lab is particularly
interested in the role of these post-translational modification sites as redox switches in
proteins.
In chapter 3, I looked at the current generation of amino acid substitution methods. In
particular, I was interested in studying the comparative performance of existing AAS
methods in relation to Mendelian mutations and complex disease variants. Many AAS
prediction methods exist but their performance is untested on common diseases. These
systems have primarily been benchmarked on the existing knowledgebase which are heavily
biased towards either diseases of Mendelian inheritance or somatic mutations of cancer. In
cancer, two different types of somatic mutations are distinguished: Loss-of-function
mutations (LOFs) and Gain-of-function mutations (GOFs), which have very different
mutation patterns and phenotypic consequences. We found that the predictions of AAS
methods were mostly incorrect for GOF mutations and variants involved in complex diseases.
Part of the problem is that they solely consider the properties of the amino acids and mostly
neglect the context of their occurrence in proteins.
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In chapter 4, I analysed the effect of two sets of variations—disease mutations and
polymorphism in coiled-coils. This study showed that mutations of high classical penetrance
tend to affect structural stability of the proteins. Polymorphisms on the other hand were found
to affect the oligomerization state of the coiled-coils and the conserved phase shifts. An
important finding from this study was the pleiotropic effect exhibited by coiled-coils, a
property that is often associated with complex diseases.
In chapter 5, I studied a novel method of acquisition of CSDs in three protein
families—AKT, ERO1 and CD4. It was found that the redox switch was not introduced as an
entire fragment but by stepwise mutation of two residues in the native sequence. This study
also suggested that successful incorporation of Cys and reduction of disulfide might be
limited to selected contexts in proteins where the active disulfide is in a strand that is
modifiable by enzymes involved in redox homoeostasis such as Trx.
The significance of these results in relation to complex diseases is discussed in more
detail below.
From Mendelian to complex diseases6.1
The ultimate goal of genetic association studies is to define the genetic architecture of
complex traits and diseases to provide new insights into normal physiology and disease
pathophysiology. Achieving that goal will require defining the causal variants that account
for the observed associations, their mechanism of action, and their target genes. As of
February 2015, GWAS and other studies have associated more than 15,000 SNPs with a
complex disease or trait (Welter et al. 2014). However, the mechanisms underlying these
associations remain largely undefined, especially the underlying architecture of complex
diseases and traits. The fundamental problem now faced by geneticists is that most variants
identified through genetic association studies are typically in linkage disequilibrium and
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pprioritizing variants that are most likely to have a phenotypic effect is a promising task
(Cooper and Shendure 2011).
AAS methods play a significant role in identifying causal nsSNPs from bystanders.
However existing methods are incapable of distinguishing variants that are likely to be
associated with more subtle alterations to protein function such as those involved in complex
diseases. One of the reasons is that some of them use physico-chemical properties of the
amino acids to classify variants. However variants involved in complex diseases imply a
different impact as opposed to Mendelian mutations.
Variants involved in complex diseases tend to interact with each other and the
environment and hence their effect may be dependent on the presence of other variants in the
same interaction network. Hence these variants should be studied in protein-protein
interaction network and pathways. Studying variants in protein-protein interaction domains
known as “coiled-coils” highlighted that polymorphisms affected the oligomerization state of
coiled-coils important for interaction specificity. It was also found that pleiotropy, often
associated with SNPs and genes involved in complex diseases and traits, was exhibited by
coiled-coil domains. It provided an indirect support in humans that genes with a larger
number of protein-protein interactions are important in pleiotropy. This is also supported by
the findings of Sivakumaran et al. (2011) who showed that pleiotropic mutations are mainly
located in exons and in domains involved in protein-protein interactions. Pleiotropy in
common diseases has implications for genetic testing and personalized medicine. For
example, a mutation that predisposes an individual to one common disease may also
predispose them to, or protect them from, other diseases (Stower, 2012).
Functional effects of variants6.2
As illustrated in chapter 3, most of the amino acid substitution prediction methods
provide either a binary outcome or a continuous score for pathogenicity. They do not
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elucidate the functional role of a variant. In order to provide a clear genotype-phenotype
correlation, methods should include an assessment of functional significance. Analysis of
variations in structural domains and signaling pathways as elucidated in this work will enable
the identification of functional effect of variants. There are two types of questions that could
be answered by using the methodology presented in this study. Firstly, whether a certain
variant is pathogenic or not, that is, whether it causes any aetiological effects indifferent to
the wild-type. Secondly, the functional effects it may cause at the protein level—whether it
increases or decreases the effect of an existing function or directs the protein to perform a
different function.
For regions under positive selection6.3
The genetic basis of complex diseases may partially be caused by positive selection
events as a result of changing environmental conditions and cultural influences (Corona et al,
2010). So, some populations are more likely to be susceptible to a disease than others. When
seven diseases studied by the Wellcome Trust Case Control Consortium were analysed, it
was found that alleles increasing susceptibility to Type 1 Diabetes (T1D), Rheumatoid
Arthritis (RA), and Crohn's Disease (CD) were under positive selection (Corona et al, 2010).
How do deleterious variants become fixed in a population? Deleterious variants
increase in frequency when a selective sweep occurs in the population due to the beneficial
effect of a mutation eliminating haplotype diversity. In such scenarios, only one haplotype
could be present in a population on which deleterious variants hitchhike along the beneficial
variants. This effect is called genetic hitchhiking which plays an important role in the fixation
of deleterious variants within populations (Riemenschneider et al., 2012). One example for
such a genetic hitchhiking effect is found on chromosome 5, where the IBD5 (inflammatory
bowel disease 5) locus contains a haplotype of about 250kb associated with an increased risk
of Crohn’s disease in the European population (Riemenschneider et al., 2012). Huff et al.
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(2012) showed the increase in frequency of deleterious variants forming the IBD5 risk
haplotype by hitchhiking, as a result of positive selection on alleles in linkage disequilibrium.
Hence it is important to identify these deleterious variants that become fixed in the
population because of positive selection.
By ignoring DNA sequence differences, current AAS methods incorrectly predict
substitutions at sites under positive selection to be neutral (Ng and Henikoff, 2006). The
approach used by this study as discussed in chapter 5 can highlight regions in proteins that
are under positive selection. The AAS prediction method of Fleming et al. (2003) which used
the DNA sequences of homologous genes in addition to protein sequences to find sites under
positive selection, showed that the Ka/Ks ratio is varied at different amino acid sites and
positions with high ratios were posited to be under positive selection. Since, most AAS
prediction methods do not take DNA sequence into account, they are more likely to miss
changes in regions under positive selection (Ng and Henikoff, 2006). The knowledge of
positively selected sites can lower the false negative error.
GOF variants in populations and their role in evolution6.4
GOF variants that enhance the existing function of a protein or introduce a new
function are increasing and the identification of such variations is necessary. The
discrimination of GOF and LOF is of immense use in cancer (Reva et al., 2011, Soussi and
Wiman, 2015) and in complex diseases. For example, consider a kinase that contains two
different variations in different individuals: one that makes the kinase “more active” than the
common version of the kinase (with the major allele frequency in the population) and another
that is “less” active than the common version of the kinase. The first variant would be a GOF
and the second a LOF. These distinctions in the context of a signaling pathway containing a
group of alleles with a cumulative LOF or GOF tendency might significantly affect the
output of the pathway.
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Results from chapter 3 indicated that the accuracy of current state-of-art methods is
dependent on whether loss-of-function or gain-of-function mutations are being tested. Most
methods were able to predict LOF mutations more accurately than GOF. The evolutionary
study of amino acid substitutions with functional consequences that have become fixed in
populations of ancestral organisms and retained throughout speciation provides a way of
studying GOF mutations. In particular we looked at the introduction of Cys residues that can
contribute to thiol-based redox signalling pathways. Cys residues are particularly interesting
because there is a strong negative selection against their introduction into proteins as
demonstrated by existence in proteins at frequencies lower than their neutral frequency.
Analysis of fixed substitutions in signalling pathways, as shown in chapter 5, can distinguish
deleterious and beneficial GOF variations in proteins. For example, to prevent over-oxidation
of Cys residues, glutathione (GSH) may be conjugated to the residue. If a Cys that is
modifiable by GSH is in a place which cannot be accessed by glutaredoxin, the enzyme that
removes glutathione adducts, the protein will likely be targeted for removal by the GSH
detoxification system. Thus, the mutation most likely will have a deleterious effect on protein
function by inducing a state of haploinsufficiency. Hence, protein contexts which allow the
post-translational modification to be recognized and reversed by existing signaling enzymes
such as phosphatases are likely to become fixed in the population whereas those that cannot
be reversed may constitute harmful gain-of-function mutations.
Limitations6.5
Although this analysis provided an in-depth understanding about the functional
effect of variants, there are some limitations such as performance of tools used to perform in
silico experiments and availability and reliability of the biological information used.
In silico tools do not mimic the in vitro environment and their performance may
affect the predictions. For example, Multicoil provides a more stringent coiled-coil prediction
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than other programs such as COILS, resulting in less false positive predictions. However, the
increased stringency might lead to prediction of fragmented domains where continuous
domains have been experimentally verified (Berger and Singh, 1997).
Additionally, this research was highly reliant on the curated and published
information in databases such as OMIM, HGMD and Swiss-Prot. Although these resources
are valuable, each of these suffers from drawbacks. For example, these databases contain
disease and phenotypic information from mutagenesis studies of individual proteins. These
studies provide mutational assessments for the proteins studied and the extent to which those
estimates are applicable to other proteins is unclear, especially when using a single viral or
bacterial enzyme to study the functionally diverse human proteome (Cooper and Shendure
2011). On the other hand, databases of known pathogenic variants relate directly to human
genes and diseases and include mutations that manifest in particular clinical phenotypes. But
mutations that give rise to lethality, subclinical disease or a distinct phenotype are often not
sampled (Cooper and Shendure 2011). Therefore, results should be interpreted with caution
and should be reported in the context of other available scientific evidence to support
causality.
Current AAS methods are widely by researchers to analyse if a variant has an effect
on a phenotype of interest. Most of the existing AAS methods largely use variants and
phenotypes information from publicly available databases for their training and testing data.
These resources contain known phenotypes and map the effect of a variant to an existing
phenotype. When variants associated with unobserved phenotypic changes are tested, they
could be classified as ‘neutral’ rather than a ‘disease’. Hence, their ability to identify variants
associated with novel phenotypes is restricted.
Since complex diseases are often associated with variants in many genes, research
should be focused on predicting the effect of a variant in the presence of other variants within
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a protein or its ‘interactome’ (set of interacting proteins). Coevolving sites among genes
could be responsible for protein functionality, e.g. a mutation in protein ‘A’ classified as
‘deleterious’, could be practically ‘neutralized’ if a specific variant appears in the interacting
protein ‘B’. If this variant is not present, the effect of mutation ‘A’ should be deleterious
(Castellana and Mazza, 2013). This could possibly enable the identification of potential
causal variants present in genes that harbor both LOF and GOF mutations. This is a complex
challenge because we are far from obtaining a complete understanding of protein–protein
interactions, structural/functional properties of protein complexes or coevolution among
protein-encoding genes (Castellana and Mazza, 2013).
Finally, the presence of many AAS prediction methods and their broad use
underscores their importance. With the increase in the number of servers, it has become
difficult for investigators to interpret the predictions. They are highly heterogeneous in their
input/output data types. For this purpose, many comparative studies have analysed the
performance of AAS methods on different set of genes (Chan et al., 2007, Thusberg et al.,
2011). However, results from none of the studies concurred on which method is a better
performer. Methods should be chosen based on the phenotype of interest. However, there are
not many disease specific methods except for Canpredict (Kaminker et al., 2007), that
predicts the effect of variants involved in cancer. Ultimately, it depends on the user to choose
appropriate methods based on their data.
Future directions6.6
This work could be extended to other functional domains that are heavily involved in
interactions and signaling pathways to gain insight into complex diseases. Resources such as
databases for association of variants with complex diseases are currently unavailable
(Mooney, 2005). This highly undermines the efficiency of prediction programs. Development
of such databases would see better performance by AAS methods.
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Furthermore, methods for predicting pathogenic nsSNPs mainly focus on protein
coding regions and the properties derived from protein sequence or structure as classification
features. Although nsSNPs in protein coding regions are important for studying the potential
causative relationship between genetic variants and human inherited diseases, variants in
intergenic regions, promoter regions, and intron regions can also strongly influence the
phenotypic outcome (Lehmann and Chen, 2013). By ignoring DNA sequence, most AAS can
miss changes that alter splice sites. So, methods for analysing variants in gene regulatory
regions are required.
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Chapter 7: Conclusions
Approaches to identify the genetic basis of complex traits and common disease are in
rapid development. This has been driven by the explosion of data produced by population-
based studies such as GWAS, which have the potential to yield more valuable data upon
further analysis, with the eventual goal of disease treatment. Although GWAS have the
ability to tag a locus associated with complex disease, the implicated SNP may not be the
causal SNP but merely in linkage disequilibrium with it. Next-generation sequencing within
the affected population is then the next step in identifying variations that are associated with
disease. For this purpose, AAS methods were developed to identify the most causal nsSNPs
that confer disease risk. However, existing AAS methods have some drawbacks and new
methods to identify disease-related nsSNPs that underlie complex diseases are essential
which is an important outcome of this project.
This work identified the potential limitations of existing AAS methods—their
inability to correctly identify GOF mutations and variants involved in complex diseases. The
pattern of disease mutations and polymorphisms in common structural motif “coiled-coils”
was studied. Analyzing disease mutations in coiled-coil domains identified the pleiotropic
effect exhibited by coiled-coil domains. It also demonstrated that polymorphisms gave
different effects on the structure of coiled-coil domains such as altering the oligomerization
state and the conserved phase shifts in coiled-coils important for interaction specificity.
Analyzing how Cys residues are incorporated into proteins through evolution showed that
incorporation of Cys residues may be limited to proteins where reduction of the Cys can be
effected by enzymes of redox homeostasis such as Trx.
While AAS methods are reasonably effective in identifying Mendelian mutations and
LOFs in cancer, a new generation of methods that can identify the more subtle variations
likely to be implicated in complex disease are needed. A modelling approach to predict the
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effect of variants in functional motifs as discussed here can possibly explain how variants
affect the protein’s function, a feature not provided by the existing AAS methods. In order to
predict the overall effect of nsSNPs, AAS methods, in conjunction with those that predict
gene regulatory and splicing variants, will guide us to a better understanding of functional
diversity in genomes.
Finally, next-generation sequencing has enabled 'next-generation genetics', wherein
variant identification is no longer the rate-limiting step. However, the challenges preventing
the optimal exploitation of available data are formidable. Development of new methods and
optimization of existing methods is essential to find the genetic answers that sequencing
promised, but which are currently hiding in plain sight.
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